BioTOP-Report 2013 - Cluster Gesundheitswirtschaft

Transcription

BioTOP-Report
2013
Biotech and Pharma in Berlin-Brandenburg
BioTOPics 46 | September 2013
BioTOP-Report
Content
Editorial
Unique Chances to Create Value in Biotechnology and Life Sciences
3
Biotechnology
More Companies, More Employees and New Deals
4
Pharma
The German Capital Region: Highly Attractive for the Pharmaceutical Industry
14
Diagnostics
An Excellent Location for the Development of Innovative Diagnostics
18
Industrial Biotechnology
Focus: Biopolymers and Bio-based Plastics
22
Global Business
New Markets and Horizons for Global Business
25
Business Location
Excellent Services for Berlin-Brandenburg
28
Technology Transfer
Technology Transfer between Science and Business
30
Life Sciences
A Science and Research Hub
Know-how in Systems Medicine and Systems Biology Biotech 2020+ 34
36
41
Biotech Parks
The BioCampus Network Berlin-Brandenburg
50
Addresses
55
Publisher: Berlin Partner für Wirtschaft und Technologie GmbH · BioTOP Berlin-Brandenburg
Fasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622–0 · Fax +49 30 318622–22 · [email protected] · www.healthcapital.de
Editor: Yvonne Küchler
Design & Production: supiran.de
Translation: Textbüro Reul GmbH · Frankfurt
Photos/Figures: BioTOP or Authors and:
Page 10 Ralfpoller*, Wladimir Bulgar*; Page 13 Werner Popp (Profile organobalance), Vanillla * (Profile BPI); Page 14 Phartisan*, Idrutu*; Page 18 Stratum*,
Stanislav Perov*; Page 20 Alx, fotolia.com (Profile Dr. Nothgi); Page 22 BASF; Page 25 C. Keating*, Moth*; Seite 32 Bayer HealthCare; Page 33 Eric1513*,
Jankaliciak*, Grafoo*, Eraxion*, Kjpargeter*, Andrey Armyagov*; Page 37 Christoph Heidrich; Page 40 Illustration: webersupiran, photo Sofiaworld *;
Page 41 Paulus Rusyanto*, Collpicto*, 18percentgrey*; Page 46 Natalia Pavlichenko*/Patho (Profile Predemtec)
*dreamstime.com
BioTOP-Report
Editorial
The German Capital Region – Unique Chances to
Create Value in Biotechnology and Life Sciences
In an emerging health environment, manufacturers of drugs, diagnostics and devices will need to be able to
prove not only the safety and efficacy but also the value of their products. Thus all players in the value chain –
reaching from scientific institutions and biotech companies to clinics and healthcare providers – are rethinking
their products, services and business models. They find perfect conditions in Berlin-Brandenburg.
Dr. Kai Bindseil
Cluster Manager HealthCapital
Director BioTOP Berlin-Brandenburg
[email protected]
www.healthcapital.de
Obviously, most participants in the value chain have realised that
cooperation is the most important factor for success and are shaping their cooperation strategies:
kkCross-innovation at the interface of life sciences, information
technology and engineering takes place everywhere. This
innovation sector will not only create value through new tools
and cost reduction in healthcare delivery, but also enable
all of us to take control of our own health and wellness. The
most recent example is the Joint Lab for Bioelectronics of
the Technische Universität Berlin and the Leibniz Institute for
Microelectronics.
kkBasic and clinical research of the Max Delbrück Center of
Molecular Medicine (MDC) and the Charité – Universitätsmedizin Berlin will come together in the Berlin Institute of
Health (BIH) to create the new flagship of German life sciences.
Berlin-Brandenburg is indeed the European hotspot for collaboration. More than 200 biotechnology and 30 pharmaceutical
companies benefit from close cooperation with five universities
and more than a dozen institutes of the Helmholtz, Max Planck,
Fraunhofer and Leibniz societies and associations, as well as
more than 130 hospitals – among them Europe’s largest university hospital: Charité – Universitätsmedizin Berlin.
As a consequence, the sector has grown more than 6% in 2012
and is growing continuously since 10 years. This fertile ground
will be further strengthened with the new master plan for the
healthcare industry. BioTOP is pleased to present the most important developments in life sciences, pharma and biotechnology
in our new annual report.
We hope you enjoy reading our report, and we invite you to play
an active role in one of the most vibrant European life sciences
networks. Don’t hesitate to contact us.
Dr. Kai Bindseil
kkScientific excellence and development experience will team
up in the CoLaborator, established by Bayer to incubate startups.
kkEntrepreneurial skills will be strengthened in the Entrepreneurial Network University of the Freie Universität Berlin,
Charité and several companies.
3
BioTOP-Report
Biotechnology
More Companies, More Employees and New Deals
The positive development of the regional corporate landscape got new momentum in 2012. The number of
employees in the sector rose by 6.5 %. Compared to average growth rates of 3.5% during recent years, this has
been a clear and very welcome sign of the dynamism in the Berlin-Brandenburg region, where 222 companies
now employ a workforce numbering 4,348 people.
Development of the Companies in 2012
BioTOP conducted its anual survey of regional companies for the
year 2012 to obtain a comprehensive overview of the current
development of the corporate scene. During 2012, twelve new
companies joined the ranks of surveyed companies, of which
nine were newly founded and three included in the survey for
the first time. Five companies ceased operations or moved to a
different region. The new companies are still smaller firms focusing on services and product development in the field of biomedicine. As an example, we refer to t-cell Europe, which received
funding from the High-Tech Gründerfonds (HTGF). The aim of
t-cell Europe, a spin-off of the Berlin-Brandenburg Centre for Regenerative Therapies, is to use its patented platform technology
to develop and market new t-cell-based regenerative therapies.
MARCH 2012
10. BIONNALE in Berlin – 10 years of success – Biggest biotech industry meeting in Berlin-Brandenburg celebrates its jubilee
APRIL 2012
NOXXON's NOX-A12 delays recidivation in preclinical glioblastoma model
++++ Epigenomics AG enrolls first participant in its FIT comparative study
with Epi proColon®
MAY 2012
MOLOGEN AG: Promising start in financial year 2012, quarterly record presented ++++ ifp and Romer Labs join in world-wide sales cooperation for
EnzymeFast® food test kits
The company’s first reference product will be a t-cell product for
kidney transplants. Another interesting start-up is Drug Response
Dx GmbH in Hennigsdorf. DRDx is developing a robust companion diagnostic test which permits secure stratification regarding
failure in TNFα blocker (TBA) therapy for rheumatism patients
and therefore addresses a very big market.
The sizes of companies barely changed during the past few years.
Smaller enterprises with less than ten employees make up 63%
of all companies, but these firms also account for only app. 15%
of all employees. More than 54% of those employed in the regional biotech sector work in the 19 companies with more than
50 employees. The thematic focus of the industry also remained
unchanged during recent years and continues lie on biomedicine,
and here particularly diagnostics.
Variant AnalysisTM and iReportTM by Ingenuity® Systems for data analysis
and interpretation
JULY 2012
Epigenomics appreciates reimbursement of Septin-9 blood test for early recognition of colon cancer by Swiss Life in France ++++ MOLOGEN AG capital
increase of 22 million Euros
AUGUST 2012
co.don® AG reaches another milestone on the path to central approval; Recruitment phase for clinical phase II trial completed successfully ++++ Merck buys
Biochrom AG ++++ Indian pharma firm Piramal invests in molecular imaging
in Germany
JUNE 2012
SEPTEMBER 2012
ORGANOBALANCE presents new research results on ACHEMA 2012: Extended application range for yeast strains in biotechnological production ++++
CellTrend GmbH and One Lambda Inc. agree to world-wide sales contract
++++ United States Patent and Trademark Office grants co.don AG patent for
production of autologous spinal disc cell transplants ++++ NOXXON initiates
phase IIa study of anti-CCL2/MCP-1 Spiegelmer® NOX-E36 for treatment of
diabetic neuropathy ++++ ATLAS Biolabs extends spectrum of services by
Epigenomics AG announces changes in executive board ++++ Charité and
Sanofi extend partnership by diabetes alliance ++++ MOLOGEN AG: Current
data of kidney cancer therapy MGN1601 shows further improved results
4
OCTOBER 2012
50 years Klosterfrau Berlin GmbH ++++ ATLAS Biolabs takes part in European
projects on the research of DNA repair and cell aging ++++ co.don® AG from
Teltow presents gentle alternative – preserve joints instead of replacing them
BioTOP-Report Biotechnology
Deals and Product Developments
Dr. Claudia Ulbrich
CEO t-cell Europe GmbH
Our T-cell-based therapies, unique throughout the world, can
help prevent organ rejection following transplant procedures,
thus significantly reducing the need for immunosuppressive
drugs. With the new funds of EUR 5.5 million raised in our
most recent financing round, we aim to commence clinical
trials already in 2014, so that we can expeditiously move forward with proof-of-concept at the patient level, then proceed
with negotiations to license our proprietary technology to a
pharmaceutical industry partner. T-cell therapy will not completely eliminate the need for immunosuppressive support.
However, even if the amount of immunosuppressive drugs
required can be reduced by one half, the costs of our therapy will be quickly recovered, generating net patient savings.
Just for one specific application, Treg therapy following kidney
transplantation, we estimate a current market potential of
more than one billion euros per year.
A number of companies closed new cooperation agreements in
2012 and achieved major milestones in product development
and approval. We present some examples of these dynamic activities:
MOLOGEN presented outstanding results in its clinical development programmes from a first evaluation of the colon cancer
study with the active pharmaceutical ingredient MGN1703. The
evaluation performed in May 2012 demonstrated the effectiveness of MGN1703 as a maintenance therapy for metastasised
colon cancer impressively. MOLOGEN also plans to investigate
the effect of MGN1703 in lung cancer therapy in the future. In
October 2012, the company presented promising new data from
its kidney cancer study with MGN1601. They showed a clear survival advantage for patients who fully completed the prescribed
therapy programme compared to patients who had to terminate
the therapy early due to the severity of their cancer disease.
Furthermore, MOLOGEN completed the preclinical phase of its
MIDGE®-based Leishmaniasis vaccine MGN1331 in June 2012
with good results.
NOVEMBER 2012
MARCH 2013
Alacris Theranostics GmbH signs agreement with GSK to apply Alacris ModCellTM system in the early phase of cancer research ++++ Entry to the pharma market: Tönnies invests 21 million Euro, majority shareholder at Heparin
specialist Pharma Action
BIOTECON Diagnostics GmbH extends its robot segment ++++ Epigenomics
AG collects 5,0 million Euros through capital increase ++++ New research collective INNO-TRACE develops innovative contrast agents for tumour imaging
DECEMBER 2012
APRIL 2013
Europe's largest clinical laboratory at Campus Virchow-Klinikum: Labor Berlin
inaugurates new site
NOXXON initiates phase IIa study on anaemia of chronical illness with antiHepcidin Spiegelmer® NOX-H94 ++++ Epigenomics releases more data on
the results of a direct comparative study between Epi ProColon® and FIT
MAY 2013
JANUARY 2013
Bayer HealthCare presents new incubator model for biotech start-ups in Berlin
Epigenomics AG hands in fourth module at FDA completes application for
approval as planned ++++ co.don® AG applied for approval of joint cartilage
product chondrosphere® in the EU ++++ Shire discovered the Munich-based
RNA specialist Ethris for itself. In cooperation the two companies want to find
therapies for rare diseases
Alacris Theranostics GmbH announces Illumina CSPro certificate for next generation sequencing ++++ Humedics co-founder Martin Stockmann receives
Von-Langenbeck Prize for development of LiMAx test
JUNE 2013
FEBRUARY 2013
Epigenomics receives notice about grant of priority review status and acceptance of the hand-in of the PMA application for Epi proColon® from the FDA
++++ Innovation forum “Biopolymers and Bio-based Plastics” in Schwarz
heide
5
NOXXON Pharma AG, a biopharmaceutical company and pioneering developer of the new active agent class spiegelmers,
successfully advanced its product pipeline. Its latest candidate
agent NOX-H94 is already the third spiegelmer to have reached
the Phase II trial stage. This is one of four Phase IIa trials NOXXON
began in 2012. The others are investigating NOX-E36 in diabetic
nephropathy therapy, NOX-A12 in the therapy of chronic lymphatic leukaemia and NOX-A12 for treatment of multiple myelo-
ma. The trial for anaemia of this chronic disease is the fourth
Phase II trial NOXXON launched in 2012.
The German-American molecular diagnostics corporation Epigenomics AG made important progress with the approval of Epi
proColon® in the USA and the development of its marketing strategy for this blood-based test for early detection of colon cancer.
The next major milestone will now be the marketing launch of
the product on the world‘s most important market – the USA.
Number of Employees According to Company Size
2.600
2.355
2.500
2.400
2.300
2.200
2.100
2.000
1.900
1.800
1.700
1.500
1.400
1.300
1.200
1.100
Number of employees
1.600
1.330
1.000
900
663
800
700
600
500
400
300
200
100
0
'03 '04 '05 '06 '07 '08 '09 '10 '11
141 companies 1-10 employees
'12
'03 '04 '05 '06 '07 '08 '09 '10 '11
61 companies 11-50 employees
'12
'03 '04 '05 '06 '07 '08 '09 '10 '11
'12
20 companies > 51 employees
In comparison to the previous year, the average number of employees per company increased by 2,7 % in the 1-10 category and 1,8 % in the 11-50
category. The average number of employees in the category > 50 employees increased by 10%. (Source: Own survey, BioTOP database, 222 companies
questioned, June 2013)
6
Getting your
innovation going.
Our tailored financing are your key to success.
Our consultants look forward to meeting you.
Contact us:
Phone: +49 (0)30 / 2125-4747
E-mail: [email protected]
www.ibb.de/wachsen
Epigenomics also found a new partner in BioChain, a leading
clinical diagnostics provider for oncological and genetic tests.
This company will offer Epigenomics customers the Septin9 test
through its independent Chinese reference laboratory in Beijing
and thereby prepare the ground for Epigenomics’ market entry
in China.
The Institut für Produktqualität (ifp) and Romer Labs, a globally leading company in the field of food diagnostics, have agreed
on the joint launch of a new product line for enzymatic food analytics. The two companies are expanding their existing cooperation with this global marketing collaboration. The new EnzymeFast® product line transfers the traditional enzymatic methods
to a microtiter plate kit format, thereby providing a significant
advantage in routine food analytics.
CellTrend GmbH announced its partnership with the American
company One Lambda Inc. The aim of this cooperation is to supply transplantation centres worldwide with innovative diagnostic products developed by CellTrend. Under the agreement, One
Lambda will receive the exclusive global distribution license for
the immunoassay EIA for quantitative determination of anti-angiotensin II-receptor 1 antibodies (AT1R). AT1R is involved in a
range of neurohumoral systems and expressed in many organs,
including the heart, liver, lung and kidneys.
co.don AG in Teltow, one of the leading manufacturers of endogenous cartilage cell transplants for the treatment of joint and
disc damage, achieved a further milestone on the road to central
approval. Recruitment for the clinical Phase-II trial was successfully completed in June 2012. In this clinical long-term study, 75
patients with cartilage defects in the knee joint were treated with
co.don chondrosphere®, an endogenous matrix-associated transplant of patient cartilage cells. The extensive approval documentation was filed with the European pharmaceuticals agency EMA
in London at the end of the year.
Biochrom AG announced that Merck closed a definitive agreement on the acquisition of Biochrom AG on 22 August 2012. The
acquisition is subject to the usual preconditions for execution
such as approval by the competent anti-trust authority. The Berlin
location of Biochrom AG is being retained. The activities of Biochrom are being integrated into the Process Solutions business
unit of Merck Millipore.
8
The Indian corporation Piramal took over the molecular imaging
pipeline of Bayer Healthcare in April 2012. The acquired PET radiopharmaceuticals have been researched and developed further
since then in the Berlin laboratories of Piramal Imaging. The portfolio also includes the rights to florbetaben, a highly specific substance for determination of beta-amyloid deposits in the brain,
which is a marker for Alzheimer’s disease. A Phase-III trial of florbetaben was completed successfully. With the development of
its innovative PET radiopharmaceuticals for molecular imaging,
Piramal is focused on a key future field in modern medicine.
Alacris Theranostics GmbH closed an agreement with
GlaxoSmithKline (GSK) which entitles GSK to use the proprietary
ModCellTM system of Alacris for pharmaceuticals stratification
with its own data from the early stages of cancer research at GSK.
The system was developed at the Max Planck Institute for Molecular Genetics and licensed exclusively to Alacris.
Dr. Ludger Dinkelborg
Managing Director of
Piramal Imaging GmbH
In the Piramal Group’s cluster-based thinking, the Berlin location unequivocally represents know-how and a long tradition
in the field of diagnostic imaging. After all, this is where the
first contrast medium was invented back in the 1930s. There
is top personnel here: the training situation is excellent, both
in companies like Bayer and in the local academic institutions.
We collaborate closely with eminent experts from Charité hospital – a key partner for clinical trials - in the field of molecular
imaging and in the diagnosis of Alzheimer’s disease In the
capital region are many small companies in the fields of radiopharmaceuticals and diagnostics, and many service providers supporting clinical research. Berlin is a global metropolis
offering a high quality of life, the kind of place where people
like to live and work. That makes it easy to recruit international experts.
A AT
GGA
AT C
G TA
TA A
CCA
AG G
GTT
TCC
ACA
GCC
TGA
GCC
G AT
AT C
G TA
AG G
GA A
CAC
CGA
GCC
CAA
AGC
ACC
TA A
AGT
GTT
T G A CAC ACG T TC GCC
C C A T C A C G A TA A A A C
GA A ACC GA A TCA GCC
T T G CA A GGC CAC CAG
AC T GGA ACA AGA TCC
STudieS & ConSulTinG
T T C G TA T T A A C T A G A
ConferenCeS AAG G A G
CTC CTG GCG GTG TCA
BookST C T C G C C A TA A
ACG G A A A C G G G T G A C
T V & VideoA C T C C G C A
TA G G C T C A A A AC G C A
CorporATe puBliShinG
C A G C T T A C C AGA T G C
inTerneT C T C C G C A C G
G T T T C C A C A GCC T G A
MAGAzineSG A T T C G T C
T C A ACC CA A GGA G T T
e V enT MAnAGeMenT T A
A AC GCC CAG TCC AT T
CAC GCT G T T CCC GGA
G G C AAA G C A C A T C C A
GGC GCA T G T T GA CAC
G C T AGA CA A ACA T C T
G T T C T C A AG GA A TGA
A C T A C G T C C T G C AT G
BIOCOM AG | Lützowstraße 33–36 | 10785 Berlin | Germany
www.biocom.de | Tel. +49 (0)30 264921-0 | Fax +49 (0)30 264921-11
G AT A A G G A A G T T AT G G A A
GGA C A A T TA C C C G AT T G G
AGT CA A GA A G C T T TC GAC
TA G C A C A C G T G C G G A A C G
AAA G C T T A T T G G A A G T G C
G C A TA C C A A T G C AT G C A C
G AT C AT T C T A A C C C T T A T
AT C C C C T T G A C C GGC C G G
A AT C A G T G A C G A C C G T G T
C G T T G G C T T A A A G C T TA G
G G G A AT C C A A C C GAC A G A
C A T T T G C G A G C T A G A ACG
T G T G C C G AT C A A G A A T G C
T T T G G A GA A C T A A C A T C T
A AG AT C T T G G G A G G C A C T
T C C A AT G G A AT C G T A TA A
G C C G A T AT C G TA AG G T G A
C T C A G T ACG T C A TA G C A A
G TA C TA C T G C G C G A A C T T
GCG TCG ACG CAC CA A T G C
AGA GAG TCA TA A GAC GCA
T G C A C A G C C AG G A C T C T T
AGA GA A TGG GAC ACG TGC
A AT C A G C C T G A T TA G C A C
W e C r e AT e k n o W l e d G e !
CGA T G T GCC T T G ACC TCG
T T G CGA T T G GGA AGA A A A
CCT
AAA
TGC
ACA
CCG
GGA
AGC
TTT
ACA
GCC
AT T
TA A
A AG
AGA
GAG
CCA
CAA
ACT
ACG
ACC
GCA
TGC
CAC
CAG
TGG
ACG
CTC
The Financing Situation
The financial position of the region’s biotech industry is stable
overall, and the consolidation efforts during recent years are now
paying off. The business models of most companies are commercially feasible and generating free funds for investments and
growth. Companies with high capital needs successfully acquired
new funds for their product developments or market approvals
in 2012.
Capital increases of listed companies alone injected more than
€ 40 million into the respective companies, headed by MOLOGEN AG, which generated € 25 million. Apart from these public
placements, there were no major financing events – with two
exceptions: The first outstanding exception was the takeover of
the molecular imaging pipeline of Bayer Healthcare by the Piramal Group into the newly founded company Piramal Imaging. Europe’s leading pork marketing company Tönnies joined the ranks
of financially strong private investors in the pharmaceuticals sector. Tönnies acquired the majority in the company Pharma Action
in Berlin. The companies aim to manufacture the coagulation in-
hibitor heparin jointly in future. This active substance is obtained
from the intestinal mucus of pigs and administered to patients
during operations or in the case of cardiac illness.
Private venture capital transactions were not significant. Once
more, the most active investor was IBB Beteiligungsgesellschaft
with two first and two follow-up investments and the HTGF with
two start-up funding investments. It should be noted that these
are both public-sector investors. The private VC business remains
dissatisfying. It is therefore time to create new drivers and incentives for venture capital.
Public-sector institutions remain very important to the financing
of product developments and investments. The two states Berlin
Employees in Biotech SMEs
4.348
4.500
4.000
3.500
3.000
2.500
2.000
Number of employees
GLYCOTOPE moved two products into Phase II clinical development. After successfully completing Phase I of its glyco-optimised therapeutic antibody PankoMabTM, the company moved
the compound to Phase II clinical development in ovarian cancer,
with further indications planned. After successful completion
of Phase I, GLYCOTOPE also advanced its glyco-optimised therapeutic protein FSH-GEXTM into Phase II clinical development in
in-vitro fertilisation.
1.500
1.000
500
0
'03
'04
'05
'06
'07
'08
'09
'10
'11
'12
Employment rose to 4.348 in 2012. This is a growth of 6,5% in
comparison to the previous year. The number of companies
went up to 222, reflecting the arrival of 10 companies and five
departures. (Source: Internal survey, BioTOP database, 222
companies questioned, June 2013)
10
and Brandenburg alone disbursed more than € 37 million in support funds to regional life sciences companies, while the German
federal government provided a similar amount of project support
funding. The leverage effect of these funds resulted in private
investments of comparable dimensions. When compared to purely private investments, it is clear how important public funding
programmes are to permit new product developments and as a
multiplier for private fundings.
Conclusion
obtaining it successfully, thereby demonstrating that investments in the life sciences are attractive for both institutional and
private investors. Apart from public-sector portfolio investors,
however, the venture capital market remains weak – a phenomenon that has been observable for many years. Although it is good
and proper that the regional and federal governments support
the research and development of innovative and promising projects with appropriate funds and thereby secure highly qualified
jobs for the future, the commitment of private investors and the
associated conditions must be developed further and improved.
Overall, the economic and financial situation of the regional biotech industry is solid. Most companies are financing themselves
with own funds, while companies requiring external capital are
Market Segments of Companies
184
83%
200
190
180
170
160
150
140
110
100
90
80
Number of companies
130
120
70
40
18%
60
30
14%
50
40
30
20
10
0
'03 '04 '05 '06 '07 '08 '09 '10 '11
Agriculture/Food
'12
'03 '04 '05 '06 '07 '08 '09 '10 '11
'12
White Biotechnology /Environmental Biotechnology
'03 '04 '05 '06 '07 '08 '09 '10 '11
'12
Biomedicine
Most companies focus on biomedicine. A total of 83 % of companies, focus primarily on development in the areas of new diagnostics, drug
development and associated services or technologies. 14 % of the companies are active in the agriculture / food sector, white biotechnology /
environmental biotechnology amounts to 18 % of all entries. (Source: Internal survey, BioTOP database, responses from 222 companies, multiple
entries, June 2013)
11
BioTOP-Report
Metanomics Health GmbH
kk Wide metabolite coverage via combination of unbiased and targeted platforms
kk Unique tox mode of action prediction
through MetaMap®Tox database
kk Excellence in systems correlation analysis of complex gene function relationships
Metanomics Health – a BASF Group company – applies comprehensive Metabolite Profiling (metabolomics) with biomedical data
interpretation. Metabolite Profiling is
defined as the parallel analysis of multiple
endogenous and xenobiotic metabolites in
biological systems. The core expertise of
Metanomics Health resides in discovery and
validation of biomarkers.
Technologies
kk Metabolite profiling platform with more
than 75 GC-MS and LC-MS/MS instruments
Major R&D-Topics
In cooperation with academic institutes and
clinical experts Metanomics Health is running a large-scale diagnostic biomarker program. Areas include metabolic syndrome,
heart failure, prostate cancer and multiple
sclerosis to mention a few.
cation, efficacy and safety markers)
kk Companion diagnostic development
kk Cell culture & bioprocess optimization
Address
Tegeler Weg 33
10589 Berlin · Germany
Contact
Dr. Tim Bölke · Managing Director
Phone+49 30 34807 400
Fax +49 30 34807 401
[email protected]
www.metanomics-health.de
Market Segments
Metanomics Health provides its services to
pharmaceutical, diagnostics and nutrition
companies. Technology applications include:
kk Mechanism of action studies
kk Mechanism of toxicity studies
kkTranslational and clinical biomarker
development (e.g. PK/PD, patient stratifi-
nanoPET Pharma GmbH
nanoPET is a biopharmaceutical company
specialized on R&D, manufacturing and marketing of innovative drug substances for
Diagnostic Imaging. We focus on relevant
cardiovascular, oncological and neurological
indications as well as on regenerative medicine. Nanotechnology is a key element of our
business. We operate in three major areas.
The first nanoparticular tracers for clinical PET: nanoPET prepares the clinical development of its patented technology platform:
inorganic nanoparticular tracers for cell- and
molecular-specific positron emission tomography (PET).
Viscover™ imaging agents – a landmark
in small animal imaging: As animal imaging is rapidly gaining relevance in pharmaceutical research, we are delighted to offer
you an exciting portfolio of specialized preclinical imaging agents covering the principal imaging modalities (MRI, CT, Ultrasound,
Optical Imaging, SPECT & PET). Get a
detailed insight into our product portfolio
and download a free copy of our imaging
guide on www.viscover.com
Consulting and Service tailored to your
needs: As a technology and service provider,
we offer our expertise to biopharmaceutical
companies and imaging equipment manufacturers. Our customers benefit from the
12
long-standing industry expertise our team
has attained in the pharmaceutical
research & development.
Address
nanoPET Pharma GmbH
Robert-Koch-Platz 4
Contact
Dr. Andreas Briel · CEO
Phone +49 30 890 49740
[email protected]
www.nanopet-pharma.com
BioTOP-Report
ORGANOBALANCE GmbH
Exploring and managing microbial
biodiversity
ORGANOBALANCE explores the potential of
probiotic bacteria and yeasts for new product developments in food, feed, personal
care, and for the pharmaceutical industry or
the production of fine chemicals. From a
large collection of microorganisms, specific
strains are selected to e.g. inactivate patho-
gens, produce new bioactives, neutralize
malodorous or toxic substances and synthesize high titers of valuable compounds.
ORGANOBALANCE works in collaboration
with partners and grants licenses for own
product developments.
ORGANOBALANCE draws on natural
resources, which are gathered in the company-owned collection of 8000+ microbial
strains, mostly originating from foodstuffs.
ORGANOBALANCE uses its OASSYS® bioassays for highly efficient screenings. The platform allows to quickly identify the most suitable strains from the microbial collection for
targeted applications.
Address
ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
ORGANOBALANCE has a broad expertise in
the field of yeast metabolic engineering.
This includes designing and developing new
production strains for industrial biotechnology applications. Specific strains of Saccharomyces cerevisiae, which carry engineered
biosynthesis pathways for the environmentally friendly production of carboxylic acids,
terpenoids, steroids and other lipid compounds are available.
Contact
Dr. Christine Lang · CEO
Phone +49 30 46307200
Fax +49 30 46307210
[email protected]
www.organobalance.com
Our experience is your success!
The German Pharmaceutical Industry Association (BPI –
Bundesverband der Pharmazeutischen Industrie e.V.)
consists of approximately 240 pharmaceutical companies.
These include not only the classic pharmaceutical firms
and service-providers, but also biotechnology companies
and manufacturers of medical devices.
All of our members use our association as a platform for
information and communication to develop collaborative
responses to the diverse challenges they face.
Our team consists of highly qualified experts in all fields
which are necessary to generate a sustainable benefit for
pharmaceutical companies, e.g. market access, regulatory affairs, law, biotechnology and political affairs.
Interested in being a member? Feel free to contact us!
[email protected] · www.bpi.de · Phone: +49 – 30 – 27909 – 0
Start Up-Companies are eligible for reduced membership fees while having the possibility to participate in
all activities of our association.
13
BioTOP-Report
Pharma
The German Capital Region:
Highly Attractive for the Pharmaceutical Industry
The pharmaceutical industry is an important economic factor and job motor in the German capital region.
According to a study by the Cologne Institute for Economic Research1 commissioned by the Association of
Research-Based Pharmaceutical Companies (vfa), the number of people employed in the industry in Berlin
grew since 2009, in contrast to the national trend. Whereas jobs in the pharmaceuticals sector declined by
2.6 % in Germany as a whole, in Berlin the number of employees grew by 1.5 % to 9,589.
One in eleven employees in the German pharmaceutical industry
works in Berlin. With sales worth € 5.6 billion, Bayer, Berlin Chemie, Pfizer, Sanofi and the more than 20 other pharmaceutical
manufacturers form the industry in the German capital with the
highest revenues. With 17 % of Berlin’s total industrial production, pharmaceutical companies come in first position, ahead of
electrical engineering and mechanical engineering.
Berlin-Brandenburg is a highly attractive location for pharmaceutical companies. International companies in the industry like
Takeda, which recently arrived in Berlin, are not just attracted by
Berlin as the German capital. The many research facilities, hospitals and biomedical companies in the region provide pharmaceutical companies with an infrastructure that will become increasingly important to them in future. The industry faces major
challenges: stricter approval regulations for new active substances, declining prices, expiring patents and mounting competition
from generics manufacturers present the need for new business
strategies. The core terms often raised in this context are: “personalised medicine” and “networks”.
Dr. Norbert Gerbsch
Deputy Director General of the
German Pharmaceutical Industry Association
(BPI)
A strong economic, medical and innovative basis and an excellent research landscape are important characteristics of a Health
Capital with special relevance for pharmaceutical companies. Berlin and Brandenburg offer all of those characteristics. It is therefore
not surprising that the number of pharmaceutical companies is steadily increasing: The region provides an extremely attractive
surrounding for an industry which relies on qualified personnel and needs to reinvent itself in the face of the challenges of the biological revolution, demographic change, budgetary pressures in health systems, and health benefit assessment. And: The German
capital region is a center for decision makers. As the German Pharmaceutical Industry Association, we are located here in order to
participate thoroughly in the discussions about healthcare reforms and to maintain an ongoing dialogue with the public as well as
other partners for the health sector.
14
1 K
irchhoff, Jasmina, Die Pharma-Industrie in Berlin: Ergebnisse der Mitgliederbefragung des Verbandes forschender Pharma-Unternehmen (vfa)
„Wirtschaftsdaten 2012“. www.pharmastandort.de
Get Old
Pfizer researches to develop the medicines
of today and tomorrow
We at Pfizer are committed to applying science and our global resources to improve
health and well-being at every stage of life. We strive to provide access to safe,
effective and affordable medicines and related health care services to the people
who need them.
www.pfizer.de
BioTOP-Report Pharma
Personalised Medicine and Networks
Many pharmaceutical and biotech companies in Berlin-Brandenburg are pursuing concepts in the field of personalised medicine
and therefore present themselves as potential cooperation partners. For example, Alacris Theranostics GmbH specialises in the
development of new processes in personalised medicine for cancer patients, focusing in particular on the development of new
approaches in diagnostics, therapy and drug stratification. Metanomics Health, a BASF Group company, on the other hand, offers
targeted and non-targeted metabolite profiling to healthcare customers in industry and academia.
Alongside companies focussed on developing “companion diagnostics”, the region is home to many specialised service providers and subcontractors which concentrate on the early phases of
pharmaceuticals development and are highly regarded internationally for their specialist know-how. Caprotech GmbH, whose
Caprotecs Capture Compound Mass Spectrometry (CCMS) permits the function-specific isolation and identification of proteins,
serves as an example. The system offers both the identification
of the mechanism of action of a molecule and determination of
its interaction partners, which may be responsible for side effects.
Another biotech company, EPO GmbH, provides a unique and
outstanding source for cancer research projects. They offer the
right models for every preclinical development phase, from target identification and validation to translational research.
In many of the region’s academic institutions, research into a
number of topics in personalised medicine is under way. The potential is huge and diverse, which makes it all the more important
that it has now been concentrated and highlighted by the establishment of two new beacons. The first is the Berlin Institute of
Health (BIH) which brings together the patient-focused research
expertise of Charité – Universitätsmedizin Berlin and the basic
research of the Max Delbrück Centre for Molecular Medicine
(MDC) even more closely than before in a joint institution. The
second is the Integrative Research Institute (IRI) for the Life Sciences, which was founded in Berlin in early March 2013 and
whose interdisciplinary work will extend from knowledge about
life at the molecular level to complex organisms (see page 36).
Berlin-Brandenburg offers a broad portfolio of potential answers
to the challenges facing the pharmaceutical industry, in particu16
Jean-Luc Delay
Managing Director
Takeda Pharma Vertrieb GmbH & Co. KG
As a global company, we want to be present in the German
capital. Takeda is Japan's as well as Asia's largest pharmaceutical manufacturer, and Berlin offers several advantages
to us: proximity to the governmental and regulatory bodies,
to important industry associations such as the Association of
Research-Based Pharmaceutical Manufacturers (vfa), and to
other pharmaceutical companies. From Berlin, we direct all
activities for the German market. And: one of our two production sites is also located in the Berlin region. The Takeda plant
in Oranienburg is a state-of-the-art production facility for various types of tablets and capsules.
lar with regards to the integration of different players from the
science and biomedical services sectors in the early phases of
development. The project OncoTrack is an impressive example.
An Outstanding Network for Personalised Therapies
OncoTrack is a consortium of more than 80 scientists that has
launched one of Europe’s largest collaborative research projects
between academia and industry to develop and assess novel approaches for the identification of new markers for colon cancer.
The project brings together top scientists from European academic
institutions offering a wide range of expertise, and partners them
with pharmaceutical companies. Consortium members from the
Berlin-Brandenburg area play a vital role in the project, with six
partners from clinics (Charité), non-university research institutes
(Max Planck Institute for Molecular Genetics), the pharmaceutical industry (Bayer HealthCare Pharmaceuticals, Pfizer) and
SMEs (Alacris Theranostics, EPO Experimental Pharmacology &
Oncology). The goal of OncoTrack is to improve our understanding of the variable make-up of tumours and how it affects the
way an individual patient responds to treatment. This project is
one example how our understanding of the fundamental biology
of colon cancer can be advanced and will open the door for personalised therapeutic management of cancer patients.
You need commitment, focus and
passion to find new ways to fight the
diseases of this world: innovation
is at the heart of it.
Innovation for better health. Our commitment
is to bring to patients around the world quality
medicines for use in diagnosing, combating and
preventing disease. Every day we work against time,
researching new pathways, new molecules, new
technologies – complementing our own capabilities
with exper tise of innovative partners from science
and industry.
www.bayerhealthcare.com
www.bayerpharma.com
The success of this work is evidenced in new
medicinesforareaswithsignificantunmetmedical
need such as oncology, cardiovascular and blood
diseases, as well as gynecology and ophthalmology.
Our aim is a better quality of life for all.
BioTOP-Report
Diagnostics
An Excellent Location for the Development of
Innovative Diagnostics
In Berlin-Brandenburg bioanalysis is a focus area of research and development. Some 100 companies and
more than 20 research facilities present the entire value chain from biomarker identification through clinical
validation to the production of in vitro-diagnostics.
Early, specific and reliable laboratory diagnostics makes a key
contribution to disease detection, therapy optimisation, and prevention. Its importance can therefore barely be overrated, given
the many challenges facing our healthcare systems. Progress in
biomedical basic research and the development of new analytical
techniques and methods has resulted in a tremendous increase
in the performance of diagnostic laboratories over the past decades.
Charité provide access to patient cohorts of the urban and rural population with some 180 different ethnic backgrounds and
covering virtually all medical themes. The development of the
German capital region as an internationally desired location for
diagnostics development is an outstanding example for the successful implementation of the Common Innovation Strategy of
the States of Berlin and Brandenburg (innoBB) and a major component of the HealthCapital cluster.
New sensor-actor molecules, autonomous biosensors, genome,
proteome and glycan-based multiplex analytics as well as metabolomics platforms provide the foundation for the development
and implementation of innovative biomarker strategies. Companion diagnostics for personalised medicine are rapidly gaining
in importance based on these new insights and developments.
Diagnostic know-how for outstanding development
and patient care
In light of this, Berlin-Brandenburg has become an internationally leading location for research and development in laboratory
medicine and for the implementation of clinical studies. The wide
range of specialised hospitals, clinics for both basic and advanced
care as well as the high-performance university medicine at the
Dr. Florian Kainzinger
Managing Director
Labor Berlin – Charité Vivantes GmbH
With our new central location, we have established the foundation for intensive interdisciplinary exchange between the
specialist laboratories and for the integration of clinical expertise. This high expertise, methodological competence and our
high routine sample volumes of more than 35 million analyses
per annum for more than 400,000 hospital and some one
million outpatients contribute to optimal patient care, while
also forming an ideal basis for the development of improved
IVD technologies.
18
Labor Berlin – Charité Vivantes GmbH is Europe‘s largest clinical laboratory, providing optimal conditions for driving the development of innovative diagnostics in cooperation with leading
companies like BioMérieux, Roche Diagnostics and Thermo Fisher Scientific. Labor Berlin is participating in the development of
a fully integrated automation solution in microbiology and has
introduced a platform for next-generation sequencing (NGS) into
routine analysis.
Since April 2013, the clinical laboratory has been standardising
its operations in a single location at the Charité Campus Vir-
BioTOP-Report Diagnostics
chow-Klinikum. More than 10,000 hospital beds in and around
Berlin will be provided with high-performance diagnostics from
this new location.
Efficient technology transfer based on regional
networks
“BioResponse” and “DiagnostikNet BB” have emerged as company-driven networks whose intensive cooperation with science
has resulted in innovative product developments like the AKLIDES system, which have become international market leaders.
The Centre for Molecular Diagnostics and Bioanalysis (ZMDB) has
driven regional and international cooperation between science
and industry as a successful platform for know-how and technology transfer since 2009. Through the ZMDB, Berlin-Brandenburg
has maintained close links with nine leading European diagnostics regions since 2010 as part of the European Diagnostics Cluster Alliance (EDCA), offering regional SMEs specific market access
support services.
The Technology Forum In vitro-Diagnostics and Bioanalysis organised by the ZMDB has been held in the capital region for the past
five years and is proving to be an excellent platform for initiating
sustainable dialogue between fundamental research and industrial as well as clinical application. The 5th Technology Forum in
June 2013 focused on mass spectrometry, protein arrays and aptamer-based biosensors. A specially designed partnering event
for diagnostics companies and research institutes permitted
meeting new cooperation partners from Europe and was aimed
at fostering and encouraging potential growth opportunities.
Achieve innovation,
shape the future
Start shot for young technology companies
High Tech Gruenderfonds is your partner for Seed Stage investing. We
help out young, high potential startups in the early phases of technology
and product development, as well as successful launching. Our assistance
is not limited to our cash investments, instead we strive to add long term
added-value to portfolio companies through our extensive network of
professional and our accredited coaches.
High-Tech Gründerfonds Management GmbH
re
e
twa
enc
Sci nce
Sof ation
e
f
Li Scie r y
nic erce
mu
ist
ial
om comm
ter Chem
c
a
e
M
el & E&
T
gy
et & edia
olo
M
ern
chn
e
Int
t
no
Na
Ind
rgy
Ene ion
t
a
ics
tom
Au oton re
Ph twa
f
l So
r ia
ust
Schlegelstraße 2 | 53113 Bonn
Phone: +49 (0)228-823001-00 | Fax: +49 (0)228-823000-50
E-Mail: [email protected]
ht tp: // www.high-tech-gruenderfonds.de
INVESTORS OF HIGH-TECH GRUENDERFONDS II
19
BioTOP-Report
Dr. Notghi Contract Research GmbH
Full service CRO
Dr. Notghi Contract Research GmbH is a high
quality service provider for large, medium
and small-sized companies in the pharmaceutical, generics and biotechnology industries. Our full-service offerings include Statistics, Clinical Monitoring, Medical Writing,
Data Management, Study Management,
Pharmacovigilance, Regulatory Affairs, IT
Solutions, & Training Solutions.
For 14 years, our clients have benefited
from our broad expertise in clinical research
to meet their business challenges. We have
successfully supported and advised hundred
of companies in the conduct and management of national and international projects,
enabling them to bring their reliable and
successful products to market in ever shorter periods of time.
Founded by Dr. Arman Notghi, the company
has its headquarters in Berlin as well as an
office in Istanbul, Turkey. Dr. Notghi Contract
Research GmbH has enjoyed continuous
and stable growth thanks to the confidence
placed in us by our longstanding customers
and the dedication of our employees. With
over 90 specialized employees available
across Europe for our clients, we can rapidly
and efficiently respond to a wide range of
requirements. The Dr. Notghi Academy,
located in Berlin, qualifies drug safety officers, clinical research associates and data
managers, offers specialist workshops and
global learning & development solutions for
the Pharmaceutical industry.
Address
Dr. Notghi Contract Research GmbH
Zimmerstraße 55
10117 Berlin
Contact
Melanie Wurzel · Deputy CEO
Phone+49 30 460 64 725
Fax +49 30 460 64 733
[email protected]
www.notghi.com
m
Benefit fro
our Compet
ence
PAREXEL International
PAREXEL International is a leading global
bio/pharmaceutical services organization,
providing a broad range of knowledge-based
contract research, consulting and medical
communications services to the worldwide
pharmaceutical, biotechnology and medical
device industries. Committed to providing
solutions that expedite time-to-market and
peak-market penetration, PAREXEL has
developed significant expertise across the
development and commercialization continuum, from drug development and regulatory
consulting to clinical pharmacology, clinical
20
trials management, medical education and
reimbursement. Perceptive Informatics, Inc.,
a subsidiary of PAREXEL, provides advanced
technology solutions, including medical
imaging, to facilitate the clinical development process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 78
locations throughout 52 countries around
the world, and has approximately 14,400
employees.
PAREXEL has a long-standing presence in
Berlin, where over 1,500 employees are
located. Clients can benefit from state-ofthe-art technologies and equipment provided through PAREXEL’s medical imaging lab
and Early Phase Units, which provide a safe,
high-quality environment for early phase
development activities in a hospital setting.
The PAREXEL Academy located in Berlin
qualifies clinical research associates and
clinical data managers, and offers a course
for a Bachelor of Science degree in Clinical
Research, validated by a British university.
Address
PAREXEL International GmbH
Klinikum Westend · Haus 18
Spandauer Damm 130
Contact
Dr. Ulf Schneider
Corporate Senior Vice President and Chief
Administrative Officer
Phone+49 30 30685 115
Fax +49 30 30685 7115
[email protected]
www.PAREXEL.com
Tradition and Innovation based in Berlin
Research is carried out here
Our research focuses on: analytical chemistry, pharmaceutical
development and clinical research. Our findings lead to innovative
and proven quality compounds. In this way, we improve quality of
life for many people.
Here we produce ...
The main focus of our product portfolio is medication for pain and
diabetes therapy as well as for the treatment of disease relating to
the cardiac and circulatory system or the thyroid gland.
Patients have placed their trust in our medicines for over 100 years.
From here we apply our know how on the market ...
Especially in the eastern European markets; there we have over 31
representative offices. We supply patients worldwide within the
Italian Menarini Group network.
BERLIN-CHEMIE, a company in the Menarini Group, stands for
tradition and innovation from Berlin.
For more information:
BERLIN-CHEMIE AG · Glienicker Weg 125 · 12489 Berlin
Phone: +49 30 6707-0 · www.berlin-chemie.de
BioTOP-Report
Industrial Biotechnology
Focus: Biopolymers and Bio-based Plastics
Bioplastics are still niche products today, but that is due to change soon. The reason: Bioplastics offer enormous
potential for business and the environment. They are expected to find application in many industries soon, be
it as biodegradable mulch foil for agriculture, “green” packaging for food, or light-construction components
for cars. Germany is investing increasingly in the development of biopolymers and bioplastics, for example as
part of its national research strategy BioÖkonomie 2030.
The term bioplastics designates three types of materials: biobased plastics, i.e. plastics produced on the basis of biomass, petroleum-based biologically degradable plastics and those which
are both, i.e. bio-based and biologically degradable.
Biopolymers are the precursor of bio-based plastics. Biopolymers
either occur naturally (like cellulose, starch, lignin and proteins)
or they are biotechnologically manufactured polymers (like bacterial cellulose) or polymers whose synthesis components are
made of renewable raw materials (like sugar or vegetable oils).
Alongside the bio-based versions of classical polymers produced
on the basis of petroleum (like PE, PP or PA) – the so-called dropin solutions – there are now new polymers like PLA or PHA.
Biopolymer market set to grow in the coming years
Market analyses predict an exciting future for the use of biopolymers with above-average growth. According to the Nova Institute, production capacity worldwide is to reach 12 million tons by
2020, tripling the volume of 2011. A great variety of materials
and products is expected. The number of manufacturers, processing companies and, above all, users is set to rise strongly during
the coming years. Materials made of biopolymers will be used
in a wide range of application areas: in the packaging industry,
the life sciences, in architecture and the design industry, in agriculture and forestry or in light construction – for example in the
transport industry.
One great advantage of the biopolymers is that they are based
on renewable resources and therefore reduce petroleum consumption. In addition, some biopolymers and bio-based plastics
(e.g. PLA) have special characteristics which cannot be achieved
with petroleum-based polymers, or only at considerable expense.
Since the production of biopolymers and bio-based plastics is to
grow strongly in the next few years, we can expect that rising production volumes and increased market penetration will reduce
22
the presently still existing disadvantages in terms of both cost
and optimised processing methods.
High potentials for cross-innovations
Plastics are everywhere and everyday life is no longer conceivable without them. Items of daily use like pens, USB sticks, mobile phone covers, breadboxes, toys or citrus presses – many
products are already on the market in bio-based versions. Innovative products are also being developed which use the specificity of biopolymers, e.g. more environment-friendly disinfestation
systems for forestry, protein foils for bio-diapers, components
for facade casings or packaging foils made of stale bread. When
developing new system solutions, it is essential to involve both
the raw material supplier and end user from the start to create
Dr. Karl Heinz Tebel
Chairman of the managing board of BASF
Schwarzheide GmbH
Cluster spokesman for plastics and chemistry of
the state of Brandenburg
As cluster spokesman for plastics and chemistry of the state
of Brandenburg, I am pleased that the establishment of
the “Innovationszentrum Bioplastics Lausitz” succeeded in
close cooperation of Fraunhofer Institute for Applied Polymer Research with Kunststoffverbund Berlin/Brandenburg
(KuVBB) and BASF, and innovative approaches to dealing
with this interesting group of products are investigated at the
newly launched Fraunhofer- “Competence Centre for Bioplastics Processing” at the BASF site in Schwarzheide. I am certain
that such projects and initiatives pave the way for additional
businesses to settle in Brandenburg.
BioTOP-Report Industrial Biotechnology
comprehensive and interdisciplinary concepts for sustainable
products.
opment – the region supports the plastics processing industry in
the introduction of biopolymers and bio-based plastics.
Innovation centre in the Lausitz
As an important source of inspiration for the innovation centre,
the innovation forum “Biopolymers and Bio-based Plastics” was
organised by BioTOP Berlin-Brandenburg, Kunststoffverbund
Berlin Brandenburg e.V., BASF Schwarzheide GmbH and the
Fraunhofer IAP in late 2012/early 2013. Some 200 experts from
the region and beyond met in three thematic workshops and a
closing conference. The opportunities and challenges in the use
of biopolymers and bio-based plastics were discussed intensely and new concepts for knowledge-based development of the
Lausitz as a centre for bio-based plastics were presented.
In Berlin-Brandenburg, attention focuses increasingly on the topic of biopolymers. The “Innovationszentrum Bioplastics Lausitz”
(innovation centre) in southern Brandenburg is emerging as a
growth driver for biopolymers, in particular as regards their processing. The logistic advantages of the BASF location and the
expertise of the “Competence Centre for Bioplastics Processing”
which was set up in April 2013 as a branch of the Fraunhofer
Institute for Applied Polymer Research (IAP) in Schwarzheide create an optimal environment for the location of more biopolymer
manufacturing and processing companies in the region. From
material selection, through process technology, to product devel-
More information is available at: www.bioplastics-lausitz.de.
Fraunhofer IBMT · Branch Potsdam
The Potsdam branch of the Fraunhofer Institute for Biomedical Engineering IBMT focuses on the development of highly innovative
solutions based on modern biotechnology.
The range of research activities and services
is characterised by extensive expertise in
the fields of cellular biotechnology, nanobiotechnology, meta-biobanking, functional
surfaces, molecular bioanalytics, lab automation, cell-free protein synthesis and
extremophile research on cryophilic snow
algae. A major focus is currently placed on
the development of systems and technologies for medical in vitro-diagnostics (ivD).
Both highly motivated scientists from different disciplines and excellently trained engineers pool their expertise at the IBMT and,
together with state-of-the-art-equipment,
provide the basis for understanding the
partner’s needs and successful projects.
We would be glad to be your reliable partner
in research and development - don’t hesitate
to contact us!
Address
Fraunhofer Institute for Biomedical
Engineering IBMT
Branch Potsdam
Am Mühlenberg 13
14476 Potsdam-Golm · Germany
Phone +49 331 58187 0
Fax +49 331 58187 199
Contact
Prof. Dr. Frank F. Bier
[email protected]
www.ibmt.fraunhofer.de
23
Biopeople
Denmark’s Innovation Network for Health & Life Sciences
Innovation across disciplines
To stimulate innovation we create meeting places that bring researchers and industry stakeholders together across disciplines, sectors and public-private boundaries.
Our aim is to benefit global health and welfare by providing a framework that helps
academia and industry to meet, co-create and develop ideas into new projects,
products and services. Among our core services are matchmaking and knowledge
sharing activities, as well as facilitation and brokerage of innovation projects.
“To stimulate innovation we create meeting places
that bring researchers and industry stakeholders together across disciplines”
Denmark’s Innovation Network for Health & Life Sciences
Biopeople embraces and gathers the vast majority of public and private research
within health and life science in Denmark. The network includes all relevant Danish
universities, research institutions and hospitals plus the Danish Health and Medicines Authority. On the private side, industry associations contribute their resources,
and we have numerous pharma, medtech, food and biotech companies as members
of Biopeople.
Collaboration across boarders
Biopeople is part of the Danish infrastructure for innovation established and cofunded by the Ministry of Science, Innovation and Higher Education. We have an
International outreach that helps Danish companies and researchers to establish
cross border collaborations and vice versa. We also welcome German companies
within life science to join the network.
For more information please contact
Science Liaison Officer
Elias Zafirakos, MSc CE, EBA
[email protected]
Universitetsparken 2
2100 Copenhagen O
DENMARK
Or visit us at
www.biopeople.dk
BioTOP-Report
Global Business
New Markets and Horizons for Global Business
The Bioregion Berlin-Brandenburg promoted the theme of internationalisation in 2012 with a wide range of
activities and events. The Dialog Forum on Life Sciences in Brussels, the first European Technology Forum on
in vitro-Diagnostics, joint events with the French, British and Canadian embassies and a major survey on the
international activities and strategies of regional companies underscore the importance of internationalisation
in the healthcare industries cluster – HealthCapital.
The Region Presents Itself in Excellent
Shape in Brussels
In May 2012, the so far largest and most international Dialog
Forum with the European Commission was held in the state representation offices of Berlin and Brandenburg in Brussels. Representatives of science and industry from Berlin-Brandenburg
presented their latest projects and innovations to an audience
of more than 100 in a plenary and three workshops. They also
received feedback from Commission representatives on funding
options in the HEALTH segment of the EU Seventh Framework
Programme for Research and gained important insights into the
new focus of European research funding under Horizon 2020.
The evening reception provided an ideal platform for networking
and exchange about future project ideas among all participants
and, above all, with representatives from seven other European
regions.
In addition, information about the funding options for non-health
related biotechnology research and development was obtained in
the joint workshop on “Knowledge Based Bioeconomy” with the
German National Life Sciences Contact Unit in September 2012.
The First IVD Conference and European
Corporate Partnering in Berlin
In June 2012, experts in the fields of in-vitro diagnostics and bioanalytics met for the 4th Berlin-Brandenburg Technology Forum
at Charité - Universitätsmedizin Berlin. The event focussed on
personalised medicine and next generation sequencing. Foreign
companies had also been invited for the first time to meet partners in this field at the event. Some 170 participants from 11
countries came to the Charité to hear lectures by experts from
science and industry. About 46% of the audience represented
companies, while 13% of all participants came from abroad.
A partnering session for companies and research facilities was
therefore organised in parallel with the conference in cooperation with the Enterprise Europe Network. In addition, 20 companies and institutions from 11 countries exhibited their products,
services and technologies in an industry show. The largest and
most international Technology Forum to date also featured an extensive accompanying programme comprising an early evening
reception, guided tours of prestigious research institutes and a
sightseeing programme.
Partner of Choice for Embassies
The German-French Expert Workshop organised jointly with the
French Embassy took place in November 2012. Some 136 registered participants attended talks on “Systems Biology: From Modelling to Therapy of Complex Diseases”. The aim of the event was
to present the current state of research, the funding programmes
currently available as well as projects in the field of systems biol25
BioTOP-Report Global Business
Dr. Tohru Noji
Head of Global Corporate Advisory Europe
Industry Research Division at
Mizuho Corporate Bank Ltd.
London/UK
Having performed a detailed cluster analysis of several European clusters, we perceive the Biotech Cluster of the German
Capital Region as one of the leading in terms of business
facilitation efforts and support. It offers the best conditions
for becoming a fertile breeding ground for collaborations
between Japan’s industry and European biotech partners.
denburg and, in particular, the region’s bioeconomics activities
during an exploratory visit to Brazil sponsored by the BMBF and
devoted to the theme of bioeceonomics. As a follow-up, representatives from the BioRegion took part in the “German – Brazilian
Partnering Event on the Way to a BioInnovation Hub” on 26 and
27 November 2012 in Sao Paulo and submitted several project
applications for the tender invitation “Bioeconomy International”.
ogy and to provide experts from both countries with a platform
for intensive exchange and discussion of possible cooperative
ventures.
Japan was another target country for international networking
in2012. For many years, the Japanese pharmaceutical industry
was mainly interested in cooperation with US biotech companies,
but Europe is gradually gaining in importance as a partnering
region. This made it all the more pleasing to see that Industry
Research Division of the Japanese „megabank“ Mizuho Corporate
described the Bioregion Berlin-Brandenburg as one of Europe’s
leading regions for biotechnology in its report “Life Sciences and
Biotechnology Industry Clusters in Europe” which was published
in February 2013.
In the context of a joint presentation of the regions Ontario and
Québec in August 2012, many representatives from the region
were able to familiarise themselves with the focus areas of research and production in the field of cardiovascular diseases in
Canada and meet experts from there in the Canadian Embassy.
In return, a delegation of Canadian entrepreneurs attended this
year’s Berlin-Brandenburg Technology Forum on In-vitro Diagnostics on 5-6 June 2013, thereby extending the international
dimension of the previously European event to overseas (see
page 19).
Innovative projects of scientists and companies from Britain and
Berlin-Brandenburg in the fields of nano- and regenerative medicine were already presented in June 2012 in the British Embassy.
In addition, BioTOP made a major contribution to the programme
design of the successful delegation tour on the occasion of the
state visit of the Grand Duke of Luxembourg in Berlin.
Focus on New Markets: South America and Japan
The BRIC states (Brazil, Russia, India and China) are markets of the
future with huge populations, high growth and partly vast investments in their technology and research infrastructures. In Berlin-Brandenburg, too, biotech companies are setting their sights
on these countries and potential BRIC cooperation partners. In
2012, BioTOP participated in two delegation tours arranged by
the German Ministry of Education and Research (BMBF) to South
America to prepare the ground for future cooperation projects.
BioTOP was an active participant in German-Columbian government discussions in Bogotá in June as an expert for the development of cluster structures in the life sciences sector, and in
August 2012 we presented a talk on the BioRegion Berlin-Bran26
Customised Services and Support based on Needs
Biotechnology is shaped by global research and marketing cooperation, so that companies are exposed to international competition from the start. Biotech companies in Berlin-Brandenburg
understand that and regard the expansion and consolidation of
their international activities as a key component of their business
operations. Nonetheless, entry into European and overseas markets is often difficult and raises a range of uncertainties especially
for small and mid-sized companies (SME).
To take proper account of the needs of the players in the HealthCapital cluster Berlin-Brandenburg in its future internationalisation strategy, BioTOP conducted a major survey of SMEs, hospitals and institutes in the life sciences sector in 2012. The survey
also included app. 70 biotech companies in the region which
were interviewed about their international business activities,
existing forms of cooperation with foreign partners, their future
target markets and their need for support as regards funding or
presentations at fairs and exhibitions. The preliminary evaluation
has already shown: Not even the smallest company can afford
to ignore the theme of internationalisation today and pursue a
purely regional or national business strategy. Supporting companies in their internationalisation efforts must be the aim of all
our activities.
PDA Europe:
The European Headquarters of the
Parenteral Drug Association in Berlin
The international non-profit organization PDA is the leading global provider of science, technology and regulatory
information and education for the pharmaceutical and biopharmaceutical community. With more than 10,000
members who are active in the development, manufacture, quality control and registration of medicinal products
worldwide, our aim is to develop scientifically sound, practical technical information and resources to advance
science and regulation for the pharmaceutical and biopharmaceutical industry as well as regulatory bodies.
PDA‘s events include conferences, meetings, and workshops held worldwide, where manufacturers, suppliers
and scientists of the industry and governmental bodies meet to discuss major issues of mutual interest. This
exchange of technical knowledge and expertise assist the advancement of pharmaceutical science and technology in the interest of public health.
PDA develops technical information, e.g. Technical Reports
(www.pda.org/Publications), comments on drafts of authority guidelines, organises events like congresses, workshops, Interest Group Meetings and training courses.
Become a member, join committees and events, and take
advantage of the exchange in expertise among experts
from the entire world.
Our members belong to the global players of the pharmaceutical industry, biotechnology companies, start-ups,
suppliers, and authorities.
Topics include everything which is important to the manufacture and quality control of pharmaceutical products.
Some of the multifarious activities include process validation, monitoring, development of freeze drying cycles, GMP
concept for gene-therapy products, virus deactivation and
visual inspection of products.
Find more information about all upcoming events on our
website under europe.pda.org or under www.my-PDA.eu
for your mobile devices.
Upcoming Events 2013 - 2014
11-12 September
Workshop, Exhibition, Training Courses
6th Workshop on Monoclonal Antibodies
24-27 September
Conference, Exhibition, Training Courses Pharmaceutical Freeze Drying Technology
Düsseldorf
8-11 October
Conference, Exhibition, Training Courses Pharmaceutical Cold Chain Integrity
Berlin
4-8 November
Workshop, Conference, Exhibition,
Training Courses
The Universe of Pre-filled Syringes
and Injection Devices
Basel
18-19 February
Conference, Exhibition
Microbiology Endotoxins RMM
Berlin
11-12 March
Conference, Exhibition
Parenteral Packaging
Brussels
For general information
please contact:
PDA Europe, Adalbertstr. 9
16548 Glienicke / Berlin, Germany
Tel: +49 (0) 33056 - 23 77 10
Fax: +49 (0) 33056 - 23 77 77
Email: [email protected]
Basel
For exhibition information
please contact:
Elke von Laufenberg
Exhibition & Sponsorship Manager
PDA Europe
Tel: + 49 (0) 33056 - 23 77 14
Email: [email protected]
europe.pda.org
Anzeige_VBKI.indd 1
03.06.13 10:49
BioTOP-Report
Business Location
Excellent Services for Berlin-Brandenburg
Due to its high concentration of science and research establishments, the Berlin-Brandenburg region offers outstanding potential for technological development and cooperation. The joint Life Sciences Team from the Berlin
Partner business development agency and the Brandenburg Economic Development Board ZAB supports the
life sciences industry with a full range of services, including marketing activities at national and international
exhibitions. Berlin-Brandenburg stands out in the life sciences because every segment of the health industry
is present here. The high concentration of international excellence facilitates interdisciplinary exchange and
makes it easier to achieve new landmark developments. At the same time, the sheer number of players can
make it difficult to find the right partner. Our staff and colleagues at BioTOP have been in direct contact with
the region’s companies and scientific institutions for many years and can provide quick access to the right
contacts and potential partners.
In 2012, the Berlin Partner Life Sciences Team supported expansion projects and provided location services to 22 companies in
the capital region, which will create around 500 new jobs in the
next three years. One of them is Takeda Pharma Vertriebs GmbH
& Co. KG. Since autumn 2012, Takeda has been directing all its
marketing and sales activities for the German market from Berlin with some 100 employees. In addition, service functions for
Austria and Switzerland are also centralised in Berlin. And one of
the company’s two production sites in Germany also located in
the capital city region: The plant in Oranienburg is a state-of-theart production facility for tablets, caplets and capsules with more
than 500 employees.
particular mention. The joint acquisition team with Berlin Partner
arranged the location of Analytica Alimentaria GmbH in Kleinmachnow, while a further direct investment supported by the
team concerns the company plusBlut GmbH in Hennigsdorf.
In 2012, the region was represented with its own booths at four
important international fairs. The aim was to position the region’s
companies on the global markets and present the cluster of the
healthcare industries in Berlin-Brandenburg – HealthCapital – as
one of Europe‘s leading health sector locations.
Berlin Partner also organised an information booth at BIO 2012
in Boston and BIO 2013 in Chicago. As in the years before, the
Berlin-Brandenburg Night was held on the opening day of BIO.
Bayer Healthcare acted as the lead sponsor once again. Both
events attracted some 400 international guests from biotechnology and pharmaceutical companies, which followed the invitation from HealthCapital and Bayer HealthCare.
Carolin Clement
Head of Unit Biotech I Pharma
Berlin Partner for Business and Technology
Phone: +49 30 39980230
[email protected]
www.berlin-partner.de
In the field of the life sciences, ZAB supported almost 70 investment and innovation projects in Brandenburg, which created
app. 150 new jobs. The successful location of technology-based
start-ups like OakLabs GmbH and t-cell Europe GmbH deserves
28
Dr. Ute Hartmann
Head of Department Healthcare Industry/Life Sciences
Brandenburg Economic Development Board (ZAB)
Phone: +49 331 20029250
[email protected]
www.zab-brandenburg.de
Life Sciences.
Living Research.
Berlin. Brandenburg.
A vibrant network
Berlin-Brandenburg is one of Europe’s leading locations for the
Life Sciences. It is also an R&D capital that magnetically attracts
the world’s top scientists. Here you’ll find attractive subsidy conditions, close linkages between business and science, the highest
concentration of R&D in Europe, a dynamic startup scene and a
multifaceted entrepreneurial environment made up of more than
500 pharmaceutical, biotech and medical engineering companies.
Come discover this one-of-a-kind landscape for scientists and
entrepreneurs.
www.healthcapital.de
BioTOP-Report
Technology Transfer
Technology Transfer between
Science and Business
Project concepts in the life sciences are usually very complex. It may sometimes take decades until ideas and
insights from basic research can be made available for commercial use. Many initiatives now exist which aim to
accelerate that process and render the usually non-linear development processes more systematic. This applies
to the research location Berlin-Brandenburg in particular. The capital region’s unique research and university
landscape possesses an enormous potential in terms of knowledge and ideas, which can be converted into new
product developments. The German federal government and the states have recognised the need for technology transfer instruments and programmes. A number of programmes to support patent commercialisation, university spin-offs and cooperation between research facilities and companies have already been implemented.
Vouchers for Transfer
Close cooperation between science and industry is a key precondition for successful transfer of technological knowledge from academic research into companies. Cooperative ventures between
SMEs and research facilities are supported by the “TransferBONUS” programme in Berlin and the “Innovation Voucher” initiative in Brandenburg. They reduce the financial costs incurred by
companies which award research assignments and ease their
Dr. Rolf Strittmatter
Managing Director
ZukunftsAgentur Brandenburg GmbH
With its innovation vouchers, the State of Brandenburg is
helping small and mid-sized companies establish and extend
contacts with universities and other academic institutions
by supporting small research and development projects. The
aim of this successful programme is to create stronger ties
between business and science, overcome barriers and foster
innovations based on cooperation. More than 300 innovation
vouchers were assigned since 2010. They enable companies
in Brandenburg to buy research expertise and obtain support
funding of up to € 15.000. More than 30 of the initiatives
supported to date were health sector projects on themes
ranging from software development for health applications,
design solutions for patient care and new telemedical applications. They all document the increasing interconnection
between the health economy and adjacent sectors.
30
access to the latest insights in science and research. These two
funding programmes thereby help improve the participating
companies’ innovation capacity and competitiveness and hence
secure a successful future for them. Up to 70 % of the contract
volume of research services can be supported in this way, with a
maximum of 15,000 Euros. Both programmes have been taken
up very well: In the health economy sector, twelve TransferBonus
projects were funded in 2012, while Brandenburg help launched
six projects with its Innovation Vouchers.
i2m: Ideas to Market
Projects in science usually aim to generate research results. Their
developments therefore often end at a point where it is hard to
convince investors and licensees that they can be translated into
a product. Scientists find it difficult to assess the commercial value of their ideas, and what is usually lacking is also the “proof of
concept”, in other words: the validation of their idea. This is the
initial point of action of the project i2m (“ideas to market”) sponsored by the states of Berlin and Brandenburg. i2m aims to transfer promising projects more quickly from the academic sphere to
commercial application and thereby close the gap between publicly funded academic basic research and industrial development.
The initiative specifically addresses scientists in basic research
and project developers who had few opportunities for commercialisation to date. For every project, the aim is to jointly develop
the proof that efficient implementation is feasible. “Impfzervix”
at the Charité is one of the projects supported. It aims to achieve
accelerated development of a therapeutic vaccine for gentle
treatment of cervical cancer. i2m supported the project launch
and funding application and thereby helped procure 1.5 million
Euros in support funding. More than 30 projects were supported
BioTOP-Report Technology Transfer
Financing and Added Value
Venture Capital
for companies in Berlin
successfully to date, and it has become clear that i2m can trigger
a cascade of development steps in many projects helping to bring
the respective product to market.
“Entrepreneurial Network University”
In the life sciences, Freie Universität (FU) Berlin and Charité –
Universitätsmedizin Berlin benefit from the nationwide competition “EXIST – University-Based Business Start-Ups”. For their
concept of an “Entrepreneurial Network University” (ENU) they
received 2.8 million Euros from the German Federal Ministry of
Economics and Technology. The two institutions can now implement the concept with support funding until 2018. They have
cooperated in founder promotion since 2009. This cooperation
is now to move to a new dimension under the umbrella of the
ENU and to be extended to additional partners. Special attention
will be devoted to the consolidation of IT-technologies with applications in the health sector into the joint focus health-IT, as the
interface between the life sciences and IT is gaining increasing
importance to the development of innovative medical processes
and products.
IBB Beteiligungsgesellschaft mbH offers equity financing for high tech companies in Berlin. For our fund
VC Fonds Technologie Berlin (€52m) we are looking
for investment opportunities in the biotechnology and
medical technology sector.
Our investment approach is based on hands-on involvement and active management support for each
portfolio company, delivered by our highly experienced investment team. VC Fonds Technologie Berlin
not only provides capital, but also helps execute the
business plan.
Are you interested? Please do not hesitate to contact us.
Prof. Dr. Peter-André Alt
President of Freie Universität Berlin (FU)
With our Entrepreneurial Network University, we want to
promote networking between science and industry and the
founder spirit among young people. The joint founding activities of Freie Universität Berlin and the Charité will concentrate
on the health economy as a focus area. Here, we can benefit
from existing networks, sector initiatives and events, from the
companies already located here, from outstanding extramural
research facilities and from the initiatives of the cluster management unit HealthCapital. And we also want to contribute
our own initiatives. One example: in the United States, private
incubators like ‘Health Box’ and ‘Rock Health’ already utilize
the increasing founder potential on the interface between IT
and the health sector. The ENU will be the first German university to establish a pre-incubator for this business field.
IBB Beteiligungsgesellschaft mbH
Mrs. Ute Mercker / Mr. Christian Seegers
Bundesallee 210
10719 Berlin / Germany
Phone: +49 (0)30 2125-3201
www.ibb-bet.de
Selected portfolio companies:
VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank
Berlin (IBB) and the State of Berlin. It is co-financed by the European Regional
Development Fund (ERDF).
31
BioTOP-Report Technology Transfer
CoLaborator: An incubator space for start-ups
Alongside many publicly funded initiatives, Bayer HealthCare announced its concept for a second CoLaborator after San Francisco
at its Berlin location in May 2013. The new CoLaborator of Bayer
HealthCare will be established in direct vicinity to the company’s
own research laboratories and provide suitable premises for rent
for up to ten bioscience start-ups whose ideas, developments
and technology platforms match Bayer’s own research activities.
Internal research at Bayer HealthCare focuses on four core therapeutic fields: oncology, cardiology, gynaecology and haematology.
The project will support the young entrepreneurs in establishing
their research labs and, if desired, act as their first contact for
cooperation with industry. The CoLaborator has a building of its
own with an area of app. 800 sqm, of which some 420 sqm are
laboratories.
Prof. Dr. Andreas Busch
Member of the Executive Committee of Bayer
HealthCare and Head of Global Drug Discovery
Cooperation with academic partners and biotech companies is
a key element of Bayer HealthCare’s innovation strategy. We
strongly believe that jointly using the enormous knowledge
inside and outside the company will help us to get a better
understanding of major disease mechanisms and to improve
drug development. The new CoLaborator in Berlin will foster
communication and cooperation with innovative partners in
Berlin.
Berlin/Bremen/Cologne/Frankfurt/Hamburg/Munich/Stuttgart
Life sciences companies are in safe hands with UHY.
UHY Deutschland AG is a joint venture of long established auditing and consulting firms with a total of 250
employees and partners.
UHY Deutschland AG has extensive experience in financial and consulting services for life sciences companies
for many years. We offer the following services:
As a member of UHY International, a global association
of independent accounting and consulting firms with
over 7,000 employees we can provide audit, accounting, tax and consulting services in 270 business centres
across the globe.
p pAudits of financial and consolidated statements
under the German Commercial Code (HGB) and
IFRS
p pAccounting & Reporting
p pDue diligence (financial and tax) and business
valuations
p pConsulting services on IPOs
p pBusiness Advisory
p pMergers & Acquisitions (M&A)
p pGerman and international taxation
32
Contact
Dr. Ulla Peters
UHY Deutschland AG Wirtschaftsprüfungsgesellschaft/Zimmerstraße 23/D-10969 Berlin
Phone +49 30 226593-0/Fax +49 30 22679050/www.uhy-deutschland.de/www.uhy.com
Life Sciences from A to Z
Excellence, Diversity and
Critical Mass in the Capital
Region
What are the main projects of the region’s researchers?
What are their answers to important future challenges
in the life sciences?
Stay informed, download BioTOPics45 at:
www.healthcapital.de/biotechnologie
BioTOP-Report
Life Sciences
A Science and Research Hub
Nationally and internationally, Berlin-Brandenburg is regarded as one of the leading life sciences hubs. The
region offers optimal conditions for this field as a TOP life sciences location with five universities, many higher
education facilities and a unique extramural research density. Its most prestigious institutions in biotechnology
and the life sciences include four Max Planck Institutes, four Leibniz Institutes, two Fraunhofer Institutes and
two centres of the Helmholtz Association. In addition, the region is home to a wide range of hospitals, headed
by one of the largest university hospitals in Europe, Charité – Universitätsmedizin Berlin.
From pharmaceutical research, through diagnostics, theranostics
and molecular genetics, to the development of innovative biomaterials for medical application, scientists from diverse disciplines, including medicine, biology, chemistry, nutrition science,
bioinformatics, pharmacology and physics, cooperate closely in
the German capital region. In addition to scientific expertise, Berlin-Brandenburg also offers an excellent infrastructure with its
wide range of networks and transfer platforms which link universities, research facilities and users. A new dimension in the transfer of insights from basic into clinical research is now provided
by the Berlin Institute of Health (BIH) which was opened in June
2013 and will further enhance the position of the capital region
as a leading centre for translational and systems medicine. You
will find more information in this topic on page 36.
Ideas for biobased products of the future
Biotechnology know-how is finding areas of application with considerable potential beyond the healthcare sector. The development and production of biomass-based plastics will be in increasing demand in the future and also offers major opportunities for
the innovation capacity and economic potential of Berlin-Brandenburg. Of special importance to this field are the Leibniz In-
APRIL 2012
JULY 2012
The Berlin scientist Tatiana Krotkova of Leibniz-Institut für Molekulare Pharmakologie (FMP) and of NeuroCure cluster of excellence at Charité-Universitätsmedizin Berlin receives this year's research award for young scientists
from Human Frontier Science Programs (HFSP) ++++ MDC-researcher Prof.
Michael Gotthardt and Prof. Norbert Hübner discover a new mechanism for
myocardial disease in collaboration with colleagues from the USA ++++ A
10.000 Euro research award of the Deutsche Rheumaliga is awarded to the
Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)
1100 years in 100 seconds: The Berlin scientist Leif Schröder at the FMP has
breakthrough with his group in new diagnosis method ++++ Neuronal stem
cells destroy brain tumours – MDC and Charité-scientists elucidate new mechanism of action
MAY 2012
Max-Delbrück-Centrum receives multi-million euro funding for a GermanIsraeli doctoral training programme ++++ A common matter of the heart for
140 top scientists: German Centre for Cardiovascular Research ++++ At the
Institute for Biomaterial Science of Helmholtz-Zentrum Geesthacht in Teltow,
a new Helmholtz graduate school for macromolecular bioscience is being set
up ++++ Transatlantic Consortium for Regenerative Medicine founded in Berlin ++++ Charité – Universitätsmedizin Berlin reaches rank 1 of Focus-ranking
"Germany's best hospital"
JUNE 2012
Charité – Universitätsmedizin Berlin attracts another graduate school in the
Excellence Initiative: Berlin School of Integrative Oncology ++++ John-Hopkins-University and Fraunhofer Heinrich Hertz Institute sign agreement in
principle to jointly develop medical applications of integrated optical sensors
34
AUGUST 2012
MDC-scientists Dr. Sandrine Sander and Prof. Klaus Rajewsky of MDC BerlinBuch discover new key element in formation of Burkitt lymphoma ++++ Gertrud Reemtsma Foundation awards HU-biophysicist Peter Hegemann as cofounder of optogenetics with the Zülch-Preis 2012
SEPTEMBER 2012
Scientists of Charité – Universitätsmedizin Berlin and Labor Berlin succeed in
deciphering the molecular signature of Hantavirus infection in humans ++++
Graduate school BSRT receives support from the Friede Springer Foundation
OCTOBER 2012
A team of scientists around Anna Flögel of German Institute of Human Nutrition (DifE) and Tobias Pischon of Max-Delbrück-Centrum (MDC) identified
14 new biomarkers for type-II diabetes which can be the foundation of the
development of new ways of therapy and prevention for the metabolic disease. ++++ The World Health Summit brings top-class participants to Berlin
for the fourth time.
BioTOP-Report Life Sciences
stitute for Agricultural Engineering (ATB) in Potsdam-Bornim
whose research focuses on resource-efficient and carbon-neutral
use of biological systems for the production of foods, raw materials and energy, and the Fraunhofer Institute for Applied Polymer
Research (IAP) in Potsdam-Golm, which is a leading provider in
the field of applied cellulose and starch research and opened a
competence centre for biopolymer processing at the BASF site
Schwarzheide in April 2013 (see on page 23).
As part of a nationwide programme of the German Federal Ministry of Education and Research (BMBF), new concepts for future
biotechnology have been developed jointly with research organisations and universities since 2010 to provide the foundation for
the development of a bio-based economy. To see which projects
in Berlin-Brandenburg are involved in this programme, please
turn to page 41.
Certified excellence
In addition to Freie Universität Berlin, the Humboldt Universität
zu Berlin also succeeded with its concept for future development
in the context of the Excellence Initiative for cutting-edge research at institutions of higher education. One of the university’s
main goals thus is the continued development of its Integrative
Research Institute (IRI) for the Life Sciences (see on page 36).
Other life sciences projects and initiatives in Berlin-Brandenburg
funded under the Excellence Initiative include the Berlin-Brandenburg School for Regenerative Therapies BSRT (a graduate
school in the field of Regenerative Medicine), NeuroCure (a Cluster of Excellence focused on the neurosciences) and UniCat (the
Cluster of Excellence “Unifying Concepts in Catalysis”).
You will find more detailed information on these Excellence Initiatives and an overview of other research projects involving scientists from Berlin and Brandenburg in our publication BioTOPics 45
“Life Sciences from A to Z”.
NOVEMBER 2012
MARCH 2013
Federal and state governments agree to found the Berlin Institute of Health
(BIH). It is created from the merging of Charité and Max Delbrück Center for
Molecular Medicine. In the future, scientists conducting basic research and
clinical research will thus work hand in hand.
Hasso-Plattner-Institut speeds up personalised medicine with new data bank
technology ++++ Integrative Research Institute for Life Sciences (IRI) founded in Berlin ++++ Paul Ehrlich- and Ludwig Darmstaedter Prize goes to MDC
scientist Dr. James Poulet
DECEMBER 2012
APRIL 2013
Christian Hackenberger receives Leibniz Humboldt professorship for chemical biology ++++ Performance of German Institute of Human Nutrition (DifE)
rated as very good to excellent ++++ MDC celebrates 20th anniversary.
Charité and Sorbonne found Virchow-Villermé Centre for Public Health ++++
EU-OPENSCREEN included in the new BMBF-roadmap for large research
infrastructures
JANUARY 2013
MAY 2013
Charité and FU are jointly successful in the competition "EXIST-Gründungskultur – Die Gründerhochschule" of the German Federal Ministry of Economics and Technology ++++ German Research Foundation extends collaborative research centre (SBF 650) at Charité – ten million Euros for research on
immunological therapy
New laboratory building of MDC opened – named after physiologist Max
Rubner ++++ Stem cell researchers in Germany pool their expertise. They
found the German Stem Cell Network (GSCN) on May 7th 2013 ++++ Evaluators praise Berlin Institute of Health (BIH). Enst Theodor Rietschel becomes
chairman
FEBRUARY 2013
JUN 13
Humboldt research award gets Ivy-League professor Klaas van Wijk to Potsdam ++++ Biopolymers – strong future field with high potential for innovation presents itself in Schorfheide
BIH officially opened ++++ Charité – Universitätsmedizin Berlin once more
reaches rank 1 of Focus-ranking "Germany's best hospital"
35
Know-how in Systems Medicine and
Systems Biology
In the past years, it has become evident that determining the function of singular genes is insufficient for
understanding the processes in our body and the development of diseases. Therefore, biomedical research
increasingly follows a holistic approach. The new key words in this context are “systems biology” and “systems
medicine”. Researchers use highly modern techniques to gain precise insight into the molecular networks of
genes and their products, the proteins, as well as their regulation and interaction, to understand their importance in the development of diseases. The resulting vast quantity of data is evaluated with help of mathematics,
informatics, and powerful computers. In the German capital region, significant know-how has been built and
structures have been created for this.
Amongst the internationally prominent names of Berlin medicine in this context are the Max Delbrück Center for Molecular Medicine (MDC) – it focuses on basic research and is part of
the Helmholtz Association – and in clinical research the Charité
- Universitätsmedizin Berlin. MDC and Charité now combine their
research in the newly founded Berlin Institute of Health (BIH). It
will be set up with public funds of 300 million Euros until 2018.
Additionally, 40 million Euros come from the benefactor Johanna
Quandt. The BIH follows a holistic, systems medical approach for
the first time in Germany. That means steering away from single
organs or disease patterns towards the overarching mechanisms
causing diseases. In doing so, systems medicine uses genetic,
cell biological, biochemical, and physiological methods, imaging
techniques, and extensive technology platforms. The aim is the
medical translation, meaning the development of new diagnostic
techniques, therapies, and preventive measures to increase and
speed up the transfer of research findings to hospitals.
Humboldt Universität (HU) is also invested in interdisciplinary
life sciences research. The Integrative Research Institute (IRI) for
Life Sciences, funded by the Excellence Initiative of federal and
state governments, is a core project of the university’s plans for
the future, having gained the status of elite university in 2012.
The scientific areas involved in the project range cover the entirety of life, from the molecular level to the complex organism. The
research focus of the IRI lies on the areas of commitment of the
36
Prof. Ernst Rietschel
CEO · Berlin Institute of Health – BIH
With the establishment of the Berlin Institute of Health (BIH),
the German federal government and the federal state of Berlin want to respond to proposals from the academic sector to
promote translational research, i.e. the transfer of research
results into clinical practice and back. In the new institute, the
MDC and Charité will combine their basic and clinical research.
In this endeavour, systems medicine plays an essential conceptual role representing a unique selling point of the BIH.
institutions supporting it: Systems biology and theoretical biology (represented by centres of HU, Charité, and MDC); Neurosciences (represented by the Bernstein Center Berlin, an excellence
cluster and a graduate school of HU) as well as infection biology
and immunology (represented by the Center for Infection Biology
and Immunity of HU). From these areas of focus, the IRI wants to
strengthen the connection between theoretical and experimental techniques as well as clinical application areas. The everyday
life in hospitals is set to profit especially from research insights
into neurological diseases (nervous system, strokes), oncological
diseases, and regenerative medicine. An important part of the IRI
will be the Berlin Institute for Medical Systems Biology (BIMSB)
of the MDC, which is a pioneer of systems biology in Germany.
Founded 2008, it focuses on the research of post-transcriptional
regulation of the genome and its influence on cancer, cardiac,
metabolic, and neurologic diseases.
Systems biology was also the theme of the annual bilateral workshop in the French Embassy in Berlin. On 23 November 2012,
German and French scientists reported to some 100 workshop
participants on the current status of systems biology research in
their countries. Opportunities for closer cooperation were also
explored.
The participants included: Prof. Nikolaus Rajewsky, Scientific Director of the Berlin Institute for Medical Systems Biology (BIMSB)
who wants to investigate with his team how the expression of
genes can be controlled after they have been read, e.g. using microRNAs.
Photo: © BBB Management GmbH / David Ausserhofer
The Bilateral Workshop “Perspectives of Systems
Biology”
Cancer research remains the key field in systems biology. This
was also confirmed by a contribution from France: The research
team under Dr. Emannuel Barillot at the Institut Curie in Paris
aims to develop data generated by high throughput methods into
an interaction map in order to observe cancer formation and tumour growth at the molecular level. Bringing together genetic sequences, proteome analyses and the results from the analysis of
tissue samples is to provide the starting point for new approaches
in the struggle against cancer.
Dr. Karin Effertz from the German Federal Ministry of Education
and Research (BMBF) reported on the new BMBF funding programme “e:Med – Measures for the Establishment of System
Medicine“. During the next eight years, the ministry will support
research in systems medicine with some 200 million Euros. Special importance is placed on the active participation in big international projects and to cross-border cooperation.
Dr. Stéphane Roy, Attaché for Science and Technology, French Embassy
Dr. anDreas eckert
founds and finances biotechnology
and medical technology companies
For one hundred years, physicians and researchers in Buch
have been working together towards the common value
of health. Dr. Andreas Eckert is one of the few venture
capital providers in Germany who have specialized in
bioscience companies. He has already contributed to the
successful founding of several biotechnology and medical
technology companies on Campus Berlin-Buch.
Get acquainted with Buch, its partners and the unique
campus atmosphere where the future of medicine is
being created.
www.berlin-buch.com
EuropEan union
European regional
Development Fund
BioTOP-Report
P NBioparks
etworks
PScientific
P CompaniesInstitutions
P
Biotech Networks
kkBioTOP Berlin-Brandenburg
kkBioHyTec Network for Biohybrid Technologies
kkBioResponse
kkCenter for Molecular Diagnostics and Bioanalytics (ZMDB)
kkDiagnostikNet-BB
kkGABI – Genome Analysis in the Plant Biological System
kkNetDDD Network for Drug Discovery & Development Berlin-Brandenburg
kkNetwork Glycobiotechology Berlin-Brandenburg
kkNutrigenomics Network Berlin-Brandenburg
kkRegenerative Medicines Initiative Berlin-Brandenburg
kkRiNA Network for RNA Technologies
Scientific Institutions
kkBerlin-Brandenburg Center for Regenerative Therapies (BCRT)
kkBrandenburg University of Technology (BTU)
kkCharité – Universitätsmedizin Berlin
kkFraunhofer Institute for Applied Polymer Research (IAP)
kkFraunhofer Institute for Biomedical Engineering (IBMT)
kkFreie Universität Berlin (FU)
kkGerman Heart Instiute Berlin (DHZB)
kkGerman Institute of Human Nutrition (DIfE)
kkGerman Rheumatism Research Center (DRFZ)
kkHumboldt-Universität zu Berlin (HU)
kkInstitute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht (Teltow)
kkLausitz University of Applied Sciences
kkLeibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB)
kkLeibniz-Institut für Molekulare Pharmakologie (FMP)
kkLeibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V.
kkMax Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
kkMax-Planck-Institute for Colloids and Interfaces
kkMax Planck Institute for Infection Biology
kkMax Planck Institute for Molecular Genetics
kkMax Planck Institute of Molecular Plant Physiology
kkRobert Koch Institute
kkTechnische Universität Berlin (TU)
kkUniversity of Applied Sciences Berlin (HTW)
kkUniversity of Applied Sciences Wildau
kkUniversity of Potsdam
38
BioTOP-Report
IFHI
39
COSMOS – Coordination of Standards in
Metabolomics
Metabolomics is applied not only in human medicine as a diagnostic tool but also in plant science.
Is a tumour malignant? Will a plant produce a large amount of
biomass? These and other questions can potentially be answered
with metabolic profiles. Metabolic profiles permit assessing the
current status and further development of cells or tissues. The
use of this technique was promoted primarily at the Max Planck
Institute of Plant Physiology (MPI-MP) in Potsdam-Golm. Prof. Lothar Willmitzer, one of the directors at the institute, is regarded as
a pioneer in this field, and Dr. Joachim Kopka and his team created
one of the first important databases for metabolomics data, the
Golm Metabolome Database (GMD). To facilitate data exchange
at the European level, the COSMOS initiative was launched. COSMOS – short for Coordination of Standards in Metabolomics – is
managed by the European Bioinformatics Institute (EBI) and aims
to create a database in which researchers from all disciplines can
store data in standardised formats together with information
about the design of their experiment. In this way, the metabolomics researchers at the MPI-MP will play a key role in organising
the integration of existing data resources. In addition to collecting the actual measurement data, the description of the experiments performed is also a major challenge. The retrievability and
comparability of studies is improved by standardised vocabulary
and computerised data entry.
It is impossible to predict traits of the full-grown plants just by looking at the seedlings, which look all too much alike. Metabolic profiles are a lot more revealing
and give information about the future phenotype and composition of the plants. (Source: MPI-MP)
40
Life Sciences
Biotech 2020+
With its funding programme “Base Technologies for Next Generation Biotechnology Processes”, the German
Federal Ministry of Education and Research (BMBF) wants to create the foundation for a bio-based economy
and promote the German production location. The research concepts receiving funding are working on the
development of entirely new biotechnological production processes.
Under the first funding stage of the programme, 35 research projects have taken up work on base technologies for next generation
biotechnological processes. They are investigating the full range
of possible new methods in biotechnology and are supported
with 42 million Euros by the BMBF. The projects are interdisciplinary, involving experts from the life sciences and engineering
as well as chemistry, physics and medicine.
The four leading German research organisations also played
a major role in defining the strategy process “Biotechnology
2020+” from the start. The topics range from a modular bioreactor for cell-free protein synthesis (Fraunhofer Society) through
synthetic biology (Max Planck Society) and printable biotechnology (Helmholtz Association) to new synthesis methods by which
natural materials can be manufactured for medicine (Leibniz Association).
In the German capital region, the Fraunhofer Institute for Biomedical Engineering (IBMT) is coordinating the national joint
research project “Biomolecules from the Production Line” at its
branch in Potsdam, while the Max Planck Institute of Colloids and
Interfaces in Potsdam is participating in the Max Planck Research
Network MaxSynBio, which will take up work in early 2014.
Other projects in the German capital region participating in the
programme are:
kk BioPICK – Modularised multi-phase biocatalysis by
enzymatically active w/o Pickering emulsions in a
membrane reactor
Prof. Anja Drews
Hochschule für Technik und Wirtschaft, Berlin
Prof. Marion Ansorge-Schumacher
Technische Universität Dresden
kk Use of solar energy for bioelectrocatalysis: development
of photobioelectrode structures for synthesis
Prof. Fred Lisdat
Technische Hochschule Wildau
Dr. Heiko Lokstein, Prof. Athina Zouni
Technische Universität Berlin
kk Synthetic biosystems – from the cell to fabrication
(Cell2Fab)
Dr. Katrin Messerschmidt, Prof. Bernd Müller-Röber
Universität Potsdam
41
BioTOP-Report
Alacris Theranostics GmbH
Alacris Theranostics GmbH, operative since
September 2011, is specialised in developing new approaches in personalised medicine for cancer patient diagnosis, treatment
and drug stratification. Alacris has built up a
next-generation sequencing laboratory for
the analysis of clinical samples and applies a
systems biology approach for patient and
Unlocking The Power Of
Individualised Medicine
drug stratification using the ModCellTM software which is exclusively licensed to Alacris.
This approach has been originally developed
in the department of Prof. Lehrach at the
Max Planck Institute for Molecular Genetics.
Based on genome and transcriptome information and including kinetic pathway information, mutation and drug databases it is
providing a “Virtual Patient” model. This
”Virtual Patient” can predict the effects of
drug treatment and optimised combinatory
treatment for personalised medicine
approaches. ModCellTM also facilitates biomarker discovery and "Virtual Clinical Trials"
for patient and drug stratification.
kk providing more rapid approval of drugs
in targeted non-randomised trials
kk repositioning of drugs or recovery of
"fallen angels" for the pharmaceutical
industry
kk complex biomarker discovery
kk reducing animal testing via virtual trials
Address
Fabeckstraße 60-62
[email protected]
www.alacris.de
Alacris' work provides the opportunity for:
kk finding targeted personalised treatment
for the patient
kk saving negative side effects
kk reducing health costs for non-necessary
treatment
kk optimising stratification of drug
treatment
Analytisches Zentrum Biopharm GmbH Berlin
Analytisches Zentrum Biopharm GmbH Berlin is a testing facility for pharmaceutical
analytics. Tests are carried out on pharmaceutical products and raw materials (stability
tests, batch tests, method development and
validation). The laboratories have all the
equipment needed for these tests according
to ICH and pharmacopoeias. Climatic chambers are available for storing samples under
ICH conditions. Narcotics, hormones and
cytostatic agents are handled on a daily
basis.
The portfolio also includes determining the
content of active ingredients in biological
matrix (e.g. plasma samples from clinical
studies on humans or availability studies on
agricultural livestock, tissue samples from
withdrawal period studies on farm animals
and others). High-performance LC-MS/MS
devices for high sample throughput are
available for this. The analytical studies are
performed according to the applicable European and FDA guidances.
42
The testing facility uses quality assurance
systems according to GLP and GMP that
have been successfully certified by the
authorities. The GLP certificate includes test
categories 1 and 8, so that physical-chemical tests are also carried out according to
REACH. The GMP certificate covers the quality control/batch check on finished medicinal products and pharmaceutical raw materials.
Further information is available from
www.az-biopharm.de
Address
Analytisches Zentrum Biopharm GmbH
Berlin
Bitterfelder Strasse 19
Contact
Dr. Ulrich Kunter
[email protected]
Phone +49 30 936520
Phone +49 30 30-93652200
BioTOP-Report
BIOTECON Diagnostics GmbH
Kits, based on real-time PCR, are developed
as easy-to-use systems to provide fast, safe
and specific results for manufacturers and
consumers.
BIOTECON Diagnostics was founded in 1998
and is established as a well-known qualified
global partner for the food and beverage
industry as well as for producers of pharmaceuticals and cosmetics.
BIOTECON Diagnostics focuses on development, production and marketing of rapid
detection systems for pathogens, allergens,
animal species, genetically modified plants
and beverage spoilage organisms in food,
feed and other matrices like environmental
samples. The foodproof®, foodproof® SL and
microproof® Detection and Quantification
Now AOAC and MicroVal validated,
BIOTECON Diagnostics has offered automated sample preparation and test setup solutions since 2009. The foodproof® RoboPrep+
Series, a fully automated system for the
analysis of pathogens, was the first system
on the market especially designed for the
needs of the food industry. The foodproof®
RoboPrep Flex offers a convenient and
robust solution for the automated extraction
and purification of plant DNA from food and
feed samples.
to provide flexible solutions to production
and processing companies through new, tailored, and economical approaches.
Address
Hermannswerder 17
14473 Potsdam · Germany
Contact
Kornelia Berghof-Jäger, Ph. D. · CEO
Alois Schneiderbauer · CBO
Phone+49 331 2300 200
Fax +49 331 2300 299
[email protected]
www.bc-diagnostics.com
BIOTECON Diagnostics additionally offers
customized contract development and production. Due to close contacts with many
different industries, the company is well
aware of customers’ current and future challenges. BIOTECON Diagnostics is thus able
BioTeZ Berlin-Buch GmbH
BioTeZ is focused on biotechnological products and services for life science research,
pharmaceutical industry and diagnostics.
In many business fields BioTeZ has own technologies with outstanding properties, e.g., in
the sphere of immunoaffinity columns, HRPlabeling, sundry streptavidin coatings and
the development of enzyme immunoassays.
On the basis of many years' experience the
powerful diagnostic tool recoveryELISA® was
created for monitoring therapies with biologics.
Business fields at a glance:
Immunoaffinity chromatography
kk Production of customized IAC
kk Coupling of different ligands,
e.g. antibodies against mycotoxins
Premium oligonucleotid synthesis
kk DNA / RNA incl. modifications
Contact
Robert-Rössle-Straße 10
Phone+49 30 94892130
Fax +49 30 9494509
[email protected]
www.biotez.de
Streptavidin coating
kk Microplates and other surfaces and
materials
kk Polystrept R for high binding capacity,
excellent for lateral flow assays
ELISA development and services
kk inclusive conjugate development,
labeling, purification etc.
Companion Diagnostics
kk recoveryELISA® – a new diagnostic
method to predict and to measure interaction between therapeutic antibodies or
biologics and their target molecules.
43
BioTOP-Report
co.don AG
co.don® AG is a public biopharmaceutical
company, founded in November 1993, since
2001 listed on Frankfurt stock exchange.
co.don® AG manufactures cell-based tissue
engineering therapeutics of the highest
purity and to the highest quality standards.
Its products represent a revolutionary process in the biological replacement of damaged articular cartilage and invertebral disc
by building up strictly autologous tissue
without the involvement of any external carrier materials or additives. The application of
the products may be minimally invasive or
arthroscopic and so surgery and rehabilitation times significantly reduced for doctor
and patient. Because no external materials
are used, the risks of rejection, inflammation
and infection are very slight.
co.don® AG is certified in accordance with
DIN EN ISO 9001:2008. Furthermore, production, quality control and quality assurance have been certified in accordance with
European Guidelines for Good Manufacturing Practice (EU-GMP) since 1997. In 1997
co.don® AG was the first biopharmaceutical
company in Europe to be granted a permit
for the manufacture of autologous chondrocyte and osteoblast transplants under section 13 of the German Drugs Law (AMG).
co.don® AG‘s technological, production and
regulatory expertise makes the company a
first mover in the market for biological cartilage disc tissue replacement and a provider
of highly effective, safe treatment options
between pain therapy and endoprothetics.
Address
co.don AG
Warthestraße21
14513 Teltow · Germany
Contact
Matthias Meißner, M.A.
Head Corporate Communications/IR/PR
Phone+49 3328 4346 0
Fax +49 3328 4346 43
[email protected] · www.codon.de
Epigenomics AG
Epigenomics is a molecular diagnostics company developing and commercializing a
pipeline of proprietary products for cancer
diagnosis. The Company’s products enable
doctors to diagnose cancer earlier and more
accurately, leading to improved outcomes
for patients. Epigenomics’ lead product, Epi
proColon® 2.0, is a second generation bloodbased test for the early detection of colorectal cancer, which is currently marketed in
Europe and has been submitted to the FDA
for US regulatory approval.
44
With clinical studies indicating a majority of
colorectal cancers are detected with the test
added to the convenience of a simple blood
draw, Epi proColon® is expected to improve
compliance for colorectal cancer screening
and save lives through early detection of disease. Laboratory test services based on this
technology are available in the U.S.A. and
Canada by our partnering laboratories Quest,
ARUP, Companion Dx and Gamma Dynacare.
Epigenomics’ product portfolio further
includes Epi proLung®, a confirmatory test
aiding in the diagnosis of lung cancer that is
marketed in Europe, and additional products
in development for colorectal, lung and
prostate cancer. The Company’s technology
and products have been validated through
multiple partnerships with leading global
diagnostic companies. Epigenomics is an
international company with operations in
Berlin, Germany, and the U.S.A.
For further information please visit
www.epigenomics.com
Address
Epigenomics AG
Kleine Praesidentenstraße 1
Phone+49 30 243450
Fax +49 30 24345555
[email protected]
www.epigenomics.com
BioTOP-Report
Evestra GmbH
Evestra GmbH, founded in July 2008, is a
fully owned subsidiary of Evestra Inc. located in San Antonio Texas. Evestra GmbH
serves as the development and commercialization center for Europe and ROW. Evestra’s
mission is to develop and commercialize
steroid-based female healthcare products.
The development strategy of the company
includes product ideas with known compounds as well as New Chemical Entities.
Evestra is conducting research and product
development in a number of in-demand, but
as yet unmet, medical need areas of women’s health such as hormonal-dependent
breast cancer and endometriosis. The company is also pursuing different projects in
fertility control, e.g. a new estrogen for oral
contraception, with superior pharmacological properties compared to the standard
drug ethinyl estradiol.
Address
Evestra GmbH
Britzer Straße 26
EU Contact
Prof. Klaus Nickisch · Managing Director
Phone +49 30 66509642
[email protected]
www.evestra.com
Several patents on new composition of matter, new technical processes and use patents
have been filed during the last years and
support the strong intellectually property
position. Evestra is concentrating on R&D
and will seek more partners for commercialization.
More detailed information can be found on
our website.
LGC Genomics (www.lgcgenomics.com) is the
genomics division of the international science-based LGC Group.
LGC Genomics merged 2011 with KBioscience, a UK-based technology company providing its own range of SNP genotyping chemistry and novel instrumentation to the life science research and quality control communities. Now we provide a full range of high quality genomics products, services and solutions
including sample preparation, nucleic acid
extraction, DNA sequencing, genotyping and
biobanking. LGC Genomics operates from
three laboratory centers in Germany, USA and
United Kingdom.
The portfolio includes:
kk Genotyping services, assays and
reagents
kk Sanger and NextGen sequencing services on Roche 454 & Illumina HiSeq and
MiSeq platforms
kk DNA and RNA extraction products and
services
kk DNA / RNA biobanking
kk Storage
kk Retrieval and analysis services
kk Reagents and consumables for molecular
biology
kk Laboratory instrumentation
kk Plate sealers
kk Liquid handling robots
kk High-throughput PCR thermal cyclers
kk Plate readers
©LGC Limited, 2013. All rights reserved.
LGC Genomics
Address
LGC Genomics GmbH
Ostendstrasse 25 · TGS Haus 8
Phone +49 30 53042200
[email protected]
www.lgcgenomics.com
45
BioTOP-Report
MOLOGEN AG
MOLOGEN AG is an innovative biotechnology company with focus on cancer immuno
therapies. Our drug candidates utilize various therapeutic approaches to fight severe
cancer diseases.
Our lead product is MGN1703 – a safe and
well tolerated DNA immuno modulator. It
has shown high efficacy in a double-blind,
placebo-controlled phase II trial in metastatic colorectal cancer and is ready to enter
phase III. The immune activation is mediated through binding at the Toll-like receptor 9
in certain immune cells. The strong and
broad activation enables the patients’
immune system to overcome the tolerance
against the cancer disease. Due to this mode
of action MGN1703 can be used to treat
several solid cancer diseases. Next target
will be lung cancer.
Second lead product is MGN1601, our
cell-based cancer vaccine. Through the use
of living human renal cancer cells we present a full set of tumor-associated antigens
(TAA) to the immune system with the aim to
induce a strong adaptive immune response
against these TAAs. MGN1601 underwent
successfully a phase I/II trial in metastatic
renal cancer.
Our research for you – for innovative
medicines that are highly effective and well
tolerated.
Contact
MOLOGEN AG
Fabeckstraße 30
Phone+49 30 841788 0
Fax +49 30 841788 50
[email protected] · www.mologen.com
Our attractive product pipeline also comprises DNA vaccines and further cancer
immuno therapies. The drug candidates are
based on our proprietary platform technologies. We are open for partnering and collaborations.
Predemtec GmbH
Predemtec GmbH is focussed on research,
development, manufacture and marketing
of novel Immunoassay PredemtecDX to
assess dementia and dementia related risk
factors before first symptoms appear. Predemtec has developed a reliable blood test
for early and reliable diagnosis of various
dementia-related disorders by analyzing a
cluster of specific biomarkers. Controlled
clinical tests indicate high specifity and reliability of our PredemtecDX. Prophylaxis and
therapeutic interventions will be more effi-
46
cient, when administered as early as possible, ideally before clinical symptoms show.
PredemtecDX will enable a major progress in
this field.
Address
Predemtec GmbH
Neuendorfstrasse 20a/c
16761 Hennigsdorf
Predemtec GmbH cooperates with the Institute of Immunology at the Kiel University
and various geriatric institutions in Germany
and Switzerland. As a member of the diagnostic network, Predemtec offers services
for early dementia diagnosis to laboratories,
hospitals and clinics.
Contact
Dr. Annegret Feuerhelm-Heidl
Geschäftsführerin
Telefon +49 3302 2021600
Mobil +49 170 314145 9
[email protected]
www.predemtecDX.com
BioTOP-Report
ProBioGen AG
ProBioGen AG is an internationally operating
Contract Development & Manufacturing
Organization (CDMO) and Technology Provider, focused on animal cell line engineering and process development including GMP
manufacturing of biopharmaceutical drug
substances (therapeutic proteins and vaccines).
Almost 20 years of experience in mammalian cell culture and biopharmaceutical manufacturing make ProBioGen a competent and
reliable contract partner. The comprehensive
technological skills and the outstanding scientific excellence, reflected in a strong intellectual property base, qualify ProBioGen to
manage even the most challenging development and manufacturing projects.
The pharmaceutical cell line development
program is based on proprietary expression
vector technology, optimized clone selection
and screening workflow complemented by
an in-house chemically defined cell culture
media platform. Two preselected CHO host
cell lines (DG44- and K1-strains for optimal
product quality) fit perfectly into the rapid
upscale processes and achieve excellent
product yields and stability. Comprehensive
analytical methods development and validation goes hand in hand with state-of-the-art
GMP manufacturing programs.
All services and technologies are embedded
in a total quality management system to
assure compliance with international ISO
and GMP standards (EMA/FDA).
An experienced project management
ensures that projects are completed strictly
in time and on budget.
Besides the state-of-the-art services, ProBioGen develops innovative technologies, such
as:
kk GlymaxX®
This fucose-targeted glyco-engineering
technology increases the binding of
antibodies to NK cells and thus enhances
ADCC. As a permanent modification it
can be rapidly applied to any existing
antibody producer cell lines or to entire
expression platforms.
kk Pathway Modulator Technology
This permanent cell modification increases productivity even for difficult to
express proteins. It is applicable to new
and pre-existing producer cell lines.
kkAGE1 Designer Cell Lines
The AGE1 cell line family was created by
defined immortalization of primary cells
for different purposes.
kkThe AGE1.CR® cell line originates from
the Muscovy Duck and was established
to replace primary chicken cells in vaccine production. The cell line allows
GMP-complaint production of a wide
spectrum of vaccines and viral vectors.
kkThe AGE1.HN® human neuronal cell line
supports complex specific glycostructures (highly sialylated, highly branched).
It is used for glycoproteins which require
manufacturing in human cells.
kk Human Artificial Lymph Node
(huALN)
The huALN is a fully human minibioreactor system to assay drug-related
effects on the immune system in vitro.
This unique 3-D matrix-based technology
uses primary lymphocytes to emulate in
vivo conditions of the human immune
system and allows long-term analyses of
immunogenicity, immunofunction and
immunotoxicity.
Founded in 1994, ProBioGen is located in
Berlin, Germany, and enjoys a global customer portfolio ranging from small biotech
firms to large pharmaceutical companies.
Address
ProBioGen AG
Goethestraße 54
Contact
Dr. Gabriele Schneider
VP Business Development
Phone+49 30 924 006 0
Fax +49 30 924 006 149
[email protected]
www.probiogen.de
47
BioTOP-Report
syneed medidata GmbH
Are you getting the whole picture? We Do.
syneed medidata GmbH is an independent,
privately owned contract research organization (CRO) that has been providing end-toend services for phase I to phase IV clinical
trials and for observational studies for more
than 25 years. Since 1995, we have also
excelled in trials with medical devices, and
in trials involving medical imaging, including
all responsibilities of an Imaging Core Lab
(ICL). With our exceptionally low staff turnover, project teams usually remain stable,
even throughout multi-year projects, and as
such facilitate project delivery in time and
highest quality.
syneed medidata GmbH combines experience with the quality, dedication and
ﬂexibility of a midsized organization. Our
proprietary EDC system, tailor-made for
multinational observational studies, gets
enthusiastic feedback from both customers
and end-users. Its advantages are, among
others, unlimited flexibility in study design
and multilingualism, compatibility with iPad
and Android tablets, and an attractive price/
performance ratio. So, for almost any trial you can think of, we
provide the expertise you need for turning
data into results.
Full-service for clinical trials
Proprietary EDC system
Address
syneed medidata GmbH
Cicerostraße 21
Phone +49 30 31172751 00
www.medidata.de
[email protected]
Contact
Dr. Achim Zinggrebe
CEO
Medical Director Imaging
[email protected]
Very high staff retention
Tailor-made services instead of
one-size-fits-all approaches
High experience of staff
High quality delivered while being
reasonably priced
syneed imaging
syneed imaging, the Medical Imaging Core
Lab of syneed medidata GmbH, offers solutions for study planning, protocol development, site evaluation, image collection and
processing and conduct of central independent reviews with a wide variety of criteria
(i.e. RECIST, 1.0 and 1.1, Choi, Cheson, irRC,
RANO, PERCIST, mRECIST).
48
Since 1995, we have managed trials involving medical imaging (oncology, neurology,
radiology, devices) and conducted central
reads in our offices in Constance and Berlin
as well as remotely. Our experience, flexibility and pricing especially for early phase trials are highly valued by Biotech clients. All
study data are hosted solely in Germany on
our servers maintained by own IT staff.
Address
syneed imaging & syneed medidata GmbH
Cicerostraße 21
Phone +49 30 31172751 00
Contact
Isabel Kloer
MD
Medical Director Imaging
[email protected]
Expertise in Life Sciences
Special
English
Industrial Biotechnology 2013 (Vol. 4)
Publication date:
February 25th, 2013
Supplement
Healthcare 2013 (Vol. 7)
Publication date:
March 30th, 2013
VentureCapital Supplement
Personalized Medicine 2013 (Vol. 3)
Publication date:
May 31th, 2013
Special edition
Biotechnology 2013 (Vol. 15)
Publication date:
September 14th, 2013
Advertising close:
September 2th, 2013
Supplement
Medical Technology 2013 (Vol. 11)
Publication date:
October 26th, 2013
Advertising close:
October 14th, 2013
Contact media sales team
Katharina Meindl
Karin Hofelich
Tel. +49 (0) 89-2000 339-53
Tel. +49 (0) 163-334 43 26
Tel. +49 (0) 89-2000 339-54
Tel. +49 (0) 177-422 52 89
[email protected]
[email protected]
Only GoingPublic Magazin’s Special “Industrial Biotechnology”
is published in English, all others in German.
Further info: www.goingpublic.de/lifesciences
BioTOP-Report
Biotech Parks
The BioCampus Network Berlin-Brandenburg
Berlin-Brandenburg boasts seven biotechnology parks, which offer optimal space for the specific requirements
of every company. This geographic concentration of specific biotech parks is unique in Germany and probably
in all of Europe. The parks differ in their offers and strategic focus and provide ideal conditions for newcomers.
More than half of the 222 companies are currently utilizing the infrastructure of a publicly or privately managed park. In addition, the young companies benefit from the closeness to science and the permanent contact
and exchange.
berlinbiotechpark
In the very heart of Berlin
berlinbiotechpark Management GmbH · Herr Frank Elsner
Max-Dohrn-Straße 8–10 · 10589 Berlin
Phone +49 30 20364205 · Fax +49 30 20364190
[email protected] · www.berlinbiotechpark.de
berlinbiotechpark is located on a 86,000 sq.m. site in the
very heart of Berlin, currently offering a total of approx.
63,000 sq.m. of office, laboratory and production space, with
a building potential for another 45,000 sq.m. of rental area.
The site, which is home to Biotech/Pharma/Service Companies is
supplied with a complete range of media for laboratory and production purposes, with production steam with possibility to upgrade to HP steam, power supply, compressed-air, nitrogen and
other inert gases, cooling water and DI-water , all being provided
at favorables rates.
The infrastructure includes conference facilities as well as works
security and waste disposal services. It is rounded off by production-relatedservices such as plant engineers and laboratory technicians, industrial safety engineers, a medical service as well as
best-buy services and communication services. Offering flexible
growth potential, production-orientated media equipment and
comprehensive industrial-specific services and infrastructure,
berlinbiotechpark is particularly attractive for growing internationally orientated technology companies. Furthermore, it offers
a permanent base in Berlin for developing companies that have
outgrown the size allowed by their limited start-up funding. The
inner-city location and the excellent public transport guarantee
short ways to all scientific institutions and hospitals of the city.
Biotech Campus Potsdam
Research on the Waterfront
Steinstraße 104-106 · 14480 Potsdam
Phone +49 331 6601628 · Fax +49 331 6601699
[email protected] · www.biotechcampus.de
Contact: Gabriele Ziegler
Just a few minutes away from Potsdam’s central railway station in the direction of Caputh, Biotech Campus Potsdam is
located on the Hermannswerder peninsula in the river Havel.
It is owned and operated by Biotech Campus Potsdam GmbH,
a fully owned subsidiary of the Investment Bank of the State
of Brandenburg.
50
BioTOP-Report Biotech Parks
The biotechnology center is housed in four buildings dating from
around 1900 and one modern complex and offers a total of
11,400 sq.m. of laboratory, office, greenhouse and storage space.
With such a large facility at its disposal, it offers biotechnology
companies an ideal environment for successful operations. All
labs are approved as S1 laboratories and meet the building requirements for approval as S2 labs. The Hermannswerder site
also includes an S3 laboratory as a special resource. The beautiful,
park-like setting of the peninsula offers an excellent environment
for research activities. The island hotel and a conference center
are located directly next to the campus.
The site also includes a self-service restaurant and small island
shop. The philosophy of Biotech Campus Potsdam was, and still
is, to create the freedom for research and innovation in the hightech sector of biotechnology. Reputable firms from the industry
can indeed be found here.
The work carried out by resident companies is multi-faceted,
ranging from green biotechnology, the development of vaccines,
the development of pharmacologically active substances based
on plant materials, the development and production of PCR tests
for food testing and preclinical contract research right through to
medical technology. A total of 200 employees work on the site.
Biotechnology Park Luckenwalde
Space for Expansion
Biotechnologiepark Luckenwalde · c/o SWFG mbH
Im Biotechnologiepark, TGZ I · 14943 Luckenwalde
Phone +49 3371 681100 · Fax +49 3371 681105
[email protected] · www.bio-luck.de
Contact: Dipl.-Ing. Christoph Weber · Director
Located just 25 miles from the new Berlin-Brandenburg International Airport (BBI) in the district of Teltow-Flaeming,
the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 35 companies from Germany, USA, UK, Korea, Israel and Russia with
about 550 employees.
Companies in the park focus on the development and production
of pharmaceuticals, recombinant proteins and diagnostic kits,
biological/chemical substances for biotech and pharmaceutical
applications, as well as fine chemicals. There are also suppliers of
medical technology, analytical services, and a Biotech Education
Center. Technical Equipment comprises completely furnished S2
laboratories (safety workbench, autoclave, dishwasher, deionized water, water purification system, central media supply (compressed air, N2, Co2, O2, H2), storage and cool rooms, pharmaceutical clean rooms category (B/C), 400 MHz NMR spectrometer,
51
meeting rooms, conference hall (300 seats), library, restaurant
with catering service.
The entire central technique meets GMP/ISO 9001 specifications. The park management offers comprehensive, individual
services and advice during the settlement and development of
firms, including support for the implementation of quality management systems and GMP certification. Currently the park offers
9.000 sq.m. labs and office space, and additional 100.000 sq.m.
industrial property ready for expansion.
Co:bios Technologiezentrum
Service for all stages of growth and expansion
co:bios Technologiezentrum GmbH
Neuendorfstraße 20 a · 16761 Hennigsdorf
Phone +49 3302 2021250 · Fax +49 3302 2021257
[email protected]
www.cobios-technologiezentrum.de
Located in the northwest of Berlin, the co:bios Technology
Center in Hennigsdorf is the congested urban area in Berlin-Brandenburg of biotechnology and life science. In the last
15 years more than 30 companies with approximately 700
international employees have settled on this site.
On more than 10.000 sq.m. we offer service space for extension
to clean rooms (class D/E/F), S1 labs, DI-water supply, compressed
air supply, special gas supply, state of the art data communication,
meeting rooms, conference hall and more. The building and central technique requirements also meet the fulfillments for S2 labs
for GMP/ISO 9001 based production specifications. As a center
of excellence for biotechnology and life science we have a selected portfolio of service and advice to young start-ups as well as
medium sized companies, in aim to support them across all stages of company growth. For those companies who have outgrown
their limited start-up funding, we additionally hold 80.000 sq.m.
developed industrial property ready for expansion.
With our holistic approach combining settlement, development,
construction and licensing issues to the point of traditional management consulting, and on the background of the high density
of innovative, research-intensive and service-oriented companies on the co:bios biotechnology park Hennigsdorf we can initiate interesting synergy effects for your business model. Within
this locational advantages the co:bios biotechnology park became a magnet for the international healthcare industry and the
percentage of international settlements on this site is growing,
fore example from USA, South America, VAI and Asia.
Campus Berlin-Buch
Interaction of Research, Clinics and Companies
Robert-Rössle-Straße 10 · 13125 Berlin
Phone +49 30 94892511 · Fax +49 30 94893812
[email protected] · www.bbb-berlin.de
Contact: Dr. Andreas Mätzold · Executive Manager
Dr. Ulrich Scheller · Executive Manager
Berlin-Buch is the location of one of the largest biotechnology parks in Germany, with 31.000 square meters of scalable
lab and office space for start-ups and maturing companies.
Situated to the northeast of the city, the Berlin-Buch Campus
is currently home to 56 companies, 40 of which are biotech
companies; the rest provides support services.
52
Beside the BiotechPark the Max Delbrück Center for Molecular
Medicine, the Leibniz Institute for Molecular Pharmacology as
well as clinical groups from the Charité University Hospital within
the Experimental and Clinical Research Center are part of the
Campus community. The Campus gives access to high-end technology platforms, state of the art infrastructure, interdisciplinary
communication, projects and expertise in a wide range of items,
especially in translational research. The BiotechPark at the Campus Berlin-Buch offers:
kk Immediately available lab and office space
kk Excellent research and clinical expertise on-site
kk Training programs for personnel on spot
kk An international community of like-minded people
kk Interdisciplinary networks and platforms
The BiotechPark including the Innovation and Incubation Center
is managed by BBB Management GmbH Campus Berlin-Buch.
Acting as a full-service company BBB’s main tasks are the settlement, accompanying and support of Biotech businesses.
Berlin Adlershof
Germany’s leading Science- and Technology Park
Adlershof Zentren für Biotechnologie und Umwelt
WISTA-MANAGEMENT GMBH
Rudower Chaussee 17 · 12489 Berlin
Phone +49 30 63922221 · Fax +49 30 63922212
[email protected] · www.adlershof.de
Contact: Heidrun Terytze
Head of Center for Biotechnology and Environment
Berlin Adlershof focuses on photonics and optical technologies, material and microsystems technology, information
and media technology, as well as biological, environmental
and energy technology. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m. of lab and office
space. The environmental, biological and energy technology
companies focus on:
kkAnalytics: Tracing substances in foodstuffs and groundwater, cosmetics, waste; Quality assurance, Identification of pollutants
kkBiotechnology: Research development and marketing or manu
facture of base materials for biotechnology and chemical processes, of biochips and biochip-based biomedical procedures, of
technical enzyme preparations
kkEnvironmental technology: Remediation work based on innovative microbiological processes for degradation of pollutants
or production of specific microbial anacultures; Research in
the field of supercritical media and high-pressure technology;
53
High-sensitivity detection systems for biotechnology and gene
tic engineering; Laser technology
Pharmacy,
Medicine and Medical Technology: Equipment enkk
gineering and measurement technology; Research for medical
chemistry
the capabilities and interests of all institutions, associations and
companies that operate at Science Park Potsdam-Golm.
Technical Equipment comprises laboratories with a basic equip
ment:security-lockers, laboratory basins, work benches, vacuum
supply, preliminary setup for supply of pure gases and compressed air, reconfiguration for further media and gases, central
cooling, preliminary setup for cold water supply in rental areas,
refitting of heat exchanger by the tenant possible.
Science Park Potsdam-Golm
Connecting Excellence
Standortmanagement Golm GmbH
Am Mühlenberg 11 · 14476 Potsdam-Golm
Phone +49 331 237351130
www.wissenschaftspark-potsdam.de · www.goin-potsdam.de
Contact: Friedrich W. Winskowski · Managing Director
Science Park Potsdam-Golm combines cutting-edge international research and the training of young scientists in a
high-powered location in the immediate vicinity of the German capital Berlin. Alongside the Faculty of Science and the
Human Sciences Faculty of the University of Potsdam, three
Institutes of the Max Planck and two of the Fraunhofer Society as well as an innovation center with currently 22 companies operate in Brandenburg’s largest science park.
More than 2500 people work at Potsdam-Golm and more than
9000 students are pursuing their academic qualifications here.
The pleasant and very family-friendly working environment on
the edge of a nature conservation area, the high quality of life
in and around Potsdam and continuous growth make PotsdamGolm a highly attractive location. Professional site management
is extending the park infrastructure and fosters the integration of
54
The GO:IN Innovation Center offers young technology-based
companies and entrepreneurs a range of office and laboratory
spaces along with extensive services and optimal support for a
successful market launch. Close proximity to the other players
at Potsdam-Golm and the intensive networking of the different
institutions and companies here offer perfect conditions for the
development and exploitation of synergies.
BioTOP-Report
Addresses
Networks56
Biotech Parks
57
Other Parks
57
IP Asset Management 57
Universities and Research Centers
57
Banks and VCs
58
Supporting Organisations
58
Pharmaceutical Companies
59
Contract Manufacturers
60
Contract Research Organisations
60
Biotech Companies
61
For Companies on the Rise
Equity Financing – building
on your strengths!
Are you looking to expand your business and maximize on growth prospects
in the technology sector in Germany? Yet, you require some support and
equity financing to get your project successfully underway in a new marketplace? Then, we are the right partner for you!
We pride ourselves in providing the best in equity financing to our 150 corporate clients totalling over 150 million in strategic financing. We are dedicated
to assisting our customers to advance their businesses in new areas and to
enable sustainable growth of business and even greater success.
Foto: ILB
Remember, your success is our success. Let us be part of your success story!
Contact us now.
www.ilb.de
BioTOP-Report
Networks
BioHyTec – Verein für Bioanalytik
und Biohybrid-Technologien e. V.
BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Bran- biohytec.de
denburg. This new field of technology is the interface between biosensor development and
microsystems technology. Biohybrid systems open up new applications in pharmaceutical
research, clinical d
iagnostics, food analysis and genetic engineering.
BioResponseNetzwerk
BioResponse is an interdisciplinary research and development organisation with mem- bioresponse.de
bers from Brandenburg, Berlin and Saxony. It focuses on the development and marketing
of multiplex assays for diagnostic antibody identification based on the proprietary BioResponse technology, which is comprised of fully automated image analysis of fluorescence-encoded microparticles and labelled cell structures.
DiagnostikNet-BB Netzwerk
Diagnostik Berlin-Brandenburg
DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro-diagnostics. Members diagnostiknet-bb.de
include biotech companies as well research institutes and clinics. Main objectives of the
network are: Development of system solutions, optimizing compatibility, close cooperation
with leading clinicians and joint marketing.
GABI – Genomanalyse im
Biologischen System Pflanze
GABI stands for Genome Analysis of the Plant Biological System and is an associative proj- gabi.de
ect supported by the German Federal Ministry of Education, Research and Technology
(BMBF) as well as a number private enterprise companies. These companies are grouped
under the Business Platform promoting Plant Genome Research GABI e. V. (WPG). A Patent
and Licence Agency associated with GABI (GVS) has the task of commercialising and protecting research results by means of licence rights.
Glykostrukturfabrik
The Network Glycobiotechnology Berlin-Brandenburg brings together scientists with many glykostrukturfabrik.de
different areas of competence in studying and utilizing complex carbohydrates. The aim is
product-oriented development of the region’s wide range of glycobiological technologies,
building a complete glycobiotechnological process chain and to establish the region as a
center of competence in the field of glycobiotechnology.
Health Capital Berlin-Brandenburg
In order to develop the scientific and economic position of the region, the governments of healthcapital.de
the states of Berlin and Brandenburg have put the master plan “Healthregion Berlin Brandenburg” into effect. Its key to a continued success is a continued close interplay between
research, development and education7vocational training with production, application
and supply. All of these activities are integrated and coordinated through the Network
“Gesundheitswirtschaft Berlin Brandenburg” under the brand of “HealthCapital”.
Network for Drug Discovery &
Development (NetDDD)
The Network for Drug Discovery & Development Berlin-Brandenburg was launched in 2007 fmp-berlin.info/technoloas an open interdisciplinary initiative with the aim to accelerate the transfer of clinical rele- gy-transfer/netddd
vant findings into innovative drugs and therapeutic concepts. The network was co-founded
by the Leibniz-Institut für Molekulare Pharmakologie (FMP) and BioTOP Berlin-Brandenburg. Next to offering support to research groups working on early drug discovery projects
the NetDDD focuses on networking activities and professional training in the field of early
drug development.
Netzwerk Nutrigenomik BerlinBrandenburg
Nutrigenomics is a highly innovative and fast-growing interdisciplinary field of research nutrigenomik.de
linking genome research, plant biotechnology and molecular nutritional research and offering new applications for medicine and nutrition. Nutrigenomics aims at providing an
understanding for how nutrition affects the balance between health and disease. Network
partners include local universities and research institutes, private enterprises, public-sector organizations and various collaborative project groups.
Regenerative Medicine Initiative
Berlin-Brandenburg
The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of ex- rmib.de
cellence for Regenerative Medicine particularly for cell-based medical biotechnology. The
RMIB promotes networking in the field and supports the further development of clinical
studies and education programs. The initiative fosters the collaboration between universities, research institutes, companies (including SMEs) and organizations in the field of
science and technology.
RiNA -Netzwerk RNA-Technologien
The RNA-Network provides ongoing support and funding for the development of RNA tech- rna-network.com
nologies with the goal to commercialize the results. One main focus is the improvement
and application of the RNA interference technology. Further projects develop RNA aptamers, cell-free protein biosynthesis systems and analyse the structure and function of RNA
molecules. The RiNA RNA-Network encourages co-operation and information exchange
between academy and industry.
Zentrum für Molekulare Diagnostik
und Bioanalytik
56
The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre operated zmdb.de
under the auspices of the Fraunhofer Institute for Biomedical Technology and the Charité
– Universitätsmedizin Berlin in close cooperation with the region’s company networks. The
aim is to bring together regional expertise in basic research, technology development, clinical research and industrial cooperation initiatives to set up joint projects that will speed up
the development of in vitro-diagnostics “Made in Berlin-Brandenburg”.
BioTOP-Report
Biotech Parks
berlinbiotechpark
berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently berlinbiotechpark.de
offering a total of approx. 57,000 m² of office, laboratory and production space, with a
building potential for another 45,000 m² of rental area. Offering flexible growth potential,
production-orientated media equipment and comprehensive industrial-specific services
and infrastructure, berlinbiotechpark is particularly attractive for growing internationally
orientated technology companies.
Just a few minutes away from Potsdam’s central railway station in the direction of Caputh, biotechcampus.de
BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in the river
Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned
subsidiary of the Investment Bank of the State of Brandenburg.
Biotechnologiepark Luckenwalde
Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International bio-luck.de
Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one
of the most modern facilities of its kind in Germany. It is home to 38 companies with 500
employees from Germany, USA, UK, Korea, India, Italy and Russia.
Co:bios Technologiezentrum GmbH The co:bios Technology Center in Hennigsdorf offers affordable rental opportunities and a cobios-technologiezentrum.
selected portfolio of services and advice to young start-ups as well as medium-sized com- de
panies. Therefore Hennigsdorf is a center of excellence for life sciences, especially in the
field of red biotechnology and medical technology.
Campus Berlin-Buch bbb
Management GmbH
Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 bbb-berlin.de
square meters of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the campus is currently home to 49 companies, 35 of
which are biotech companies; the rest provide support services.
Adlershof Zentren für
Biotechnologie und Umwelt
Berlin Adlershof is one of the most successful high-tech locations in Germany with focus adlershof.de
on Photonics and optical technologies, material and microsystems technology, information
and media technology, biological, environmental and energy technology. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m of lab and office space.
Other Parks
Science Park Potsdam-Golm
GO:IN Golm Innovationszentrum
GmbH
Science Park Potsdam-Golm is one of the most innovative and promising locations in Bran- wissenschaftsparkdenburg. In the GO:IN facility, innovative companies will find an excellent working envi- potsdam.de
ronment where they will benefit from the synergy effects of the location and the specific goin-potsdam.de
equipment offered by its laboratories. The location provides a wide range of services and
consulting, as well as integration into the existing regional networks.
Innovationspark Wuhlheide
Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International bio-luck.de
Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one
of the most modern facilities of its kind in Germany. It is home to 38 companies with 500
employees from Germany, USA, UK, Korea, India, Italy and Russia.
IP Asset Management
Ascenion
Ascenion advises public life science research institutions, universities, hospitals, freelance ascenion.de
inventors and companies in all aspects of intellectual property asset management.
ZukunftsAgentur Brandenburg
GmbH Brainshell
Brainshell is an independent consulting agency specializing in intellectual property ser- brainshell.de
vices for businesses.Brainshell manages and markets the patent portfolios of all colleges,
universities, and research institutes in the State of Brandenburg.
BAM Federal Institute for Materials Research and Testing
bam.de
Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
b-crt.de
BfR Federale Institute for Risk Assessment
bfr.bund.de
Brandenburg University of Technology
tu-cottbus.de
Charité - Universitätsmedizin Berlin
charite.de
Deutsches Rheuma-Forschungszentrum Berlin
drfz.de
Fraunhofer Institute for Applied Polymer Research (IAP)
iap.fraunhofer.de
Fraunhofer Institute for Biomedical Engineering (IBMT)
ibmt.fraunhofer.de
Freie Universität Berlin
fu-berlin.de
German Heart Instiute Berlin
dhzb.de
57
BioTOP-Report
German Institute of Human Nutrition (DIfE)
dife.de
Humboldt-Universität zu Berlin
hu-berlin.de
htw Berlin – University of Applied Sciences
htw-berlin.de
Institute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht (Teltow)
hzg.de
Institute for the Reproduction of Farm Animals Schönow Inc.
ifn-schoenow.de
Lausitz University of Applied Sciences
fh-lausitz.de
Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB)
atb-potsdam.de
Leibniz-Institut für innovative Mikroelektronik
ihp-microelectronics.com
Leibniz-Institut für Molekulare Pharmakologie (FMP)
fmp-berlin.de
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
mdc-berlin.de
Max Planck Institute for Infection Biology
mpiib-berlin.mpg.de
Max Planck Institute for Colloids and Interfaces
mpikg.mpg.de
Max Planck Institute for Molecular Genetics
molgen.mpg.de
Max Planck Institute of Molecular Plant Physiology
mpimp-golm.mpg.de
Robert Koch Institute (RKI)
rki.de
Technische Universität Berlin (TU)
tu-berlin.de
University of Applied Sciences Berlin
beuth-hochschule.de
University of Applied Sciences Wildau
tfh-wildau.de
University of Potsdam
uni-potsdam.de
Banks and VCs
BC Brandenburg Capital GmbH
bc-capital.de
Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge
lbb.de
Berliner Volksbank eG
berliner-volksbank.de
bmp Life Science AG
bmp.com
Business Angels Club Berlin
bacb.de
Commerzbank AG
commerzbank.com
Creathor Venture
creathor.de
Demeter Partners
demeter-partners.com
Deutsche Bank AG
db.com
High-Tech Gründerfonds Management GmbH
high-tech-gruenderfonds.de
IBB Beteiligungsgesellschaft mbH
ibb-bet.de
Investitionsbank Berlin
ibb.de
Investitionsbank des Landes Brandenburg
ilb.de
KfW-Mittelstandsbank
kfw-mittelstandsbank.de
Peppermint Venture Partners GmbH
peppermint-vp.de
Ventegis Capital AG
ventegis-capital.de
Berlin Partner für Wirtschaft und
Technologie GmbH
Support of international and domestic companies in all issues regarding locating to Berlin. berlin-partner.de
BioTOP Berlin-Brandenburg
BioTOP Berlin Brandenburg is the central contact and coordination office for all issues biotop.de
concerning biotechnology in the German capital region.
Investitionsbank Berlin (IBB)
Company financing and consultation on subsidies and processing grant applications in ibb.de
Berlin.
Investitionsbank des Landes
Brandenburg
Company financing and consultation on subsidies and processing grant applications in ilb.de
Brandenburg.
Landesamt für Gesundheit und
Soziales Berlin (LAGeSo)
One Stop Agency for all licensing and approvals, for questions concerning biomedicine, berlin.lageso.de
biotechnology and pharmaceuticals and for more general issues connected with health,
disease control and public health in Berlin.
58
BioTOP-Report
TCC Technologie Coaching Center
Specific Coaching offers for innovative high tech companies.
coachingbonus.de
Technologie Stiftung Brandenburg
The technology Foundation Brandenburg is dedicated to the advancement of science and ts-bb.de
research, especially in the field of innovative technologies.
TSB Technologiestiftung Berlin
Gruppe
The TSB Technology Foundation Berlin Group is a public private partnership in the German tsb-berlin.de
capital region to develop science and industry networks for technology transfer, joint projects, and regional innovation strategies.
ZAB Zukunftsagentur Brandenburg
The Brandenburg Economic Development Board functions as a one-stop agency for all zab-brandenburg.de
kinds of business support services.
ZAK Zentrale Anlauf- und
Koordinierungsstelle Senats
verwaltung für Wirtschaft, Arbeit
und Frauen
Helps you find your way through the Berlin administration. Supports complex urban devel- berlin.de/sen/wirtschaft/zak
opment policy and investment projects.
Advance Pharma GmbH
Contract manufacturer of solid drugs.Galenic development and admissions, analytics and advance-pharma.eu
microbiology, coating and granulation (organic and aqueous), compacting, packaging.
ALPHAMADE GmbH
Customized formulations as medications: parenteral feeding, intradialytic parenteral feed- www.alphamade.de
ing, omega-3 fatty acids, cytostatics.
Bausch & Lomb Dr. Mann Pharma
Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing bausch-lomb.de
life for consumers around the world. Core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical
products.
Bayer Pharma Aktiengesellschaft
Bayer Pharma is one of the ten largest specialty pharmaceutical companies in the world bayerhealthcare.com
and the company's goal is a leading market position in each of its specialist fields. With
its distinctive expertise in research, the company develops new medicines and therapies
which make an essential contribution toward improving patient's quality of life.
BERLIN-CHEMIE Aktiengesellschaft
BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, which was berlin-chemie.de
formed in 1886 and is headquartered in Florence, was developed over the generations to
become a global, owner-managed pharmaceutical company. Research is centred on the
development of innovative drugs for the following areas: inflammatory diseases and pain,
cardiovascular diseases, oncology, viral disease.
Chemisch-pharmazeutisches Labor,
Rolf Sachse GmbH
CPL S: Custom synthesis development of active pharmaceutical ingredients (API’s), Con- cpl-sachse.de
tract manufacture of active pharmaceutical ingredients from laboratory to kiloscale, Pharmaceutical analysis.
CT Arzneimittel
CT Arzneimittel is a pharmaceuticals company that focuses on generics production. Pre- ct-arzneimittel.de
scription medicines form the bulk of the product portfolio, which includes some 1,200
drugs with more than 200 different active agents that are used to treat the most common
clinical syndromes.
Dr. Kade Pharmazeutische Fabrik
GmbH
The company’s activities concentrate on the production and marketing of drugs in the kade.de
fields of gynecology, proctology, pain relief/ rheumatism and urology. The potential of
proven drugs is expanded systematically by galenic developments to produce innovative
products.
Haupt Pharma AG
With&nbsp,nine production sites Haupt Pharma is one of the leading contract man- haupt-pharma.de
ufacturers for pharmaceutical products in&nbsp,the world&nbsp,today.&nbsp,About
2.000&nbsp,employees produce for an established clientele of more than 200 important
international pharmaceutical companies, amongst which 15 of the international TOP 25.
Heyl chemisch pharmazeutische
Fabrik GmbH & Co. KG
HEYL is an independent, entrepreneurial family business that has its headquarters in prob- heyl-berlin.com
ably the liveliest German metropolis, Berlin, since its establishment in 1926. In cooperation with our international subsidiaries, the main focuses of our work are the Regulatory
Affairs and marketing of medicines as well as the sale of active pharmaceutical ingredients
(API's) and special chemicals.
Klosterfrau Berlin GmbH
For more than 175 years Klosterfrau has been developing, manufacturing and market- www.klosterfrau.de
ing pharmaceutical products. The profile of traditional yet modern natural medicines has
grown significantly in recent times. Based on the latest scientific discoveries combined
with the development of new markets, the range is constantly being expanded with innovative products.
medphano Arzneimittel GmbH
medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective pharmaceutical medphano.de
preparations. Main products are analgesics/anti-rheumatics, antibiotics, dermatics, diuretics, drugs to stimulate blood circulation, drugs for treatment of gastro-intestinal disorders,
vitamins, expectorants, lipid-lowering agents, ophthalmics, cosmetics, food supplements,
diet foods and foods.
59
BioTOP-Report
MUCOS Pharma GmbH & Co.KG
As a specialist in enzyme preparations Mucos supplies a steadily growing market with mucos.de
specific and variably dosed enzyme combinations. The company leads the world market in
oral enzymes for therapeutic purposes.
Nycomed Oranienburg GmbH
As the competence centre for the development, production and packaging of solid dosage nycomed.de
formulations Nycomed Oranienburg plays an important part in the global Nycomed operations network. It supplies the global pharmaceutical markets in more than 100 countries,
from Europe to the US and Japan. The products include corporate Nycomed products and
contract manufacturing for third parties.&nbsp.
Pfizer Pharma GmbH
Pfizer is the world's largest research-based biomedical and pharmaceutical company.
Pharma Action
Pharma Action has extensive expertise in global pharmaceutical marketing and manufac- pharma-action.com
turing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in
Europe and abroad.
Piramal Imaging GmbH
Piramal Imaging is a start-up business within the Life-Science division of the Mum- imaging.piramalenterprises.
bai-based Piramal Enterprises Group. The company is dedicated to the clinical research & com
development and the global commercialization of Nuclear Medicine / Molecular Imaging
products for detection, characterization and monitoring of disabling and life-threatening
diseases in neurology, oncology and the cardio-vascular space.
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis is a leading global pharmaceutical company based in Paris and operating sanofi-aventis.de
in over 100 countries. R&amp,D teams work on a global approach to patients, offering innovative therapeutic strategies in thrombosis, cardiovascular diseases, diabetes, vaccines,
oncology, the central nervous system disorders and internal medicine.
Shire Deutschland GmbH
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that www.shire.de
focuses on meeting the needs of the specialist physician. Shire focuses its business on
attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal
diseases.
Spreewälder Arzneimittel GmbH
Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food sup- spreewaelder-arzneimittel.de
plements, diet foods and cosmetics in liquid, semi-solid and solid administration forms.
Steiner & Co. Deutsche
Arzneimittelgesellschaft mbH &
Co. KG
Production and marketing of pharmacy and prescription drugs, particularly plant-based steinerarznei-berlin.de
drugs (tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well as gynecological and urological drugs), analgesics and mineral preparations.
Steripharm Pharmazeutische
Produkte GmbH & Co. KG
Production and marketing of folic acid products.
pfizer.de
steripharm.de
Contract Manufacturers
Advance Pharma GmbH
Contract manufacturer of solid drugs.Galenic development and admissions, analytics and advance-pharma-berlin.de
microbiology, coating and granulation (organic and aqueous), compacting, packaging.
ALPHAMADE GmbH
Customized formulations as medications: parenteral feeding, intradialytic parenteral feed- alphamade.de
ing, omega-3 fatty acids, cytostatics.
Ayanda
Ayanda is an innovative business partner and manufacturer of consumer ready pharmaceu- ayanda.com
ticals and food supplements. In Pritzwalk, Brandenburg, the company has a pharmaceutical
soft gel encapsulation plant.
Chemisch-pharmazeutisches Labor,
Rolf Sachse GmbH
CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredients cpl-sachse.de
(API’s); Contract manufacture of active pharmaceutical ingredients from laboratory to kiloscale; Pharmaceutical analysis.
Haupt Pharma AG
With nine production sites Haupt Pharma is one of the leading contract manufacturers haupt-pharma.de
for pharmaceutical products in the world today. About 2.000 employees produce for an
established clientele of more than 200 important international pharmaceutical companies,
amongst which 15 of the international TOP 25.
Pharma Action
Pharma Action has extensive expertise in global pharmaceutical marketing and manufac- Pharma-action.com
turing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in
Europe and abroad.
Spreewälder Arzneimittel GmbH
Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food sup- spreewaelder-arzneimittel.de
plements, diet foods and cosmetics in liquid, semi-solid and solid administration forms.
analyze & realize ag
60
analyze & realize ag is a leading CRO and consulting firm, which primarily give complete analyze-realize.com
advice and guidance to companies in the natural products sector.
BioTOP-Report
Assign International GmbH
Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO with assigngroup.com
six offices in five countries.Our expertise meets development requirements of pharmaceutical and biotechnological industries. We manage clinical trials from study set-up to final
clinical report.Our services, among others, comprise Data Management and Biostatistics,
integrated EDC-Systems, Pharmacovigilance, Protocol Writing, Laboratory Services and
Quality Management.
BLS Preclinical Services
BLS Preclinical Services is a contract research organization (CRO) located in Berlin. BLS pro- bls-germany.com
vides a range of highquality and integrated preclinical services in animal models. Through
our highly skilled scientific partners we provide a “one-stop” service and tailored solution.
We take the time to understand your business needs and provide comprehensive tailored
solutions either in-house or in co-operation of our network. We are backed by a highly
skilled scientific team with a wealth of experience in all disciplines of preclinical development.
Charité Research Organisation
GmbH
Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration charite-research.org
with Berlin‘s famous Charité University Hospital. This relationship fosters a level of cooperation with centers of clinical excellence that we think is unique in the industry. The
CRO offers a whole new approach to the concept of partnering with centers of clinical
excellence to facilitate access to patients, clinical expertise and specialist methodologies
in support of early clinical development programs.
Cooperative Clinical Drug Research
and Development (CCDRD) AG
CCDRD is an independent contract research organization (CRO). CCRDR is dedicated to ccdrdag.com
offer creative and innoative full service from planning to market authorization to its customers in the pharmaceutical, biotechnological and medical device industry.
CSG Clinische Studien Gesellschaft
mbH
Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbH has focussed on csg-germany.com
aligning clinical research with public health demands, with special attention to facilitating
access by physicians and patients to clinical studies.CSG cooperates closely with the largest
research institute for public health in Germany, the IGES Institut.
Dr. Notghi Contract Research
Dr. Notghi Contract Research GmbH is a service provider for large, medium and small-sized notghi.com
companies in the pharmaceutical, generics and biotechnology industries. We support and
advise you in the conduct and management of national and international projects.
Klinische Forschung Berlin GbR
Klinische Forschung Berlin is a study centre that implements clinical studies from phases klinische-forschung-berlin.de
IIA to IV for the pharmaceuticals industry.
Klinische Forschung Gruppe Nord
GmbH
The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network of in- kfgn.de
dependent investigator institutes with five centres in Northern Germany, two of them in
Berlin.The Klinische Forschung Gruppe Nord has carried out trials with up to 250 patients.
Phase II and III studies are the core competence. The test centres have altogether 30 overnight accommodation places for phase I and IIa studies.
PAREXEL International GmbH
The German subsidiary of the US clinical research organization PAREXEL employs more parexel.com
than 1,400 people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab beds)
and an annual enrollment of approximately 2,500 volunteers in Berlin, more than 75 clinical studies are performed each year.
Sacura GmbH
Sacura is a full-service contract research organization granting a high level of quality (FDA sacura-cro.com
approved), flexible structures and qualified staff.
Biotech Companies
3B Pharmaceuticals GmbH
3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based 3b-pharma.com
in Berlin, Germany. The company is dedicated to the development of peptide-based pharmaceutical and diagnostic products. 3BP is pursuing projects in hemophilia and nuclear
medicine.
8sens.biognostic GmbH
8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for dif- biognostic.de
ferent markets (human and veterinary diagnostics, food control). Our products are the
QuickSens®-tests for h-FABP, TropI, CRP and hs-CRP and the Reader for quantification
QuickSens®OMEGA. Development-on-demand, feasibility studies and production-on-demand are also offered.
ABiTEP GmbH
The ABiTEP GmbH is working in development and production of biotechnological products abitep.de
for sustainable agriculture. The team of ABiTEP works for development of non GMO customer specific technologies in laboratory scale and scale up with modern equipment and
Know how. Capacities for fermentation up to 5.000 L, down stream equipment as well
as freeze drier with capacity of 90 L are available for services. A molecular biology lab is
available for basic science.
Accelero Bioanalytics GmbH
Accelero® Bioanalytics GmbH is a biotech CRO focussing on GxP compliant bioanalytical accelero-bioanalytics.com
ligand binding assays. The company supports PK and PD preclinical/ clinical drug development on microRNA, miRNA, siRNA, aptamers, plasmid APIs, antisense drugs, as well as
peptide hormones, biosimilars, antibody therapeutics, or cell-based therapeutics (ATMP).
The Applied Biosystems Viia7 real-time qPCR system with IVD label for human Dx operates
in full compliance to Good Laboratory Practice (GLP).
61
BioTOP-Report
Biotech Companies
Adrenomed AG
Development of biologics against severe sepsis.
Aevotis GmbH
The core competencies of aevotis lie in the targeted conversion of simple carbohydrate aevotis.com
containing substrates (e.g. agricultural by-products, waste streams, inexpensive sugars)
to high-value carbohydrate based products, their characterization, processing and testing.
Marketable products include novel /optimized enzymes, expression systems,&nbsp, specialized biotransformation and down-stream processes, customized oligomers and polymers for food and non-food uses.
AFOSA GmbH
Development, production and marketing of diagnostics (ELISA kits), primarily for use in afosa.com
veterinary medicine.
Aglycon Mycoton GmbH
Aglycon Mycoton GmbH is active in the research, development and application of bio- aglycon-mycoton.net
polymers as well and their manufacture and the sales and marketing of products based
on these.
AJ Innuscreen GmbH
The AJ Innuscreen GmbH is a young life science company working in the field of biotech- aj-innuscreen.de
nology and boosts the life science unit of Analytik Jena AG. Innovative technologies and
products are developed and produced for the isolation and purification of nucleic acids.
Reagent systems for molecular biology, as well as technologies and products for molecular
diagnostics, are also included in the product portfolio. The company is EN ISO 9001:2008
and EN ISO 13485:2003 + AC:2009 certified.
Alacris Theranostics GmbH is a company based in Berlin specialised in developing new alacris.de
approaches in personalised medicine for cancer patient diagnosis, treatment and drug
stratification. Alacris is applying a systems biology approach that has been developed in
the Department of Prof. Lehrach at the Max Planck Institute for molecular Genetics and is
exclusively licensed as ModCellTM to Alacris.
Alcat Europe GmbH
Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the original alcat-europe.com
developer of the Alcat test technology. The company is specialized to identify intolerant
reactions of the leucocytes to foreign substances like foods, drugs or chemicals.
Algenol Biofuels Germany GmbH
The company focuses on the biotechnological use of cyanobacteria, especially the devel- algenol.com
opment and optimization of cyanobacteria for the production of environmentally friendly
biofuels and chemical feedstocks.
ALRISE Biosystems GmbH
ALRISE is a drug delivery company that specializes in the nano- and micro-encapsulation of alrise.de
active ingredients. Using its globally patented ImSus® technology, ALRISE are developing
parenteral deposit pharmaceutical forms for proteins, peptides or small molecules. Customers are mainly large pharmaceutical companies who are developing improved administration forms for active ingredients whose patents are expiring together with ALRISE as
part of their “Product Lifecycle Management”.
Amocol Bioprocedures Ltd.
Amocol Bioprocedures Ltd is a life science research & development and manufacturing amocol.com
company headquartered in Germany. Our mission is to supply innovative affinity chromatography media products and protein purification tools for research scientists and clinical
customers in public sector institutes and industry.
AnaKat Institut für Biotechnologie
GmbH
AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of anakat.de
pharmaceutical ingredients.
Analyticon Discovery GmbH
AnalytiCon is a biotechnology company focusing on the development of compound librar- ac-discovery.com
ies consisting of natural product (NP) and synthetic small molecules. As the global market
leader in NP small molecule screening compounds, AnalytiCon is the only company which
is able to provide vast collections with completely disclosed structural information. As a
pure compound provider the company is offering its products and services to the pharmac.,
chemical, biotech, cosmetical and nutraceutical industry.
Analytisches Zentrum Biopharm
Berlin GmbH
Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization providing analytisches-zentrumservices on pharmaceutical analysis and bioanalysis for active compounds in the dosage biopharm.de
form, for the quantitative determination of analytes in a biological matrix and also the
determination of physicochemical parameters of chemicals according to OECD guidelines.
AZB carries out these services in compliance with GLP and GMP and has the GLP certificate.
AnaTox GmbH & Co. KG
The AnaTox GmbH & Co. KG deals with the development and optimization of analytical anatox.de
methods and devices for HPLC and dissolution.
Anau Berlin-lab GmbH
Development and distribution of lab devices.
ANiMOX GmbH
Development of applications for the use of natural peptide / amino acid mixtures in chem- animox.de
istry and biotechnology, f.i. as a scavenger material in formaldehyde bounded formulations,
foaming or hydrophobic Tensid compounds or as a N-source in biotechnological fermentation processes, distribution of a technology for the production of such basic materials
from raw and residual materials.
Aokin AG
Aokin AG is a Berlin biotechnology company that is specialized in the development and aokin.com
commercialization of innovative analytical systems on the base of the rapid kinetic assay
technology. The aokin systems are unique in their precision and operating speed. Areas
of application are food and antibody analytics as well as clinical diagnostics. We also offer
laboratory services in the area of food analytics, Pharmacoanalytics and chemical synthesis.
62
adrenomed.com
BioTOP-Report
Biotech Companies
AptaRes AG
AptaRes is a developer and manufacturer of aptamers as an alternative to antibodies. The aptares.de
aptamers are isolated in vitro by using a proprietary technology. AptaRes is also developing aptamer-supported processes and analytical methods. It provides also consumables
required for the aptamer applications. In collaboration with financial partners AptaRes
supports with its enabeling technology entrepreneurs and the expansion of biotechnology
companies.
ARGUS Umweltbiotechnologie
GmbH
ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remediation argus-umwelt.de
of contaminated groundwater, soil, waste water and waste air. ARGUS is able to elaborate
a specific remediation program in each different pollution case considering economic aspects beside ecological aspects. All necessary treatment steps can be planned and carried
out. The combination of microbiological steps with classic processes leads to a successful
remediation of complex contamination.
ASCA GmbH Angewandte
Synthesechemie Adlershof
ASCA is a partner for contract research in the field of medicinal chemistry. The synthesis asca-berlin.de
and optimization of lead structures, the development of new active structures and their
check on a laboratory scale are offered. We take a lot of care on working out the synthetic
schemes, rapid preparations and exact analysis of the samples. All our results are carefully documented for our customers. Access to literature databases and in-house analytical
facilities are available.
Astra Biotech GmbH
Astra Biotech GmbH offers high quality reagents, allergens, antibodies, recombinant pro- astrabiotech.de
teins, and assays for the determination of hormones, allergies, tumour markers and infectious diseases. Quality is one of the key cornerstones on which Astra Biotech maintains its
reputation and with which we strive to increase customer satisfaction and gain growing
customer loyalty. We take great pride in our highest quality assays, which are all IVD compliant and therefore suitable for direct, accurate and reproducible diagnostic purposes, as
well as for research.
ATLAS Biolabs GmbH
ATLAS Biolabs GmbH is a leading provider of microarray based genomic services such as atlas-biolabs.com
genome wide gene expression and SNP analysis, CGH analysis and diagnostic services
for registered doctors and hospitals, as well as for pharmaceutical, biotechnological and
diagnostic enterprises.
Attomol GmbH Molekulare
Diagnostika
The company’s aim is to develop, produce and distribute medical diagnostics for human attomol.de
medicine in the field of molecular genetics, infectious and autoimmune diseases.
AudioCure Pharma GmbH
AudioCure is focus on the clinical development of drug candidates for neurodegenerative audiocure.de
diseases with high unmet medical need.
AutoTissue GmbH
The company is engaged in the development, production and marketing of medical devices autotissue.de
for cardiovascular surgeons. The products are specially made for the patients and have less
side effects. The first certified product was a pulmonary heart valve (Matrix P) for the right
ventricular outflow tract reconstruction (RVOT). The second product is also a heart valve
which considerably shortens the operation time (Matrix P plus). Meanwhile a complete
glutaraldehyde free valve is available called Matrix P plus N.
Bbi-biotech GmbH
In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bio- bbi-biotech.com
reactors for all applications in the biotechnology, pharmaceutical, food, cosmetics and
chemical industry. In addition, bbi-biotech develops components - in especially disposable
ones - for the preparation of a new generation of fermentors and bioreactors and offers
consulting and planning services for biotech projects, its implementation and services.
BEB BioEnergy Berlin GmbH
Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropower bebgmbh.de
plants, Preplanning, Feasibility Studies and Research activities in the field of renewable
energies, Optimization of the process in existing biogas plants.
BG Berlin-Genetics GmbH
BG Berlin-Genetics GmbH is a new provider for genetic diagnostics and consulting in ge- bg-berlin-genetics.de
netic diagnostics. We are a team of experienced human geneticists and have worked for
many years in the field of human genetic science and human genetic diagnostics. Our aim
is the development of innovative cooperation concepts, to connect classical patient-based
medical care centers with modern technology-based service centers. In future, these cooperation forms will enable efficient, high quality, and patient-based genetic diagnostics.
Bioanalyt GmbH
Bioanalyt develops and distributes the worldwide first easy-to-use and portable test kits for bioanalyt.com
the analysis of vitamins and micro nutrients. The iCheck-iEx test kits enable food producers,
food authorities and NGOs to monitor their ongling food programms more efficiently and
at low-cost. The company was founded in 2006 by Prof. Dr. F. J. Schweigert as a spin-off of
the University of Potsdam. Read more on our website www.bioanalyt.com.
Bioassays GmbH
Service related to the development of medical in vitro-diagnostic products. Basic science bioassay-online.de
to clinical development. Profiling of biomarkers in clinical trials.
Biochrom AG
Biochrom is Germany’s largest manufacturer of cell culture products (media, sera, and biochrom.de
others) and sterile liquids. They are distributed to universities, industrial cell culture laboratories and industrial manufacturers. Service is of special significance for users of cell
cultures. Special media developments and production optimizations are offered.
BIOCYC Gesellschaft für
Biotechnologie und Recycling mbH
& Co.KG
Production of bio-chemicals, peptides, in vitro-diagnostics, test-kits. Development of con- quartett.com
sumer service for peptides and biochemicals.
63
BioTOP-Report
Biotech Companies
BioGenes GmbH
BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) devel- biogenes.de
opment company with outstanding problem solving capabilities specializing in challenging
projects that are carried out by an exceptionally experienced and interdisciplinary team.
Bioline GmbH
Our mission is to provide customers with a range of products which are fast and easy to bioline.com
use, guaranteed to work and developed by scientists who understand what our customers
are trying to achieve so they can focus on their scientific goals. Bioline reagents are used
by molecular biologists and other research scientists to perform test-assays and research
in many fields from medical, biotechnology and marine biology.
BioMedion GmbH
IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term-Ar- biomedion.com
chiving and Digital Signature, SOP-Management, CAPA, Raw Data Management, Consulting for Validation of Computerized Systems according to GAMP4/5.
Biorefinery.de GmbH
Based on main precursors of plants, carbohydrates in kind of sugar, starch and cellulose, biorefinery.de
and proteins, the biorefinery.de company has developed four complex product lines (Biorefinery systems) which leads to a great number of valuable products with the help of chemistry and biotechnology.
BioRepro GmbH
BioRepro is the first pharmac. company, whose core competency is the breeding of leech- biorepro.de
es under controlled laboratory conditions for medical therapies. We concentrate on the
establishment of GMP breeding procedures and will be able to provide leeches with standardized quality while equally allowing scalability to supply medical demand. Additionally,
through the re-initiation of fundamental research, we will gain deeper understanding of
further potential in medical and cosmetic treatment areas.
BioS Biotechnologie Schönow
GmbH
Embryo transfer and associated biotechnologies in animals. Service, training and research bios-schoenow.de
in this field.
BioSilta Europe GmbH
BioSilta is an international company that specializes in advanced tools for microbial cell biosilta.com
cultivation, protein production, enzyme screening and food spoilage testing. The patented
EnBase® technology resembles fed-batch mode and provides a cultivation environment
with glucose-control, pH maintenance and inhibition of growth-limiting metabolites without the need for traditional mechanical pumps. EnBase® is provided in ready-to-use liquid
or tablet products. BioSilta specializes in small-scale cultures and it?s products offer customer solutions from multi-well plates to small-scale bioreactors. Learn more about our
products and applications at www.biosilta.com.
BIOSYNTAN Gesellschaft für
bioorganische Synthese mbH
BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of modified biosyntan.de
peptides (e.g. glyco- and phosphopeptides, dye labeled peptides) and hapten modifications for the conjugate synthesis. In cooperation with BIOGENES GmbH Berlin we offer
poly- and monoclonal antibodies.
Biotech-Laboratorium für
Environment BLE GmbH
Development of detection systems which are able, economically and rapidaly, to detect oil mobiclup.de
contaminations and industrial oil waste, in soil and in water and their biological depletion.
The BLE GmbH is concerned with the biological degradation of oil contaminations and the
development of a set of bio-preparations consisting of different bacterial strains which
break down oil.
biotechrabbit GmbH
biotechrabbit GmbH is determined to offer the newest and best life science products and biotechrabbit.com
innovative solutions to scientists leading the fight againstdisease and fueling our lives
with innovations. We supply ultra pure enzymes and high-quality antibody services for
diagnostics and a life science product portfolio(including reagents for PCR and nucleic
acid purification)for molecular biology and proteomics. The biotechrabbit advantage is
our combination ofpassion for excellent research with the agility of true entrepreneurship.
BIOTECON Diagnostics has been well known as a qualified partner in the field of molecular bc-diagnostics.com
and microbiology for the last 13 years. We focus on development, production and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers solutions for the
food and beverage industry as well as for producers of pharmaceuticals and cosmetics.
Services (Custom DNA and RNA Oligonucleotide synthesis, Immuno affinity columns) - De- biotez.de
velopment of Enzyme Immunoassays, e.g. for Therapeutic Antibodies- Bio Conjugates - Immobilization of Bio Molekules for better Signalling-R&D (Aptamer).
BIOWORX -BiotechnologielaborThomas Grimm
BIOWORX offers services in the fields of contract research for customer-specific Biotrans- bioworx.de
formations, the screening, isolation and production of Biocatalysts from microorganisms
and plants and the bioanalytic syntheses. Further organic compounds and metabolites will
be synthesized with enzymes for customer in kg scale.
BiRDS Pharma GmbH
BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the field birdspharma.com
of drug development to pharmaceutical and biotech companies, including management of
drug development projects as well as consulting services. The company also pursues own
drug development projects based on intellectual property generated within BDD/CCDRD
group, with a focus on drug candidates derived from Atomic Substitution Technology (AST).
Blue Biolabs GmbH
Blue Biolabs is a spin-off company from the TU-Berlin, which specialises in the develop- bluebiolabs.de
ment of products and services in the field of environmental analysis using methods of
microbiology and molecular biology.
64
BioTOP-Report
Biotech Companies
Botiss medical AG
Botiss biomaterials is a privately owned biotech company, headquartered in Berlin. botiss botiss.com
is the leading German specialist for dental bone and tissue regeneration (BTR). We focus on
the development of innovative regenerative materials and clinical marketing / distribution
in over 50 countries world-wide. The botiss subsidiary Cell+Tissue Bank Austria is a leading
European manufacturer of allogenic materials for hard tissue regeneration.
Breecon GmbH
The breecon GmbH is an innovative service company in life science with focus on green breecon.com
biotechnology. The objectives of the company are consulting, application and mediation
of biotechnological-analytical services as well as their development and marketing. The
breecon GmbH offers his services to plant breeders and companies of the industrial biotechnology and supports the utilization of genetic diversity in the context of SMART breeding.
BST Bio Sensor Technology GmbH
BST develops and produces biosensors to provide high quality analysis at moderate prices. bst-biosensor.de
In 1982 BST brought on the market the first multi-way biosensor based blood glucose
analyzer in Europe and is since then market leader in Europe. Today BST sells more than
60.000 sensors a year. Since 2008 BST is besides biosensors also manufacturer of POCT
and laboratory instruments.
Caprotec bioanalytics GmbH
Caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows separation caprotec.com
and isolation of proteins based on functionality. For many applications, CCMS is clearly
superior to conventional methods - thus addressing an unmet need in the proteomics
research community. The company is commercializing the CCMS technology through ImproMed projects with pharmaceutical and biotechnology companies. The focus on these
collaborations is on investigating mechanisms of drug action (MoA) and identification of
on- and off-target proteins to understand potential adverse effects of drug candidates on
a molecular level. This can be easily carried out in the lead optimization process, or even
earlier to increase the probability of success later on in the clinic.
Capsulution Pharma AG
Capsulution Pharma AG develops innovative nano- and micron-sized capsules. The com- capsulution.com
pany applies its worldwide-patented so-called LBL-Technology®. Based on their minute
size, their functionality and their highly reproducible production process the capsules can
be used for a multitude of different applications. Accordingly, the precisely sized capsules
(500 nm to 50 µm) can be made to function in a manner to suit the intended application,
and can be given the appropriate biochemical, electrical, optical and magnetic properties
as required by the customer.
Celares GmbH
Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of celares.com
Biopharmaceuticals with polyethylene glycol in order to substantially improve pharmacological properties. Offers the unique CelaSYS-PEGylation technology, which is patented
by celares. CelaSYS: non-dispersed, highly branched polyethylene glycol based reagents.
Additionally celares offers customized PEGylation solutions as well as synthesis of customized PEG-reagents.
CellServe GmbH
CellServe is a service provider for research groups in regenerative medicine and fills an cellserve.de
important gap in the conversion of applied treatment concepts from research into marketable products. Furthermore CellServe develops own innovative cell-based products for
cardiology and uses novel cardiac derived cells ("From the Heart to the Heart") for the
treatment of chronic heart failure.
CellTrend GmbH
Celltrend is certified according to ISO 9001, ISO 13485 and GMP Cell culture systems for celltrend.de
research on active substances (bioassays, preclinical research, for quality control)Development and production of antibody-based detection systems (ELISA) Chemosensitivityassay
for optimisation of chemotherapy (tumor patients).
Chemicell GmbH
Chemicell develops and produces magnetic, fluorescent and coloured nano- and micropar- chemicell.com
ticles, reactive fluorescent dyes and special chromatography-materials for the separation or
detection of cells, bacteria, viruses, proteins or DNA/RNA and new gene transfer systems.
Chipron GmbH
Chipron GmbH specializes in production and distribution of array based detection systems chipron.com
for DNA/pathogens.
CHIRACON GmbH
chiracon is a qualified partner to develop chiral intermediates at a constant high qual- chiracon.de
ity for innovative drugs regarding economic, environmentally acceptable and scaleable
aspects. We offer support through expert knowledge and key technology to meet your
increasing needs. Our core competence is chirality. In addition we have a broad variety
of chiral building blocks as an inhouse raw material source for high-level API production
and development.
CMZ-Assay GmbH
Marketing of diagnostic reagents for measuring concentrations of proteins, hormones and cmz-assay.com
their isoforms, exclusively for research purposes.
co.don® AG
co.don® AG is one of the leading biopharmaceutical companies in the area of Regenerative codon.de
Medicine/Tissue Engineering. Since 1997, co.don® AG has developed, manufactured and
distributed human Tissue engineering therapeutics for the regeneration of articular cartilage and intervertebral discs.
65
BioTOP-Report
Biotech Companies
CONGEN Biotechnologie GmbH
CONGEN is specialized in food testing by molecular analytics based on DNA and RNA de- congen.de
tection. CONGEN has been a pioneer for over a decade in the development and application
of food and feed analytics by real-time PCR. The methods are available as complete analytic
kit as well as a Service. Our mission is to serve the food industry with an excellent service
and with standardized and reliable test kits in order to realize highest possible food safety
and food quality.
Cyano Biotech GmbH
Cyano Biotech identifies and characterizes natural products from cyanobacteria and opti- cyano-biotech.com
mizes their pharmacological activities employing a biocombinatorial approach. The company conduct further development of identified lead structures till the preclinical phase.
Diaglobal GmbH
Development, production and distribution of in vitro-diagnostics for analytical purpose diaglobal.de
and the distribution of medical products.
DIZG Deutsches Institut für Zellund Gewebeersatz gemeinnützige
GmbH
DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue preser- dizg.de
vation as well as in cell and tissue replacement, and provides tissue preparations of human
origin to clinics, teaching and research organisations. Further service is culturing of skin
cells (keratinozytes) for serious burns and other skin defects not healing well or affecting
large areas. DIZG supplies cell cultures to help avoid experimentation with animals e.g. in
the cosmetics industry.
Drug Response Dx GmbH
"DRDx makes drug response predictable: Challenge and necessity of personalized medicine drdx.de
and individualized therapies demand for convincing and reliable companion diagnostics.
The first field of activity of DRDx is Rheumatoid Arthritis (RA). The goal of our company is
the technical and clinical validation of an IVD test kit for the reliable prediction of therapy
response to TBAs ahead of treatment.
Dr. Götz Verfahrenstechnik
Biotechnik Umwelttechnik
Contract research and contract manufacturing using bacteria, yeasts and fungi.
Dr. Lerche KG
Innovative company engaged in development, production and marketing of specialized lerche-biotec.com
microcapsules for bio- and medical technology - Development and production of novel
DNA-Purification-Kits with proprietary technology - Production and marketing of microcapsules (LUMiTainer), microbeads and cell based sedimentation standards for blood analysis (Sedi-Val ESR standards) - Encapsulation of cells - Contract analysis for characterization
of microcapsules, porous membranes and hollow fibres.
Dr. Otto GmbH
Handling with research and development of ecological products its process of develop- dr-otto-gmbh.de
ment also its production and marketing - Production and refinement of plantingredients
- Operate an analytical laboratory of renewable resources and chem. Analysis.
Dr. Rölleke Labor für Genetische
Analytik GmbH
Dr. Roelleke is specialized on the identification of microorganisms, particularly in the area dr-roelleke.de
of food safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for courts
and the private sector.
DSM Biopract GmbH
Service and Additives (enzymes, trace elements, microbes) for biogas and waste water dsmbiogas.com
sludge treatmentEnzyme analysis in agriculture industryContract reserach feed additives.
Durakult GmbH
Durakult GmbH discovers and optimizes starter cultures and novel whole-cell catalysts for durakult.de
customers in the food, chemical and renewable energy industries. durakult provides a new
technology to explore microorganisms from natural untapped biodiversity for industrial
applications. durakult stabilizes genetically manipulated cells which show weak growth or
unstable metabolic properties and fits them to industrial purposes.
E.R.D.E.-AAK-Diagnostik GmbH
E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for commercial aak-diagnostik.de
purposes.
EMP Biotech GmbH
Production of fluorescent dyes and chemiluminescent reagents. Contract chemical syn- empbiotech.com
thesis of small molecules. Contract labeling and purification of proteins, antibodies and
oligonucleotides. Production of size-exclusion gels, columns and filter plates. Production
of high quality reagents for DNA synthesis.
Epigenomics AG
Development and commercialization of innovative molecular diagnostic test products epigenomics.com
based on DNA methylation for cancer screening and for cancer specialty applications.
Epinamics GmbH
Epinamics GmbH, a newly established Berlin based pharmaceutical research and devel- epinamics.com
opment dedicated company, is owner of a proprietary film forming formulation technology platform, the ?Invisible Patch? system. The system is offering a broad basis for the
development of formulations for treatment of dermatological diseases as well as for the
development of transdermal systems.
Epiontis GmbH
Establishing methylation fingerprinting as Gold Standard for quality control in Regenera- epiontis.com
tive Medicine and Immunomonitoring.
Epo Experimentelle Pharmakologie
& Onkologie GmbH
The pharmaceutical and oncological testing of new drugs or treatment concepts for cancer epo-berlin.com
is a specialized market segment. Using the equipment available, all experimental techniques can be carried out in first-rate quality. That means that EPO is an attractive partner
for the drug development section of large pharmaceutical companies, for partners from
the Biotech industry and for research institutions.
Eurovir Hygiene-Institut/Dr.
Thraenhart
Laboratory service for testing the efficiency of products against viruses (virucides) and of eurovir.de
processes for inactivating or eliminating viruses (virus safety).
66
drgoetz.de
BioTOP-Report
Biotech Companies
EVESTRA GmbH
EVESTRA is a newly founded biotech company focusing on developing female health evestra.com
products. The companies expertise resides with steroid chemistry and biology. EVESTRA’s
product pipeline includes products for contraception, hormone replacement therapy, gynecological disorders and hormon dependent cancers.
F.A.T. Forschungsinstitut für
Antioxidative Therapie GmbH
Measuring instruments and kits for evaluating the antioxidant properties and the degree antioxidant-research.eu
of oxidative damage in biological substrates.
Fermtec GmbH
Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid fer- fermtecgmbh.de
mentation, innovative foods and beverages and auxiliary substances for the food industry.
Ferropharm GmbH
Development of very small super para-magnetic nano particles as contrast agent for MRI.
FILT Lungen- und Thoraxdiagnostik
GmbH
Development of innovative, non-invasive diagnostic methods in the area of respiratory filt.de
diseases and allergies.
Formula GmbH
Galenical development of liquids and solid formulations Lyophilization Technolgy also formula-pharma.de
apllicable for biochemical products Granulation, drying and coating using fluid bed drying-technology, tabletting Development and validation of analytical methods including
UPLC Stability testing (ICH / GMP related to on going) Import of medicinal poducts from
non-EU-countries, manufacturing, quality control (re-test) and release for market in accordance with §16 AMWHV for medicinal products and clinical supplies GMP-certificat /
Manufacturing license in accordance with §13 AMG.
GA Generic Assays GmbH
Development, manufacturing and distributing of in vitro-tests, focussing on autoimmune genericassays.com
diseases, hereditary and infections diseases.
Gene Analysis Service GmbH
Gene Analysis Service is specialized on genetic testing of a number of rare hereditary dis- gene-analysis-service.de
eases and provides nucleic acid based molecular biological services like PCR and custom
DNA sequencing for healthcare providers and research institutes worldwide.
GenExpress Gesellschaft für
Proteindesign GmbH
GenExpress is a flexible company providing services in molecular biology. For over a de- genexpress.de
cade we have successfully worked for customers in clinical laboratories, research institutions and the industry. We offer cloning of PCR targets, preparation of synthetic genes,
expression of proteins, evaluation of LightCycler® assays, furthermore production of internal controls and standards for Real Time PCR systems, also cloning, expression and
purification of proteins.
GILUPI GmbH
GILUPI is a medical diagnostics company with an initial focus on the prenatal and cancer gilupi.com
market. The company is developing an innovative new diagnostic product based on nanotechnology. Our goal is to catch specific cells, which can be found only in very low concentration in the blood. The first application for our new nanosensor device will be prenatal
diagnoses of chromosomal aberration out of maternal blood. The second application will
focus on the early diagnosis of cancer.
GlucoMetrix PVS GmbH
The GlucoMetrix AG focuses on the early detection and management of diabetes melli- glucometrix.de
tus-aftermath. At the foreground of research and development is the enhancing the quality
of life of diabetics. In addition, the life science company develops some IT-based diagnostic
procedures and medical devices as well as biopharmaceuticals and other highly effective
products in order to raise the quality of life of diabetics sustainably.
Glycon Biochemicals GmbH
Production of carbohydrate components used for the synthesis of new pharmaceutical glycon.de
compounds or diagnostics.
Glycotope GmbH
Glycotope is a leading company in glycomics and immunotherapeutics. It has developed glycotope.com
novel therapeutic antibodies and unique platform technologies to optimize the glycosylation of new biological entities. Glycotope Biotechnology, with 25 years of experience in
GMP-production, enables us to offer the entire process of biopharmaceutical development
with a dedicated focus on our unrivalled expertise in protein glycosylation from the gene
to production and fill & finish of clinical grade material.
Götz Protein Engineering
Offering a wide range of protein technology up to the final purified protein.
HealthTwiSt GmbH
HealthTwiSt is a service provider for “Genetic Contract Research” in the fields of Func- healthtwist.de
tional Genomics, Epigenetics, Proteomics or Functional Food / Nutriceuticals. In particular,
HealthTwiSt is offering access to extensively characterized human subjects and samples as
well as prospective studies in twins, together with know-how in the analysis of complex
genetic traits. Furthermore, database development, data management and statistical analyses for clinical projects are provided.
HF Biotec Berlin GmbH
Development, selling and operating of digestion plants using liquid substrates of industrial hf-biotec.com
and agricultural provenience, Development and operating of combined plants to upgrade
biogas into bio methane useable in public gas grids with parallel production and selling of
high quality PCC, Development of innovative biotechnological processes and plants.
Human BioSciences GmbH
The biotech-company Human BioSciences Inc. is specialized in manufacturing and distri- HumanBioSciences.de
bution of modern collagen based wound and skin care products.
ferropharm.de
goetz-protein-engineering.de
67
BioTOP-Report
Biotech Companies
HUMAN GmbH
For over 35 years HUMAN has been serving the healthcare sector. HUMAN develops and human.de
manufactures in Germany laboratory diagnostic products for the world market. HUMAN
stands for quality and service in over 160 countries. In our new competence centre for
autoimmune diagnostics, an expert team of highly specialized scientists and technicians
develop and produce the IMTEC product line, a range of high-quality autoimmune diagnostic products. Further innovative products are to be launched soon!
Hybrotec GmbH
Hybrotec GmbH is specialized in the development of monoclonal antibodies and immuno- hybrotec.com
assays (preferably homogenous assays) as customs service. Our main focus lies on antibodies binding low molecular weight substances (e.g. toxins, fluorophores, hormones) as well
as antibodies against novel proteins.
ICI GmbH
ICI – immunochemical intelligence gmbh – is dedicated to the development and produc- ici-diagnostics.com
tion of innovative immunoassay components and kits for research use. Their goal is to provide individual solutions, exactly tailored to the client’s needs and to create lasting relationships by providing outstanding services and high quality products to demanding clients.
Icon biotech
Icon biotech is an innovative biotechnology company, which uses the extraordinary charac- icon-biotech.com
teristics of Ciliates for the development of bio-analytical and toxicological model systems.
IDrug GmbH
IDrug supports business strategies with innovative methodologies in analytical and bio- idrug.de
pharmaceutical chemistry
Ifp Institut für Produktqualität
GmbH
Ifp Institut für Produktqualität is a laboratory and competence centre for state-of-the-art produktqualitaet.com
food, drinking water and pharmaceutical analysis. The accredited and GMP-certified company focuses on comprehensive services for the food and pharma industry. An additional
core competence of ifp is the development and production of innovative diagnostics comprising the real-time PCR kits of the brand “mericon” (QIAGEN), vitamin tests in microtiter
plate format, enzymatic microtiter plate kits for sugars/acids, and allergen tests in lateral
flow and ELISA formats.
IGV Institut für
Getreideverarbeitung GmbH
The range of services offered by the Biotechnology Division of the private research IGV igv-gmbh.de
GmbH institute is based on 25 years of experience in R&amp,D for the cultivation of phototropic micro-organisms. Excellent, world-wide contacts to biomass producers, food producers, to the pharmaceutical and cosmetics and energy industry provide the fundament for
innovative, market-oriented developments. In focus are development of photo bioreactor
technology and active substances from algae.
IKDT Institut Kardiale Diagnostik
und Therapie GmbH
IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laboratories ikdt.de
on Viral Infections of Heart Muscle Tissue and Dilatated Cardiomyopathy (DCM) in Germany. IKDT lab is performing a comprehensive molecular diagnostic examination of endomyocardial biopsies as one of a limited number of specialized cardiological labs worldwide.
Its service enables physicians firstly to start an efficient, pathophysiologically based causal
therapy.
ILBC GmbH
Research, consulting, production, trade & services in the areas biology, molecular biology mobiclup.de
and protein chemistry - Expression and production of antimicrobial peptides.
ImaGenes GmbH
RZPD spin-off, today part of Source BioScience plc, a premier service center for genome imagenes-bio.de
research and healthcare in Europe, provides one of the largest clone collections in the
world via its clone search engine GenomeCube®. Certified Service Provider for illumina
Next Generation Sequencing services and comprehensive microarray application on Affymetrix, Agilent, and NimbleGen platforms. ISO 9001:2008 certified.
In.vent DIAGNOSTICA GmbH
in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the project-ori- inventdiagnostica.de
ented provision, processing and distribution of biological raw material for development
and production of diagnostics and control material. We are your reliable partner for the
customised development of assays for medical in vitro-diagnostics.
inbion GmbH
inbion GmbH provides services to support research in the interface between university, inbion.de
students and industry. For companies, we provide the benefit of outsourcing projects
quickly and cost-efficiently to competent teams. Cooperation with research groups in the
university is also facilitated, so that targeted knowledge transfer can take place here.
Innovative Optische Meßtechnik
GmbH
Fluorescence Assay Solutions and Instrumentation (Microplate Readers).
Institut für Medizinische
Gene tests for prenatal, predictive and tumor -diagnostics.
Molekulardiagnostik (IMMD) GmbH
iom-berlin.de
immd.de
Institut für Molekular- und
Systemmedizin I.M.S.M. GmbH
Scientific-practical works in the area of System medicine with the purpose of the patenting
of new treatment methods, e.g. to the treatment of diabetes. International cooperation
in this area.
InterMune GmbH
InterMune is a biotechnology company focused on the research, development and com- intermune.de
mercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a
progressive and fatal lung disease.
68
BioTOP-Report
Biotech Companies
InVivo Biotech Services GmbH
As a contract manufacturing company (CMO) Invivo offers a wide range of services: the invivo.de
development and production of monoclonal antibodies and recombinant proteins for diagnostic and pre-clinical use (endotoxin-free antibodies and compliant documentation), cell
line development and transient transfection. We are an ISO9001:2008 certified company.
InvivoContrast GmbH
InvivoContrast provides globally high quality MRI (Magnetic Resonance Imaging) contrast invivoContrast.com
agents and professional support for preclinical imaging in academic and commercial institutions.
JPK Instruments AG
JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - partic- jpk.com
ularly atomic force microscope (AFM) systems and optical tweezers - for a broad range of
applications reaching from soft matter physics to nano-optics, from surface chemistry to
cell and molecular biology. From its earliest days applying atomic force microscope (AFM)
technology, JPK has recognized the opportunities provided by nanotechnology for transforming life sciences and soft matter research.
JPT Peptide Technologies GmbH
JPT is an ISO 9001:2008 certified provider of innovative peptide products and services and jpt.com
a partner for research projects focusing on the development of novel immune therapeutics & diagnostics, profiling of various enzyme classes and proteomics. JPT has developed
a portfolio of proprietary technologies and a series of unique products which support a
worldwide customer base. Since 2011 all catalog products such as peptide microarrays &
peptide pools are avalaible through an online shop.
Klinomed GmbH
Development of new technologies for manufacturing bio-active nano particles / develop- klinomed.de
ment of therapeutic formulations based on nano particles.
KNAUER - Wissenschaftliche
Gerätebau Dr. Ing. Herbert Knauer
GmbH
KNAUER UHPLC and HPLC systems as well as columns are used in research and devel- knauer.net
opment, quality control and production plant laboratories around the world. Customers
are typically governmental and industrial organizations as well as universities. Fields of
application are wide-ranging and include pharmaceutical and medical research, analysis of
foodstuffs and cosmetics, as well as environmental analysis. With our biochromatography
solutions we focus on high resolution separations.
L.U.M. Gesellschaft für
Labor-, Umweltdiagnostik &
Medizintechnik mbH
Analysis, diagnosis and sensor technology as well as stability, rheology and segregation lum-gmbh.de
behavior of dispersions.
Labor Berlin – Charité Vivantes
Services GmbH
Labor Berlin – Charité Vivantes
GmbH
Labor Berlin Services is the service subsidiary of Europe’s largest hospital laboratory for laborberlin.com
clinical pathology and offers complete solutions for any kind of testing for the ivd industry,
CROs, the pharmaceutical industry, life science companies and research facilities, while
Labor Berlin is the exclusive laboratory partner of Charité - Universitätsmedizin Berlin and
the Vivantes Network for Health. Labor Berlin and Labor Berlin Services both perform over
35 million analyses in clinical pathology per year and provide the diagnostic services for approximately 400.000 in-house patients a day and some one million out-patients per year.
LAROVA Biochemie GmbH
Research, development and production of nucleotides, nucleosides, oligonucleotides in larova.com
natural and modified forms.
LGC Genomics GmbH
LGC Genomics is the division of LGC with specific expertise in high quality, cutting-edge lgcgenomics.com
genomic and related services and products. LGC Genomics delivers:- Next generation sequencing services- DNA sequencing- Genomics services- Nucleic acid extraction servicesDNA extraction products. LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards (www.lgc.co.uk).
LGC GmbH
Production of calibration substances for purity testing of drugs.
Limetec Biotechnologies GmbH
The core competence lies in the development of high-speed and high-quality proof systems limetec-biotechnologies.de
for the detection of pathogens, as well as in the allelic discrimination of hereditary diseases.
All products are marked with the CE-Certificate. The second area of expertise is the creation
of communication networks which connect out-patient and hospital patient treatments, intensify data exchange and provide information to all health institutions, thus establishing
partner relationships between them.
mikromol.de
Lipidomix GmbH
LC/MS/MS based high trouput analytic of lipid mediators and metabolites. Analytical meth- lipidomix.de
od development, analytical support for LC/MS/MS in life science, food safety, forensic science.
MagForce AG
MagForce AG is a leading medical technology company focusing on nanomedicine in on- magforce.com
cology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted
treatment of solid tumors through the intratumoral generation of heat via activation of
magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components
of the therapy and have received EU-wide regulatory approval as medical devices for the
treatment of brain tumors.
Marinpharm GmbH
Development and marketing of genetically altered cell lines on the basis of new fluores- marinpharm.com
cence markers. Generation of stably transfected fluorescent cell lines.
MedInnovation GmbH
MedInnovation GmbH has developed a new method and a special ESR-analyser, which for medinnovation.de
the first time allows a simple routine laboratory test for evaluation of functional characteristics of plasma proteins and further opens a reliable possibility for cancer diagnostic,
named MMS-technology (mobility of molecular structure).
69
BioTOP-Report
Biotech Companies
Medipan GmbH
Development, manufacturing and international distribution of radioactive (125J-IRMA) medipan.de
and non-radioactive (Elisa) in vitro-diagnostic tests, covering the field of Autoimmunity,
mainly in Thyroid and Diabetes Typ 1 and automated interpretation of cell-based immunofluorescence tests by the AKLIDES system.
MerLion Pharmaceuticals GmbH
The business purpose of the Company is the research, production, optimization and the merlionpharma.com
development by way of pre-clinical as well as clinical trials of new molecules for the treatment of infectious diseases.
Merz Pharmaceuticals GmbH /
Standort Potsdam
Merz is one of the leading research-based health care companies. Merz Pharmaceuticals merz.de
has achieved a leading position in Alzheimer’s research with the world’s first drug for the
treatment of moderate to severe Alzheimer’s disease. With high quality products from
tetesept® and Merz Spezial®, Merz is making a key contribution to health and wellbeing.
Metabolomic Discoveries GmbH
Metabolomic Discoveries is an analytical service and research company. We provide mass metabolomicdiscoveries.com
spectrometry based metabolite profiling and fingerprinting of biological material, as well
as single compound measurements.
Metanomics GmbH
Metabolite Profiling for identification of gene function relationship in plants, metabolite
biomarkers and metabolic networks.
Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and nu- metanomics-health.de
trition.
MetrioPharm AG
MetrioPharm AG develops innovative therapies for infectious diseases on the basis of new metriopharm.com
and innovative medicines.
Mfd Diagnostics GmbH
The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and development mfd-diagnostics.com
company for diagnostic and therapeutic application of innovative laser technologies. The
main advantages of the developed technologies are the non-/minimally-invasive measurement methods, the non-artificial approach and the possibility of real-time measurement.
Therefore, those are promising tools for the diagnosis and therapy monitoring in the neurological practice and in the perinatal surveillance.
MicroDiscovery GmbH
MicroDiscovery GmbH is a leading provider of high quality software for biomolecular re- microdiscovery.de
search, innovative diagnostics and personalised medicine. The company is ISO 9001 certified and has a strong track record in creating software systems in accordance with relevant
regulatory directives for the life science and IVD industry. Customised services ranging
from biostatistical data analysis to bioinformatical design and support of complex research
projects complete the product line of MicroDiscovery.
Microparticles GmbH
Development, manufacture, surface modification and characterization of mono-disperse microparticles.de
polymer particles in the nano- and micrometer range. In addition to classic polystyrol and
polyacrylate-based polymer particles, microparticles GmbH has launched new melamine
resin particles on the market with exceptional chemical and physical qualities. The main
areas of application are in particle measurement technology, medicine, biochemistry and
microelectronics etc.
Minerva Biolabs GmbH
Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for con- minerva-biolabs.com
tamination control, especially mycoplasma in cell cultures and biopharmaceutical products.
Minerva Biolabs is also active in ensuring water quality with sensitive processes for detecting legionella. Our distributors ensure that our products are available worldwide, quickly
and at a good price.
mivenion GmbH
mivenion is a life-science company founded in Berlin aiming on the development and mivenion.com
commercialization of diagnostic and therapeutic products. The company is built on two
innovative technologies: the fluorescence camera system Xiralite for diagnostic imaging of
early rheumatoid arthritis and a proprietary bioactive polymer drug development platform.
Xiralite is mivenion´s first product on the market.
MLB Mikrobiologisches Labor
GmbH
Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens,
D-PL-13398-01-00, EN 17025. Accreditation according to VDI 6022.
MolConcept GmbH
We offer computational drug design, rational drug design, and efficient simulation algo- molconcept.com
rithms for molecular systems.
Molnar-Institut für angewandte
Chromatographie
Molnar-Institute, established in 1981, offers you a complete scientific and technical ser- molnar-institute.com
vice for all problems concerning Quality by Design (QbD) for HPLC-methods. We develop
for you the Design Space for your HPLC-separation and establish Critcal Quality Attributes
(CQA’s). We offer detailed DryLab-courses and show you, how to develop robust methods
in the Design Space and how to save time. We supply and implement the DryLab-software
and train your coworkers. We assist you in automated method development processes and
support you in the selection of proper instruments, their installation and use.
MOLOGEN AG
MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in the de- mologen.com
velopment of novel DNA-based medicines against cancer and vaccines against infectious
diseases. The proprietary platform technologies MIDGE® and dSLIM® build the foundation
for all business activities. The company was founded 1998 and was one of the first biotechnology companies to go public.
70
metanomics.de
mikroberlin.de
BioTOP-Report
Biotech Companies
moloX GmbH
moloX GmbH is a company focusing on custom protein production in bacterial and in- molox.de
sect cell expression systems and subsequent protein purification to ultra-high purity. On
customer demand a team of experts can perform protein crystallization experiments and
determine the 3D structure of target proteins by X-ray crystallography.
MRI.TOOLS GmbH
MRI.TOOLS´s main focus is the development, sales and services of innovative hardware mritools.de
and novel technology for magnetic resonance imaging (MRI), computed tomography (CT)
and positron emission tomography (PET). Our product portfolio encompasses enabling
radiofrequency (RF) coils tailored for a broad range of applications, devices designed for
reliable cardiac gating of imaging plus accessories that will make your daily life more comfortable. MRI.TOOLS is also very proud to offer consulting services such as validation and
certification of medical devices.
Nano Access Technologies Ltd.
The company addresses the combined access to key technologies such as life science and nano-access.com
nanotechnology. As a first product, a low cost AFM for operation with so-called active cantilevers has been developed. Besides this, functionalized cantilevers for future biosensors
are another focus of the company.
Nanolytics Gesellschaft für
Kolloidanalytik mbH
We are a contract laboratory specializing in the physico-chemical characterization of phar- nanolytics.de
maceutical proteins, biopolymers, nanoparticles and colloidal systems. Our core-competences are Analytical Ultracentrifugation, in combination with Static and Dynamic Light
Scattering as well as spectroscopic (CD, fluorescence) and thermodynamic techniques (ITC,
DSC).
Nanopartica GmbH
Nanopartica GmbH optimizes existing products of other companies, but are also devel- nanopartica.com
oping new products and materials. In particular, companies in surface-, bio-, and medical-technology can benefit from nanopartica. By means of functionalized polymers, we can
encapsulate guest molecules (drugs, dyes, vitamins), particles (gold, silver, platinum), or
ions. This will indirectly change the guests properties and expands its scope.
nanoPET Pharma GmbH
As a technology and service provider to the biopharmaceutical industry nanoPET focuses nanopet-pharma.com
on the R&D, production as well as marketing of innovative drug substances for diagnostic
imaging based on novel nanoparticular materials. nanoPET offers consulting and contract
research services, preclinical contrast agents (MRT, CT, US, NIR, PET) as catalog items and
pursues the preclinical development of its patented core technology of inorganic nanoparticle PET tracers.
New Medical Enzymes AG
Medical Enzymes AG is a privately held innovative biopharmaceutical company with a fo- medical-enzymes.com
cus on therapeutically useful enzymes. The company has developed a new product family
based on amino acid depleting enzymes. This unique approach is highly effective against
cancer - the major target market of Medical Enzymes AG.
NovaBiotec® Dr. Fechter GmbH
Microbiological and chemical investigations, in particular of soil, water and air samples, novabiotec.de
planning / inspection of sanitation, in particular analytics and sanitation support for mould
and dry rot, incl. education in this field. Delivery of production auxilliaries and support for
biogas plants with biological treatment processes incl. application, insulation and preservation of enzymes. Research, development and marketing of test kits for breweries and
malthouses.
Novamol GmbH
Development and manufacture of human and veterinary food supplements and health-en- novamol.com
hancing products.
NOXXON Pharma AG
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new noxxon.com
class of proprietary therapeutics called Spiegelmers. Spiegelmers are the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio
of clinical stage Spiegelmer therapeutics: Spiegelmer® NOX-E36, Spiegelmer® NOX-A12,
Spiegelmer® NOX-H94. The Spiegelmer platform provides the Company with powerful and
unique discovery capabilities, which have generated a number of additional leads under
preclinical investigation. Located in Berlin, Germany, NOXXON is a well financed mature
biotech company with a strong syndicate of international investors, approx. 60 employees
and a highly experienced management team.
NutriNeu GmbH
NutriNeu GmbH develops a new generation of pre and probiotics. First products are based
on microorganisms that were isolated with our proprietary GlycoScreen technology (antibody directed isolation of microorganisms expressing specific carbohydrate structures).
Besides developing own products, NutriNeu GmbH offers services in the fields of microbiology, process development and Glycoanalytic. NutriNeu GmbH also helps customers to
investigate the probiotic properties of their microorganisms.
OakLabs GmbH
OakLabs provides the most flexible products and services for large scale custom SNP ge- oak-labs.com
notyping on the market. OakLabs offers several formats for analysing a variable number of
SNPs in any sequenced organism.
OctreoPharm Sciences GmbH
OctreoPharm Sciences GmbH is a clinical development company focusing on diagnostic octreopharmsciences.com
radiopharmaceuticals.
71
BioTOP-Report
Biotech Companies
OpTricon Entwicklungsgesellschaft
für optische Technologien mbH
OpTricon develops and produces mobile readers for quantitative analyzes of Immunoas- optricon.de
says for Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional business segments are components and Systems for signal transmission and sensors for lbioanalytics. opTricon develops the devices in partnership with the customers and works as
OEM-suppliers and is certified by TÜV Rheinland according EN ISO 13485:2003+AC: 2007
and EN ISO 9001:2008.
ORGANOBALANCE GmbH
ORGANOBALANCE is a company specializing in microbial strain development and screen- organobalance.com
ing. As a R&D contractor ORGANOBALANCE develops new biological products in the areas
of nutrition, personal care and health care. The company draws on its own collection of microbial strains suitable for food applications and its OASSYS® bioassay systems. In the field
of “metabolic engineering” ORGANOBALANCE exploits Saccharomyces cerevisiae yeast for
synthesis of substances for the industrial and pharmaceutical industry.
ORGANOBALANCE Medical AG
ORGANOBALANCE Medical AG funds and promotes the research and development of nov- organobalancemedical.com
el therapies based on specific probiotic cultures, aiming to develop active substances and
mechanisms for innovative medicinal products and medical devices, as well as offer new
therapeutic concepts for hitherto inadequately treatable indications.
ovalehn GmbH
Production and application of specific recipes -containing IgY for diagnostics and oral, pas- ovalehn.de
sive immune therapy.
Pentracor GmbH
In the case of cardiac infarction, C-reactive protein (CRP) results in an increase of the pri- pentracor.com
mary damage. Based on a new prototype, the company Pentracor GmbH aims to develop
an adsorber for therapeutic reduction of CRP, lead it to approval, establish its certified
production and market the product after clinical validation.
Peptides&elephants GmbH
Custom synthesis of peptides and peptide libraries Development parallel Synthesis tech- peptides.de
nologies Distributor of Peptide Synthesis Automation.
PharmaSol GmbH
Modification of ingredients or introduction of new metabolic pathways in plants with pharmasol-berlin.de
gene-technology methods.
PlasmaChem GmbH
PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in plasmachem.com
nanomaterials, plasma- and ultra-thin film technologies. The company manufactures nano-coated medical implants (stents), nanomaterials, additives for metal plating (applied
e.g. by Siemens AG), new additives to engine oils on the base of nanodiamonds and other
industrial nanoproducts.
PolyAn, Gesellschaft zur
Herstellung von Polymeren für
spezielle Anwendungen und
Analytik mbH
PolyAn is specialised in Molecular Surface Engineering (MSE). Using our surface modifica- poly-an.de
tion expertise PolyAn optimises the performance of analytical systems by improving the
signal-to-noise ratio as well as the reproducibility of consumables for multiplex diagnostics,
LifeScience research and screening applications. PolyAn?s product portfolio includes functionalised microarray slides, microparticles for multiplex bead arrays and functionalised
membranes for medical diagnostic applications.
Preclinics Gesellschaft für
präklinische Forschung mbH
Preclinics is a commercial cooperation partner for preclinical research and development. preclinics.com
As a competent, creative and experienced partner preclinics investigates pharmaceutical
substances, therapeutic methods and proceedings as well as medical products during the
preclinical phase. Additional we provide custom antibody production in llama, goat, sheep,
rabbit and other species.
Predemtec GmbH
Predemtec GmbH is a company focused on the research, development and manufacture of predemtecDX.com
innovative diagnostic tests for use in the detection of dementia-related risk factors. The
goal has been to make the early and reliable diagnosis of various dementia-related illnesses a reality through the use of our innovative diagnostics tests.
ProBioGen AG
ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and Tech- probiogen.de
nology Provider, with extensive expertise in cell line engineering, process development
(upstream- and downstream process) and GMP manufacturing of biopharmaceuticals. Offering state-of-the-art contract development and manufacturing services as well as access
to proprietary cell lines (AGE1.cell lines®) for the manufacturing of biopharmaceuticals and
vaccines. The company possesses the manufacturing authorization from the competent
authority and meets the quality standards required by the EMA and the FDA guidelines.
ProteaImmun GmbH
ProteaImmun is a specialized proteomic company providing purified human proteins, an- proteaimmun.net
tibodies and ELISAs. Our proteins are designed for structural and functional studies of
proteases screening and evaluation of protease inhibitors and modulators. Furthermore
we develop highly sensitive ELISA kits and antibodies. Our Focus: MMPs, ADAMTs, HtrAs.
ProteaImmun produces a unique range of recombinant proteases for medical and pharmaceutical research. The main focus is on human Matrix Metalloproteases (MMPs), ADAMTS
and HtrA proteins which play an important role in neurodegenerative disease, ancer and
arthritis. Customer Service: ProteaImmun provides activity analysis by zymography adapted for MMPs.
PROTEKUM - Umweltinstitut GmbH, We plan to eliminated fluid und solid waste products in a manner which is compatible with protekum.de
Oranienburg
environment protection. Our methodology is largely based on painstaking analysis. We
use modern equipment and scientific methods. Protekum offers high-quality products and
services in environmental analysis redevelopment.
72
BioTOP-Report
Biotech Companies
Proteome Factory AG
Biomarker & target discovery, validation, analysis of food and ingredients, absolute quan- proteomefactory.com
tification of proteins and peptides, sequencing and characterization of proteins and antibodies (CDR), 2DE and LC-MS based proteomics studies, pharmacokinetics, pharmaco,
immuno and membrane proteomics, protein identification, characterization of proteins
and peptides (PTMs, e.g. phosphorylation, glycosilation), quality control, mass determination, N-terminal amino acid sequencing, silver staining kit etc.
Provitro GmbH
Provitro combines more than ten years of experiences in commercialisation of cell culture provitro.de
technologies, Tissue Microarrays and immunohistochemical analyses with the scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality management
system according to ISO 9001:2008, we provide our customers not only with high-quality
products, CE marked in vitro-diagnostics and state-of-the-art services but also with individual solutions for their specific requests.
Rapidozym Gesellschaft für
Laborhandel und DNA Diagnostika
mbH
Expertise of cell biologists cell manufacturing and clean room technology specialists. Fo- rapidozym.de
cuses on clinical stem cell product development portfolio are stroke, myocardial infarction
and plastic surgery.
RENESA UG (haftungsbeschränkt)
Manufacturing and distribution of rapid tests, mainly for medical purposes (Point of Care renesa.de
Testing).
RiNA GmbH
RiNA has developed systems for cell-free protein biosynthesis based on pro- and eukary- rina-gmbh.eu
otic cell lysates. A synthesis service is realised in RiNA’s own laboratories and complements
the EasyXpress Kits (Qiagen). The purchase of Roche´s RTS-products enables RiNA now to
be a key player in the field of cellfree biosynthesis with a large variety of products. Another
research focus is the development of aptamers (DNA and RNA) for biosensors.
RIPAC-LABOR GmbH
RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poultry, ripac-labor.de
pigs and cattle, but also in other farm and domestic animals. The company uses pathogen
differentiation to provide quick and effective methods for fighting pathogens. It performs
resistance tests and epidemiological analyses and also focuses on producing herd-specific
vaccines.
RNL Europe GmbH
Manufacturing of stem cells from bone marrow and adipose tissue for therapeutic and rnleurope.com
plastic-aesthetical application. Manufacturing of adult stem cells for research (mesenchymal stem cells, endothelial precursor cells). Banking of stem cells.
Roboklon GmbH
Distribution, Marketing and Development of Products for Molecular Biological Research roboklon.de
and Genetic Engineering.
ROVALAB GmbH
Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our rovalab.com
high quality critical raw materials and reagents such as DNA Polymerases and dNTPs are
designed to help you successfully and rapidly solve your scientific and manufacturing tasks.
Royal Biotech GmbH
Royal focuses on developing, manufacturing and marketing innovative kits, portable or royalbiotech.com
micro-structured systems, and the next generation of diagnostic chips for near real-time
environmental, food safety, disease and laboratory diagnostics.
Scienion AG
Scienion is a life science company in the markets of dispensing systems and microarray scienion.de
technologies. The product portfolio comprises hardware, consumables and services. Scienion’s leading product is the sciFLEXARRAYER dispensing system, available in a product
line of six size versions. The dispenser allows the aspiration of ultra low liquid volumes
from different reservoirs and non-contact micro drop delivery in the picoliter to microliter
range onto a variety of carriers.
Sepiatec GmbH
Production, development and sales of automated HPLC machines for high-throughput pu- sepiatec.com
rification and fractioning of complex substance compounds.
Seramun Diagnostica GmbH
Seramun offers peptide synthesis, purification and conjugation of proteins, production of seramun.com
antibodies, customer research, in vitro-Diagnostics. We focus on the development and
production of enzyme immunoassays for diagnosis of viral and bacterial infections and
autoimmune diseases of the gastrointestinal tract, the development of multi-parameter
assays as microtitre plate assays and as membrane immunoassays, as well as development
of ready-to-use substrate solutions and for protein stabilizers.
SGS INSTITUT FRESENIUS Berlin
GmbH & Co. KG
Analytical laboratory services and consulting for development, production and quality con- institut-fresenius.de
trol of drugs.
SIFIN Institut für Immunpräparate
und Nährmedien GmbH Berlin
Development, production and purification of monoclonal antibodies for use in diagnostics. sifin.de
Development and production of blood grouping reagents, Serafol® bedside cards and test
reagents for serotyping of Salmonellae, Shigellae, E. coli and Yersiniae. Development and
production of culture media for microbiological diagnosis.
Signature Diagnostics AG
Signature Diagnostics is dedicated to the discovery, validation and commercial develop- signature-diagnostics.de
ment of novel diagnostic products that predict outcome and drug response in patients with
colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian cancer. Signature
believes that patient selection and stratification based on molecular gene signatures will
soon become an important component of routine cancer treatment.
73
BioTOP-Report
Biotech Companies
Silence Therapeutics AG
Silence Therapeutics AG is a leading RNAi therapeutics development company and offers a silence-therapeutics.com
novel, proprietary siRNA technology (AtuRNAi) and proprietary systemic delivery systems
for siRNA (AtuPLEX, DACC and DBTC). SILENCE pipeline consists of both partnered and
internal programs of which 3 clinical phase II and 1 clinical phase I programs are partnered
with Pfizer/Quark (2 ophthalmic indications) and Novartis/Quark (2 kidney indications).
Silence?s internal lead compound Atu027 is currently in a Phase I clinical study for the
treatment of solid tumours.
SINA Science Services GmbH
SINA is a modern company providing elaborate services in molecular biology and protein sina-science-services.de
biochemistry. Together with our industrial partners and customers from research institutions we develop complex cloning and mutagenesis strategies including high-throughput
applications. We offer cloning of genes, expression and purification of proteins, DNA and
RNA isolation from numerous biological materials and the production of competent cells
with high transformation efficiency.
SLM- Speziallabor für angewandte
Mikrobiologie GmbH
Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drinking speziallabor.com
water, foodstuff, monitoring in clean rooms.
STRATEC Molecular GmbH
STRATEC Molecular GmbH is a globally active provider of innovative system solutions for invitek.de
nucleic acid sample collection, stabilization, and both manual and automated purification from any sample type. Since 1992 the company is internationally respected for its
outstanding and high performance technology platforms and offers a broad spectrum of
superior products for molecular diagnostics, drug discovery and Life Science research.
Strix Diagnostics GmbH
Strix Diagnostics is a medical diagnostics company specializing in customized develop- strix-diagnostics.de
ment of certified analytical systems for multiparameter in vitro-diagnostics.
Surflay Nanotec GmbH
Surflay Nanotec GmbH, a spin-off company from Capsulution NanoScience AG, is special- surflay.com
ized on coating colloidal and planar materials with functional films. Key technology is the
patented LbL-Technology® with polymers. Applications are in the fields of separation materials, pigment encapsulation, bio-sensing and diagnostic particles. In addition to customer
tailored projects Surflay offers an unique range of products of tunable multifunctional
nano-or microparticles and dye-labeled polymers.
t-cell Europe GmbH
t-cell Europe GmbH, a spin-off of the Berlin Brandenburg Center for Regenerative Medi- t-cell.de
cines (BCRT), is aiming to become the world’s technology leader in the application of T-cellbased therapies used in transplantation medicine. Over the next few years, with its three
proprietary platform technologies, the company will develop and clinically validate novel
T-cell-based products and corresponding diagnostics to regulate the immune system and
treat viral infections. The company’s lead reference product will be a first-in-class Treg cell
product/therapy for kidney transplantation that suppresses organ rejection in recipients
Thanares GmbH
Development, use and marketing of analytical process for diagnostic and therapeutic pur- thanares.com
poses. Future business activities: detection process for bioactive substances in bodily fluids,
isolation, characterization and investigation of bioactive compounds from plants, in particular insoluble proteins or low concentrations of proteins, development of low cost genetic
systems for over-expression and/or production of such proteins.
TheraKine BioDelivery GmbH
Development of antibody drug delivery systems and related tasks.
Thermo Fisher Scientific –
B·R·A·H·M·S GmbH
Thermo Scientific Biomarkers (B·R·A·H·M·S GmbH) explores, develops and produces thermoscientific.com/
new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of brahms
life-threatening illnesses. This takes place with over 470 employees, in the disease areas
infectiology, cardiology and pneumology as well as thyroid, autoimmunity and cardiology
on the basis of our own patented biomarkers. Since October 2009 B·R·A·H·M·S GmbH
is part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science.
TIB MOLBIOL Syntheselabor GmbH
In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In ad- tib-molbiol.com
dition to designing and synthesizing primers and probes for Real-Time PCR assays, we
develop and produce LightMix® Kits for Roche Diagnostics LightCycler® Instruments, covering applications in Clinical Chemistry, Pharmacogenetics, Pathogen Detection, as well as
Cancer Research. TIB MOLBIOL is ISO 13485 and ISO 9001 certified.
TissUse GmbH
TissUse is a vibrant growth company providing high-value services in the area of tissue tissuse.com
culture analysis of drug candidates, cosmetics, chemicals and consumer products.
TransTissue Technologies GmbH
TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since September transtissue.com
2001. With more than 15 years of experience in regenerative medicine, the scientists of
TransTissue Technologies have developed second-generation autologous tissue replacements, e.g. cartilage and bone grafts. We are mainly concerned with inventions and the
development of tissue engineering products for regenerative medicine. We offer a broad
panel of services in the field of regenerative medicine.
UGA Biopharma GmbH
UGA Biopharma a private Research and Development company, focuses on Research, De- ugabiopharma.com
velopment and Commercialization of Biopharmaceutical products under contract with
other Biopharmaceutical companies. UGA Biopharma conducts power of biosciences to
develop high-tech, last generation of biomedicine, diagnostic kits, molecular biology items
and also offers world class services in biotechnology area.
74
therakine.com
BioTOP-Report
Biotech Companies
Umwelttechnik Dr. Bartetzko GmbH Feasibility studies, development, planning, construction and operation of biotechnological bartetzko.com
plants for groundwater, process water and waste water purification. Accredited microbiological laboratory for the investigation of drinking water, groundwater, bath water, soils,
food, anti-microbial active ingredients and sterility according to Ph.Eur, approved in accordance with BiostoffV and the German infection protection act (Infektionsschutzgesetz).
VasoTissue Technologies GmbH
The company is active in the field of product development for advanced medical therapies. vasotissue.de
For its first product - the endothelialised vascular graft (“VasoGraft”)- VasoTissue obtained
a manufacturing license in 2008. Currently, VasoTissue´s focus is on conducting its first
clinical trial.
Zellwerk GmbH
Zellwerk produces the proprietary Z® RP cell cultivation system, comprising rotating bed zellwerk.biz
bioreactor, GMP Breeder, Control Unit, software. Bioreactors with 50-5000 ml volume,
0,2-2 m² seeding surface, different cell carriers, can be delivered. In this culturing system
cells grow tissue-like, being embedded in self-generated extra-cellular matrix. The technology opens unique opportunities for the GMP-compliant expansion of stem cells and
primary cells, manufacturing of cell-seeded implants as well as production of recombinant
proteins. In addition, we have recently developed a new bioreactor for expansion of immune cells for cell therapy of leukemia and several types of cancer.
Zentrum für molekulare Onkologie
GmbH
Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics molekulare-onkologie.eu
(K-RAS, PCA3, Septin9, ...) - Chemoresistance assay for prediction of chemotherapy - Pathology Development of new biomarkers and analytical services for studies.
Zytomed Systems GmbH
Zytomed Systems´ focus is the development, production and distribution of antibodies zytomed-systems.de
and detection systems for immunohistochemical cancer diagnostics as well as reagents
and kits for in-situ hybridisation.
75
BioTOP is a joint initiative of the state of Berlin and the state of Brandenburg under the umbrella of the Berlin Partner für Wirtschaft und Technologie GmbH and takes part in the
Cluster Management HealthCapital. BioTOP is funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, co-funded by the European
Union (European Fund for Regional Development). Investing in your Future

BioTOP-Report 2013 - Cluster Gesundheitswirtschaft

Transcription

Similar documents

Whatl Saw

and DEUTZ-FAHR Erntesysteme GmbH

HSW GmbH

product suite

Initial Announcement

elotest is

Recycling for next generation

elotest b300

berlin university residences

Picturing family matters